
<html lang="en"     class="pb-page"  data-request-id="2e893c19-5937-4918-9abc-f99691d4ba63"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;issue:issue:10.1021/jmcmar.2014.57.issue-6;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/jm500007h;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Identification and Optimization of New Dual Inhibitors of B-Raf and Epidermal Growth Factor Receptor Kinases for Overcoming Resistance against Vemurafenib" /></meta><meta name="dc.Creator" content="Huimin  Cheng" /></meta><meta name="dc.Creator" content="Yu  Chang" /></meta><meta name="dc.Creator" content="Lianwen  Zhang" /></meta><meta name="dc.Creator" content="Jinfeng  Luo" /></meta><meta name="dc.Creator" content="Zhengchao  Tu" /></meta><meta name="dc.Creator" content="Xiaoyun  Lu" /></meta><meta name="dc.Creator" content="Qingwen  Zhang" /></meta><meta name="dc.Creator" content="Jibu  Lu" /></meta><meta name="dc.Creator" content="Xiaomei  Ren" /></meta><meta name="dc.Creator" content="Ke  Ding" /></meta><meta name="dc.Description" content="Epidermal growth factor receptor (EGFR) amplification has been demonstrated to be critical for the inherent and/or acquired resistance against current B-RafV600E inhibitor therapy for melanoma and ..." /></meta><meta name="Description" content="Epidermal growth factor receptor (EGFR) amplification has been demonstrated to be critical for the inherent and/or acquired resistance against current B-RafV600E inhibitor therapy for melanoma and ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="March 18, 2014" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm500007h" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2014 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm500007h" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm500007h" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm500007h" /></link>
        
    
    

<title>Identification and Optimization of New Dual Inhibitors of B-Raf and Epidermal Growth Factor Receptor Kinases for Overcoming Resistance against Vemurafenib | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm500007h" /></meta><meta property="og:title" content="Identification and Optimization of New Dual Inhibitors of B-Raf and Epidermal Growth Factor Receptor Kinases for Overcoming Resistance against Vemurafenib" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm500007h/production/images/large/jm-2014-00007h_0009.jpeg" /></meta><meta property="og:description" content="Epidermal growth factor receptor (EGFR) amplification has been demonstrated to be critical for the inherent and/or acquired resistance against current B-RafV600E inhibitor therapy for melanoma and colorectal cancer patients. We describe the discovery and structure–activity relationship study of a series of 1H-pyrazolo[3,4-b]pyridine-5-carboxamide analogues as novel dual inhibitors of EGFR and B-RafV600E mutant. One of the most promising compounds, 6a, potently inhibited both of the kinases with IC50 values of 8.0 and 51 nM, respectively. The compound also strongly suppressed the proliferation of a panel of intrinsic and acquired resistant melanoma and/or colorectal cancer cells harboring overexpressed EGFR with submicromolar IC50 values. Further mechanism investigation revealed that 6a could sustainably inhibit the activation of the MAPK path way in the resistant SK-MEL-28 PR30 melanoma cancer cells and WiDr colorectal cancer cells with EGFR amplification. Our results support the hypothesis that the EGFR/B-RafV600E dual inhibition might be a tractable strategy to overcome the intrinsic and acquired resistance of melanoma and/or colorectal cancers against the current B-RafV600E inhibitor therapy." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm500007h"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm500007h">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm500007h&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm500007h&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm500007h&amp;href=/doi/10.1021/jm500007h" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2014</span><span class="cit-fg-volume">, 57</span><span class="cit-fg-issue">, 6</span><span class="cit-fg-pageRange">, 2692-2703</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/57/6" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm401982j" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm500022q" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Identification and Optimization of New Dual Inhibitors of B-Raf and Epidermal Growth Factor Receptor Kinases for Overcoming Resistance against Vemurafenib</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Huimin++Cheng">Huimin Cheng</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yu++Chang">Yu Chang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lianwen++Zhang">Lianwen Zhang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jinfeng++Luo">Jinfeng Luo</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Zhengchao++Tu">Zhengchao Tu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xiaoyun++Lu">Xiaoyun Lu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Qingwen++Zhang">Qingwen Zhang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jibu++Lu">Jibu Lu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xiaomei++Ren">Xiaomei Ren</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ke++Ding">Ke Ding</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Institute of Chemical Biology, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, #190 Kaiyuan Avenue, Guangzhou 510530, China</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">University of Macau, Avenue Padre Tomás Pereira Taipa, Macau, China</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">Shenyang Pharmaceutical University, #103 Wenhua Road, Shenyang 110016, China</span></div><div class="corresp-info"><strong>*</strong>Tel: +86-20-32015276. Fax: +86-20-32015299. E-mail: <a href="/cdn-cgi/l/email-protection#7e1a17101921151b3e19171c16501f1d501d10"><span class="__cf_email__" data-cfemail="ddb9b4b3ba82b6b89dbab4bfb5f3bcbef3beb3">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm500007h&amp;href=/doi/10.1021%2Fjm500007h" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2014</span></span><span class="cit-volume">, 57</span><span class="cit-issue">, 6</span><span class="cit-pageRange">, 2692–2703</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">March 3, 2014</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>3 January 2014</li><li><span class="item_label"><b>Published</b> online</span>18 March 2014</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 27 March 2014</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm500007h" title="DOI URL">https://doi.org/10.1021/jm500007h</a></div><div class="article_header-article-copyright"><strong>Copyright © 2014 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D2692%26pageCount%3D12%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DHuimin%2BCheng%252C%2BYu%2BChang%252C%2BLianwen%2BZhang%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D57%26issueNum%3D6%26contentID%3Djm500007h%26title%3DIdentification%2Band%2BOptimization%2Bof%2BNew%2BDual%2BInhibitors%2Bof%2BB-Raf%2Band%2BEpidermal%2BGrowth%2BFactor%2BReceptor%2BKinases%2Bfor%2BOvercoming%2BResistance%2Bagainst%2BVemurafenib%26numPages%3D12%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D2703%26publicationDate%3DMarch%2B2014">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm500007h"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2793</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">18</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm500007h" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Identification and Optimization of New Dual Inhibitors of B-Raf and Epidermal Growth Factor Receptor Kinases for Overcoming Resistance against Vemurafenib&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Huimin&quot;,&quot;last_name&quot;:&quot;Cheng&quot;},{&quot;first_name&quot;:&quot;Yu&quot;,&quot;last_name&quot;:&quot;Chang&quot;},{&quot;first_name&quot;:&quot;Lianwen&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Jinfeng&quot;,&quot;last_name&quot;:&quot;Luo&quot;},{&quot;first_name&quot;:&quot;Zhengchao&quot;,&quot;last_name&quot;:&quot;Tu&quot;},{&quot;first_name&quot;:&quot;Xiaoyun&quot;,&quot;last_name&quot;:&quot;Lu&quot;},{&quot;first_name&quot;:&quot;Qingwen&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Jibu&quot;,&quot;last_name&quot;:&quot;Lu&quot;},{&quot;first_name&quot;:&quot;Xiaomei&quot;,&quot;last_name&quot;:&quot;Ren&quot;},{&quot;first_name&quot;:&quot;Ke&quot;,&quot;last_name&quot;:&quot;Ding&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2014&quot;,&quot;month&quot;:&quot;03&quot;,&quot;day&quot;:&quot;18&quot;,&quot;issue&quot;:&quot;6&quot;,&quot;volume&quot;:&quot;57&quot;,&quot;pages&quot;:&quot;2692-2703&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm500007h&quot;},&quot;abstract&quot;:&quot;Epidermal growth factor receptor (EGFR) amplification has been demonstrated to be critical for the inherent and/or acquired resistance against current B-RafV600E inhibitor therapy for melanoma and colorectal cancer patients. We describe the discovery and structure–activity relationship study of a series of 1H-pyrazolo[3,4-b]pyridine-5-carboxamide analogues as novel dual inhibitors of EGFR and B-RafV600E mutant. One of the most promising compounds, 6a, potently inhibited both of the kinases with IC50 values of 8.0 and 51 nM, respectively. The compound also strongly suppressed the proliferation of a panel of intrinsic and acquired resistant melanoma and/or colorectal cancer cells harboring overexpressed EGFR with submicromolar IC50 values. Further mechanism investigation revealed that 6a could sustainably inhibit the activation of the MAPK path way in the resistant SK-MEL-28 PR30 melanoma cancer cells and WiDr colorectal cancer cells with EGFR amplification. Our results support the hypothesis that the EGFR/B-Ra&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm500007h&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm500007h" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm500007h&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm500007h" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm500007h&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm500007h" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm500007h&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm500007h&amp;href=/doi/10.1021/jm500007h" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm500007h" /></input><a href="/doi/pdf/10.1021/jm500007h" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm500007h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm500007h%26sid%3Dliteratum%253Aachs%26pmid%3D24588073%26genre%3Darticle%26aulast%3DCheng%26date%3D2014%26atitle%3DIdentification%2Band%2BOptimization%2Bof%2BNew%2BDual%2BInhibitors%2Bof%2BB-Raf%2Band%2BEpidermal%2BGrowth%2BFactor%2BReceptor%2BKinases%2Bfor%2BOvercoming%2BResistance%2Bagainst%2BVemurafenib%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D57%26issue%3D6%26spage%3D2692%26epage%3D2703%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/57/6" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jmcmar.2014.57.issue-6/production/jmcmar.2014.57.issue-6.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm500007h/production/images/medium/jm-2014-00007h_0009.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm500007h/production/images/large/jm-2014-00007h_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500007h&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Epidermal growth factor receptor (EGFR) amplification has been demonstrated to be critical for the inherent and/or acquired resistance against current B-Raf<sup>V600E</sup> inhibitor therapy for melanoma and colorectal cancer patients. We describe the discovery and structure–activity relationship study of a series of 1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridine-5-carboxamide analogues as novel dual inhibitors of EGFR and B-Raf<sup>V600E</sup> mutant. One of the most promising compounds, <b>6a</b>, potently inhibited both of the kinases with IC<sub>50</sub> values of 8.0 and 51 nM, respectively. The compound also strongly suppressed the proliferation of a panel of intrinsic and acquired resistant melanoma and/or colorectal cancer cells harboring overexpressed EGFR with submicromolar IC<sub>50</sub> values. Further mechanism investigation revealed that <b>6a</b> could sustainably inhibit the activation of the MAPK path way in the resistant SK-MEL-28 PR30 melanoma cancer cells and WiDr colorectal cancer cells with EGFR amplification. Our results support the hypothesis that the EGFR/B-Raf<sup>V600E</sup> dual inhibition might be a tractable strategy to overcome the intrinsic and acquired resistance of melanoma and/or colorectal cancers against the current B-Raf<sup>V600E</sup> inhibitor therapy.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12148" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12148" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The Raf proteins belong to a serine/threonine kinase family and are critical components in the mitogen activated protein kinase (MAPK) signal transduction pathway.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1, 2)</a> Three isoforms of Raf kinase, i.e., A-Raf, B-Raf, and C-Raf, have been identified.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Aberrant activation and/or constitutively activating mutation of Raf kinase have been linked with multiple types of cancers.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> In particular, B-Raf mutations have been identified in various cancers including malignant melanoma (50–60%), papillary thyroid (30–50%), colorectal (10–15%), and lung (∼3%) cancers, hairy cell leukemia (∼100%), and others.<a onclick="showRef(event, 'ref5 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref5 ref6 ref7">(5-7)</a> The Val <sup>600</sup> → Glu <sup>600</sup> (V600E) transition is the most common mutation and accounts for over 90% in all of the B-Raf oncogenic mutants reported to date. The identification of B-Raf mutation in multiple human cancers promoted the extensive efforts to develop B-Raf inhibitors as new potential antitumor agents.<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8, 9)</a> Recently, two selective B-Raf inhibitors, vemurafenib (<b>1</b>, PLX4032)<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> and dabrafinib (<b>2</b>),<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> were approved by the US Food and Drug Administration (FDA) for the management of late-stage or unresectable melanoma harboring B-Raf<sup>V600E</sup> mutation (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>).<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12, 13)</a> The drugs have achieved remarkable clinical benefit for melanoma patients with B-Raf<sup>V600E</sup> mutation.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> For instance, drug <b>1</b> treatment produces a 60–80% overall response rate and a median progression-free survival of approximately 7 months in the B-Raf<sup>V600E</sup> mutated melanoma patients.<a onclick="showRef(event, 'ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref15 ref16">(15, 16)</a> The similar clinical efficacy has also been reported for drug <b>2</b>.<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17, 18)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm500007h/production/images/medium/jm-2014-00007h_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm500007h/production/images/large/jm-2014-00007h_0002.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of FDA approved B-Raf<sup>V600E</sup> inhibitors vemurafenib (<b>1</b>) and dabrafinib (<b>2</b>), EGFR inhibitor gefitinib (<b>3</b>), and the new B-Raf/EGFR dual inhibitor <b>4</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm500007h/production/images/large/jm-2014-00007h_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500007h&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Although the antitumor effects of drugs <b>1</b> and <b>2</b> in melanoma are highly promising, intrinsic and acquired resistance limits the therapeutic benefit of current drugs.<a onclick="showRef(event, 'ref19 ref20 ref21 ref22 ref23 ref24 ref25 ref26 ref27 ref28 ref29 ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref19 ref20 ref21 ref22 ref23 ref24 ref25 ref26 ref27 ref28 ref29 ref30 ref31">(19-31)</a> For instance, a majority of colorectal cancer patients display inherent resistance against drug <b>1</b>, although they were detected to harbor B-Raf<sup>V600E</sup> mutation, and the overall response rate is less than 5% in a clinical investigation.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> The exact mechanism for the significant difference in the efficacy of drug <b>1</b> between B-Raf<sup>V600E</sup> mutated colorectal cancer and melanomas remains elusive. The most recent results from two independent groups strongly suggested that the epidermal growth factor receptor (EGFR) activation might be a critical cause of the inherent resistance against B-Raf<sup>V600E</sup> inhibition in colorectal cancer.<a onclick="showRef(event, 'ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref25 ref26">(25, 26)</a> A combinational therapy of drug <b>1</b> with an EGFR inhibitor has been conducted to effectively overcome the resistance both <i>in vitro</i> and <i>in vivo</i>. More encouragingly, a clinically successful case for the off-label combination of cetuximab (an EGFR monoclonal antibody) with sorafenib (a Raf inhibitor) to treat the metastatic colorectal cancer patient with B-Raf<sup>V600E</sup> mutation was recently reported.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> It was also demonstrated that upregulation of v-erb-b2 avian erythroblastic leukimia viral congene homologue 3 (ERBB3), another member of EGFR kinase family, contributes greatly to the adaptive resistance of melanoma against drug <b>1</b>. Combination of drug <b>1</b> with an ERBB2/EGFR inhibitor lapatinib successfully reduced tumor burden and extended latency of tumor growth in both cultured cancer cells and mouse xenograft models through inactivation of the ERBB3 signal.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Combinational therapy of FDA approved drugs with different mechanisms of action (MOA) is a powerful strategy for the treatment of various cancers.<a onclick="showRef(event, 'ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref35 ref36">(35, 36)</a> However, a synergistic hepatotoxicity was observed in melanoma patients after combinational treatment of drug <b>1</b> with another FDA approved antimelanoma antibody ipilimumab, suggesting the requirement of careful protocol design for combinational therapies to avoid the potential drug–drug interaction.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Thus, dual inhibition of B-Raf and EGFR by using a single compound may provide a novel promising and manageable strategy for the treatment of colorectal cancer patients with B-Raf <sup>V600E</sup> mutation.</div><div class="NLM_p last">Several molecules have been reported to show nonselective dual inhibition against both B-Raf and EGFR kinases.<a onclick="showRef(event, 'ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref38 ref39">(38, 39)</a> However, to the best of our knowledge, there is rarely a successful report on the treatment of intrinsic resistant colorectal cancers by using a B-Raf/EGFR dual inhibitor. Herein, we would like to describe the discovery of a class of 1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridine-5-carboxamides as novel dual inhibitors of B-Raf<sup>V600E</sup> and EGFR kinases. The compounds potently inhibited the kinase activities of both B-Raf<sup>V600E</sup> and EGFR with low nanomolar IC<sub>50</sub> values. Furthermore, the compounds also displayed potent inhibition on the proliferation of a panel of vemurafenib-resistant cancer cells with high levels of EGFR, representing new leads for further development of B-Raf/EGFR dual inhibitors to overcome the resistance against FDA approved drug <b>1</b>.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41426" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41426" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The synthesis of compounds <b>4</b>, <b>5a</b>–<b>o</b>, and <b>6a</b>–<b>f</b> is illustrated in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>. Briefly, commercially available compound <b>7</b> was coupled with different carboxylic acids <b>8</b> under the catalysis of benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) to produce the benzamides <b>9</b>. Compounds <b>9</b> were hydrogenated to provide the anilines <b>10</b>. Compounds <b>10</b> could react with different aromatic acids <b>13</b> or <b>16</b> to afford the final products <b>4</b>, <b>5a</b>–<b>o</b>, and <b>6a</b>–<b>f</b> by using another coupling reagent 1-[bis(dimethylamino)methylene]-1<i>H</i>-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (HATU). It was noteworthy that the amino group in <b>13a</b> should be protected with the butoxycarbonyl group before it could effectively couple with the aniline <b>10</b> to afford inhibitor <b>5f</b>. The commercially unavailable intermediates <b>13</b> and <b>16</b> could be readily prepared by using compounds <b>11</b> or <b>14</b>, respectively, by utilizing the Pd-catalyzed carbonyl insertion coupling reaction,<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> followed by standard hydrolysis.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm500007h/production/images/medium/jm-2014-00007h_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm500007h/production/images/large/jm-2014-00007h_0006.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Syntheses of Compounds <b>4</b>, <b>5</b>, and <b>6</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm500007h/production/images/large/jm-2014-00007h_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500007h&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) PyBOP, Et<sub>3</sub>N, THF, rt, 12 h, 46–85%; (b) H<sub>2</sub>, 10% Pd/C, CH<sub>3</sub>OH, rt, 8 h, 68–92%; (c) HATU, DIEA, DMF, rt, 12 h, 47–62%; (d) Pd(OAc)<sub>2</sub>, 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene, Et<sub>3</sub>N, CH<sub>3</sub>OH, CO, 100 °C, 12 h, 52–83%; (e) LiOH, MeOH:THF:H<sub>2</sub>O (1:1:2), rt, 3.0 h, 44–89%.</p></p></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88868" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88868" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In order to identify novel B-Raf/EGFR dual inhibitors for overcoming the intrinsic resistance of colorectal cancers against the current B-Raf inhibitor therapy, we conducted a random screening on our self-constructed-kinase-inhibitor focused library. Compound <b>4</b> was discovered to display good inhibitory activities against both B-Raf<sup>V600E</sup> and EGFR, with IC<sub>50</sub> values of 551 nM and 550 nM, respectively (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). Similar to the reported data, drug <b>1</b> potently inhibits the kinase activity of B-Raf <sup>V600E</sup> mutant with an IC <sub>50</sub> value of 26 nM,<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> but it is almost totally inactive against EGFR. However, gefitinib (<b>3</b>), an FDA approved EGFR inhibitor, strongly inhibits EGFR with a 1.0 nM IC<sub>50</sub> value,<a onclick="showRef(event, 'ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref42 ref43">(42, 43)</a> but its potency on B-Raf is minor.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. <i>In Vitro</i> Kinase Inhibitory Activities of the New Inhibitors against B-Raf <sup>V600E</sup> and EGFR and Their Antiproliferation Effects</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm500007h/production/images/medium/jm-2014-00007h_0007.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm500007h/production/images/medium/jm-2014-00007h_0008.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">B-Raf <sup>V600E</sup> kinase activity assays were performed using the FRET-based Z′-Lyte assays according to the manufacturer’s instructions.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> The compounds were incubated with the kinase reaction mixture for 1–1.5 h before measurement. Reported data are the means from 2 independent experiments.</p></div><div class="footnote" id="t1fn3"><sup>Table b</sup><p class="last">EGFR kinase activity assays were performed using the FRET-based Z′-Lyte assays according to the manufacturer’s instructions.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> The compounds were incubated with the kinase reaction mixture for 1–1.5 h before measurement. Reported data are the means from 2 independent experiments.</p></div><div class="footnote" id="t1fn2"><sup>Table c</sup><p class="last">The antiproliferative activities of the compounds were evaluated using the MTS assay. Data are reported as the means ± SDs (standard deviations) from at least three independent experiments.</p></div></div><div></div></div><div class="NLM_p">Extensive structural optimization of the lead compound (<b>4</b>) was conducted to improve its dual inhibition against EGFR and B-Raf<sup>V600E</sup> (Chart <a class="ref internalNav" href="#cht1" aria-label="1">1</a>) and the results are summarized in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>. We first investigated the potential impact of the nitrogen atom in aromatic ring A of compound <b>4</b> on its dual inhibition against EGFR and B-Raf <sup>V600E</sup> kinases by altering the position of the N-atom. It was found that the position of the N-atom displayed diverse effects on the inhibitory activity on EGFR and B-Raf <sup>V600E</sup>. Although the 2-pyridinylcarboxyl-derivative (<b>5a</b>) displayed similar potencies on both EGFR and B-Raf <sup>V600E</sup> to that of compound <b>4</b>, the 4<i>-</i>pyridinylcarboxyl-compound <b>5b</b> totally lost its suppressive effect on EGFR, while its inhibitory potency on B-Raf<sup>V600E</sup> was improved about 5-fold. Interestingly, the benzamide compound <b>5c</b> also selectively suppressed the kinase function of B-Raf<sup>V600E</sup> with an IC<sub>50</sub> value of 240 nM, while the inhibitory effect on EGFR was totally abolished. Pyrazine-2-carboxamide (<b>5d</b>) and pyrimidine-5-carboxamide (<b>5e</b>) analogues were also designed and synthesized. Both of the compounds showed moderate inhibitory activities against both B-Raf and EGFR kinases with IC<sub>50</sub> values of 280 and 670 nM, and 3.90 and 1.92 μM, respectively. Further investigation revealed that the introduction of a 2-amino group (<b>5f</b>) in compound <b>5e</b> hardly affected its suppressing potency on B-Raf <sup>V600E</sup>, but the inhibitory effect on EGFR was significantly improved about 50-fold. The IC<sub>50</sub> values of compound <b>5f</b> against B-Raf and EGFR were 410 and 43 nM, respectively, representing a new lead compound for further structural optimization. However, when a 6-hydroxyl group was introduced in compound <b>4</b>, the resulting compound <b>5g</b> totally failed to suppress the function of B-Raf. Its inhibitory potency on EGFR was also obviously decreased about 3-fold.</div><figure id="cht1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm500007h/production/images/medium/jm-2014-00007h_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm500007h/production/images/large/jm-2014-00007h_0001.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 1. Strategies for the Structural Optimization of Initial “Hit” Compound <b>4</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm500007h/production/images/large/jm-2014-00007h_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500007h&amp;id=cht1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We further investigated the impact of the substituent on the 2-amino group on the B-Raf/EGFR dual inhibition by adopting compound <b>5f</b> as a new starting point. It was found that the compound is well tolerated to the N-substitution for the dual inhibition on B-Raf and EGFR. The <i>N</i>-methyl (<b>5h</b>), <i>N</i>-ethyl (<b>5i</b>), <i>N-</i>iropropyl (<b>5j</b>), <i>N-</i>cyclopropyl (<b>5k</b>), and <i>N</i>-cyclopentyl (<b>5l</b>) analogues displayed similar potencies on both B-Raf<sup>V600E</sup> and EGFR to that of compound <b>5f</b>. Interestingly, although the <i>N</i>-phenyl compound <b>5n</b> showed an IC<sub>50</sub> value of 210 nM on B-Raf <sup>V600E</sup> similar to that of <b>5f</b> (about 410 nM), its EGFR inhibitory effect is 10-fold more potent, and the IC<sub>50</sub> value is about 6.0 nM. However, the <i>N</i>-cyclohexyl derivative (<b>5m</b>) showed about 8 times more improvement on the B-Raf suppressing effect, while its inhibitory activity on EGFR was almost identical to that of the lead compound <b>5f</b>. The IC<sub>50</sub> values of compound <b>5m</b> on B-Raf<sup>V600E</sup> and EGFR were 37 and 47 nM, respectively. Further investigation suggested that the N,N-disubstitution is detrimental to the compound’s inhibitory activity on EGFR kinase, although it barely affects the inhibition on B-Raf. For instance, the <i>N,N</i>-dimethyl analogue (<b>5o</b>) displayed an IC<sub>50</sub> value of 300 nM on B-Raf<sup>V600E</sup>, which is almost identical to that of <b>5f</b>, but its IC<sub>50</sub> value on EGFR is over 100 times greater than that of the lead compound, highlighting the critical role of a hydrogen bond donating moiety for the EGFR suppressing function.</div><div class="NLM_p">Inspired by the above investigation, compounds containing either a pyrrolo[2,3-<i>b</i>]pyridinyl (<b>6a</b>) or 1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridinyl (<b>6b</b>) motif were designed by utilizing a conformation-constraining strategy. It was shown that both <b>6a</b> and <b>6b</b> displayed potencies against B-Raf<sup>V600E</sup> similar to that of <b>5m</b>, with IC<sub>50</sub> values of 51 and 48 nM, respectively, but their activities against EGFR differentiated obviously. Compound <b>6a</b> inhibited EGFR with an IC<sub>50</sub> value of 8 nM, which is approximately 6-fold more potent than that of compound <b>5m</b>, while <b>6b</b> displayed an IC<sub>50</sub> value of 30 nM, which is almost identical to that of <b>5m</b>. However, when a 1<i>H</i>-indol-5-yl group was introduced (<b>6c</b>), the resulting compound totally abolished its inhibitory effect on EGFR, and its potency on B-Raf<sup>V600E</sup> was also decreased by a factor of 4. The strongly dual inhibition of compound <b>6a</b> against both EGFR and B-Raf <sup>600E</sup> makes it a highly promising lead compound for further investigation.</div><div class="NLM_p">Further structural modification on <b>6a</b> suggested that the methyl group in ring B is optimal for the dual inhibition against B-Raf and EGFR. When the methyl was removed, although the resulting compound <b>6d</b> maintained a strong inhibition again B-Raf<sup>V600E</sup> with an IC<sub>50</sub> value of 48 nM, its potency on EGFR was dramaticly decreased about 90-fold. Whereas, the replacement of the methyl group with a relatively larger group, i.e., an ethyl (<b>6e</b>) or an isopropyl (<b>6f</b>), induced a significant potency loss both on B-Raf and EGFR.</div><div class="NLM_p">The antiproliferation effects of the new inhibitors against the vemurafenib-induced resistant SK-MEL-28-PR30 melanoma cancer cells (<a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>), which were demonstrated to harbor the B-Raf<sup>V600E</sup> mutant and overexpression of EGFR (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>A), together with the parental SK-MEL-28 cells with B-Raf<sup>V600E</sup> mutation but low level of EGFR, were also investigated (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). Highly consistent to the previous investigation, drug <b>1</b> potently inhibited the growth of the B-Raf<sup>V600E</sup> mutated SK-MEL-28 cells with an IC<sub>50</sub> value of 0.48 μM<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> but is almost totally inactive to suppress the proliferation of the PR30 cancer cells, which express high level of EGFR. Whereas, the selective EGFR inhibitor <b>3</b> did not show obvious growth inhibition on either SK-MEL-28-PR30 or SK-MEL-28 cells. Consistent with their weak dual inhibition against B-Raf <sup>V600E</sup> and EGFR, compounds <b>4</b> and <b>5a</b> only displayed minor suppressing effect on the growth of SK-MEL-28-PR30 and/or SK-MEL-28 cells. Not surprisingly, compounds <b>5b</b>, <b>5d</b>, <b>5e</b>, and <b>5g</b> are inactive to show an antiproliferative effect on the cancer cells, which might be a consequent effect of their poor inhibition against both B-Raf <sup>V600E</sup> and EGFR kinases. However, the dual inhibitor <b>5f</b> displayed moderate inhibition on both of the cancer cell lines with IC<sub>50</sub> values of 1.84 and 1.89 μM. Other novel dual inhibitors, i.e., <b>5h</b>, <b>5i</b>, <b>5j</b>, <b>5k</b>, <b>5l</b>, <b>5m</b>, <b>5n</b>, <b>6d</b>, <b>6e</b>, and <b>6f</b>, also showed low micromolar values to suppress the growth of both vemurafenib-sensitive and vemurafenib-resistant melanoma cancer cells. Encouragingly, we were pleased to find that the two most potent B-Raf <sup>V600E</sup>/EGFR dual inhibitors, <b>6a</b> and <b>6b</b>, displayed the strongest inhibition against the cellular proliferation for both of the cancer cell lines. The compounds potently inhibited the growth of vemurafenib-sensitive SK-MEL-28 melanoma cancer cells with similar IC<sub>50</sub> values to that of clinical drug <b>1</b>, which are 0.13, 0.54, and 0.48 μM. More significantly, they also displayed strong suppression on the proliferation of vemurafenib-resistant SK-MEL-28-PR30 cancer cells with IC<sub>50</sub> values of 0.45 and 0.78 μM. It was also noteworthy that both of the compounds displayed almost identical potencies on the vemurafenib-sensitive and vemurafenib-resistant cancer cells, indicating their potential application to treat the intrinsic and acquired resistant melanoma and/or colorectal cancer cells with both B-Raf<sup>V600E</sup> mutaition and EGFR overexpression.</div><figure id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm500007h/production/images/medium/jm-2014-00007h_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm500007h/production/images/large/jm-2014-00007h_0003.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Clinical drug <b>1</b> potently and sustainably inhibits the activation of the MAPK path way in SK-MEL-28 melanoma cancer cells, but its effect on p-Erk is transient in the vemurafenib-resistant SK-MEL-28-PR30 cells. (A) The vemurafenib-induced resistant cancer cells harbor a high level of EGFR as determined by Western blot analysis but not k-Ras or n-Ras mutation. (B) Drug <b>1</b> potently and sustainably inhibits the activation of the MAPK path way in SK-MEL-28 melanoma cancer cells, but p-Erk reaccumulation was observed in the vemurafenib-resistant SK-MEL-28-PR30 cells after 24 h of treatment of <b>1</b>. Western blots were preformed after SK-MEL-28 and SK-MEL-28-PR30 cells were treated with drug <b>1</b> for the indicated time (2, 24, and 48 h).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm500007h/production/images/large/jm-2014-00007h_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500007h&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Further investigation also revealed that the compounds indeed displayed strong inhibition against the growth of a panel of colorectal cancer cells harboring different states of EGFR and B-Raf mutation (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). For instance, compound <b>6a</b> potently inhibited the growth of HT-29, COLO205, and WiDr colorectal cancer cells which carry the B-Raf <sup>V600E</sup> mutant and a high level of EGFR with IC<sub>50</sub> values of 0.48, 0.22, and 0.67 μM, respectively. Interestingly, the compound also strongly suppressed the proliferation of HCT116 and LOVO colorectal cancer cells with IC<sub>50</sub> values of 1.33 and 0.17 μM, respectively, although the cells harbor wild-type B-Raf.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Compounds <b>6a</b> and <b>6b</b> Potently Inhibit the Proliferation of a Panel of Colorectal Cancer Cells Harboring Different States of EGFR and B-Raf Mutation</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" colspan="7" align="center">Cell Growth Inhibition (IC<sub>50</sub>, μM)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compds</th><th class="colsep0 rowsep0" align="center">cell lines</th><th class="colsep0 rowsep0" align="center">HT-29</th><th class="colsep0 rowsep0" align="center">COLO205</th><th class="colsep0 rowsep0" align="center">HCT116</th><th class="colsep0 rowsep0" align="center">LOVO</th><th class="colsep0 rowsep0" align="center">WiDr</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">B-Raf</th><th class="colsep0 rowsep0" align="center">V600E</th><th class="colsep0 rowsep0" align="center">V600E</th><th class="colsep0 rowsep0" align="center">WT</th><th class="colsep0 rowsep0" align="center">WT</th><th class="colsep0 rowsep0" align="center">V600E</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">EGFR<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">++</th><th class="colsep0 rowsep0" align="center">+</th><th class="colsep0 rowsep0" align="center">++</th><th class="colsep0 rowsep0" align="center">–</th><th class="colsep0 rowsep0" align="center">+</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6a</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.48 ± 0.04</td><td class="colsep0 rowsep0" align="left">0.22 ± 0.02</td><td class="colsep0 rowsep0" align="left">1.33 ± 0.07</td><td class="colsep0 rowsep0" align="left">0.17 ± 0.01</td><td class="colsep0 rowsep0" align="left">0.67 ± 0.14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6b</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.78 ± 0.03</td><td class="colsep0 rowsep0" align="left">0.36 ± 0.04</td><td class="colsep0 rowsep0" align="left">1.38 ± 0.19</td><td class="colsep0 rowsep0" align="left">0.48 ± 0.02</td><td class="colsep0 rowsep0" align="left">1.35 ± 0.07</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">The level of EGFR were detected by immunoblotting (<a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>, Figure S1).</p></div><div class="footnote" id="t2fn2"><sup>b</sup><p class="last">The antiproliferative activities of the compounds were evaluated using the MTS assay. Data are reported as the means ± SDs (standard deviations) from at least three independent experiments.</p></div></div></div><div class="NLM_p">The selectivity profile of <b>6a</b> against a panel of 456 kinases (including 395 different wild-type kinases) was also investigated by using the KINOMEscan platform (Ambit Bioscience, San Diego, USA) at a concentration of 1.0 μM, which was about 20–125 times its IC<sub>50</sub> values against B-Raf<sup>V600E</sup> and EGFR kinases, respectively. It was found that, in addition to its dual inhibition against EGFR and B-Raf<sup>V600E</sup>, compound <b>6a</b> also exhibited strong suppression on ERRB2, ERRB4, and PDGFRβ kinases, which have been demonstrated to indirectly mediate (i.e., ERRB2 through ERRB3<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a>) or directly link (PDGFRβ<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a>) with the acquired resistance of melanoma. However, special attention is also required to further investigate the potential safety issue of <b>6a</b> associated with its relatively broad inhibition on a panel of other kinases (<a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>).</div><div class="NLM_p">In order to further validate the dual inhibitory effects of new inhibitors, we investigated their suppressive functions on the activation of the MAPK signal pathway and the phosporylation of EGFR protein in self-constructed SK-MEL-28-PR30 cells which have been demonstrated to harbor B-Raf<sup>V600E</sup> mutation and EGFR amplification (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>A) by taking compound <b>6a</b> as an example. As shown in Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>, the treatment of compound <b>6a</b> indeed caused a dose-dependent reduction of the phosphorylation of Erk in SK-MEL-28-PR30 cells, indicating the blockage of the MAPK signal pathway. Furthermore, the activation of EGFR was also obviously inhibited by <b>6a</b>, while the total protein levels of EGFR, Erk, and GAPDH remained unchanged. Further investigation demonstrated that the compound also potently blocked the MAPK signal pathway and suppressed the activation of EGFR in WiDr, HT29 colorectal cancer cells, and A375 melanoma cancer cells which express a relatively high level of EGFR and B-Raf<sup>V600E</sup> mutation.</div><figure id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm500007h/production/images/medium/jm-2014-00007h_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm500007h/production/images/large/jm-2014-00007h_0004.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Inhibitor <b>6a</b> dose-dependenty inhibits the activation of the MAPK path way and the phosphorylation of EGFR in SK-MEL-28 PR30, A375 melanoma cancer cells, and WiDr, HT29 colorectal cancer cells. Western blots were performed after the cells were treated with <b>6a</b> for 2.0 h.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm500007h/production/images/large/jm-2014-00007h_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500007h&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Similar to the previous data obtained from WiDr colorectal cancer cell models,<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> our investigation also demonstrated that although drug <b>1</b> induced highly potent and sustainable suppression on the activation of MAPK signal pathway in vemurafenib-sensitive SK-MEL-28 melanoma cancer cells, its effect on p-Erk is transient, and significant reaccumulation of p-Erk could be observed in the vemurafenib-resistant SK-MEL-28-PR30 cells after 24 h (Figures <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>B and <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>). The unsustainable inhibition on the MAPK pathway may contribute greatly to the intrinsic and acquired insensitivity of B-Raf mutated melanoma and/or colorectal cancer cells to drug <b>1</b>. In order to get a better understanding on the strong inhibition of <b>6a</b> against the proliferation of vemurafenib-resistant SK-MEL-28-PR 30 cells, we also investigated the suppressing effect of this compound on the activation of p-Erk at different time courses. It was shown that compound <b>6a</b> sustainably inhibited the phosphorylation of Erk at a concentration of 1.0 μM and that p-Erk suppression was successfully maintained after 48-h treatments. As a parallel comparison, drug <b>1</b> only displayed a transient inhibition on the phosphorylation of Erk at 1.0 μM, and the p-Erk was significantly reaccumulated in 48 h, which may be due to a consequent upregulation of erbB3 by the transphosphorylation partner EGFR.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> A similar sustainable inhibition of p-Erk by <b>6a</b> was also observed in WiDr colorectal cancer cells. These results strongly support the potential of these compounds to overcome the intrinsic and acquired resistant melanoma and/or colorectal cancer cells with EGFR overexpression.</div><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm500007h/production/images/medium/jm-2014-00007h_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm500007h/production/images/large/jm-2014-00007h_0005.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Inhibitor <b>6a</b> potently and sustainably inhibits the activation of the MAPK path way in SK-MEL-28 PR30 melanoma cancer cells and WiDr colorectal cancer cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm500007h/production/images/large/jm-2014-00007h_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500007h&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In summary, a series of 1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridine-5-carboxamide analogues were identified as novel dual inhibitors of the EGFR and B-Raf<sup>V600E</sup> mutant. The compounds potently inhibited both of the kinases with low nanomolar IC<sub>50</sub> values and strongly suppressed the proliferation of a panel of intrinsic and acquired resistant melanoma and/or colorectal cancer cells harboring overexpressed EGFR with submicromolar IC<sub>50</sub> values. Furthermore, the representative compounds <b>6a</b> also displayed potent and sustainable inhibition against the activation of the MAPK path way in the resistant SK-MEL-28 PR30 melanoma cancer cells and WiDr colorectal cancer cells, suggesting that the EGFR/B-Raf<sup>V600E</sup> dual inhibition, at least in part, might be a tractable strategy to overcome the intrinsic and acquired resistance of melanoma and/or colorectal cancers against the current B-Raf<sup>V600E</sup> inhibitor therapy. Further structural optimization to improve pharmacokinetic properties, <i>in vivo</i> pharmacodynamic evaluation, and molecular mechanism studies on this class of compounds are in progress and will be reported in due course. However, it is also noteworthy that EGFR amplification is not the only key player for the intrinsic and acquired resistance of melanoma and/or colorectal cancer cells against current B-Raf inhibitors. New medicinal chemistry efforts based on an understanding of the extensive mechanism will be highly worthwhile for overcoming the resistance.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18766" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18766" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> General Methods for Chemistry</h3><div class="NLM_p last">All reagents and solvents were used directly as purchased from commercial sources. Flash chromatography was performed using silica gel (300 mesh). All reactions were monitored by TLC, using silica gel plates with fluorescence F<sub>254</sub> and UV light visualization. <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were recorded on a Bruker AV-400 spectrometer at 400 MHz and a Bruker AV-500 spectrometer at 125 MHz. Coupling constants (<i>J</i>) are expressed in hertz (Hz). Chemical shifts (δ) of NMR are reported in parts per million (ppm) units relative to an internal control (TMS). Low resolution ESI-MS were recorded on an Agilent 1200 HPLC-MSD mass spectrometer and high resolution ESI-MS on an Applied Biosystems Q-STAR Elite ESI-LC-MS/MS mass spectrometer. The purity of compounds was determined by reverse-phase high performance liquid chromatography (HPLC) analysis to be >95%. HPLC instrument, Dionex Summit HPLC (column, Diamonsil C18, 5.0 μm, 4.6 × 250 mm (Dikma Technologies); detector, PDA-100 photodiode array; injector, ASI-100 autoinjector; pump, p-680A). A flow rate of 1.0 mL/min was used with a mobile phase of MeOH in H<sub>2</sub>O with a 0.1% modifier (ammonia or trifluoroacetate, v/v).</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> 4-Methyl-<i>N</i>-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-nitrobenzamide <b>9a</b></h3><div class="NLM_p last">4-((4-Methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)aniline <b>7</b> (7.97g, 44.0 mmol) and 4-methyl-3-nitrobenzoic acid <b>8a</b> (10.00g, 36.6 mmol) were stirred in 20 mL of dry tetrahydrofuran (THF) at room temperature. To the mixture, PyBOP (28.60g, 54.9 mmol) and triethylamine (8.2 mL, 58.56 mmol) were added. The resulting mixture was stirred at room temperature overnight, and then the organic solvent was removed under vacuum. The resulting residue was diluted with water and extracted with ethyl acetate (2 × 50 mL). The combined organic layer was dried over anhydrous sodium sulfate and concentrated under vacuum and then purified by column chromatography over silica gel to afford pure compound <b>9a</b> (7.50g, yield: 50%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.61 (s, 1 H), 8.53 (d, <i>J</i> = 1.6 Hz, 1 H), 8.14 (dd, <i>J</i> = 9.6 Hz, 1.6 Hz, 1 H), 8.10 (d, <i>J</i> = 2.0 Hz, 1 H), 7.81 (dd, <i>J</i> = 8.4 Hz, 1.6 Hz, 1 H), 7.91 (d, <i>J</i> = 8.4 Hz, 1 H), 7.41 (d, <i>J</i> = 8.0 Hz, 1 H), 3.62 (s, 2 H), 3.31–2.23(m, 8 H), 2.83 (s, 3 H), 2.59 (s, 3 H). Compounds <b>9b</b>–<b>d</b> were synthesized by using a similar procedure; yield, 46–85%.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> 3-Amino-4-methyl-<i>N</i>-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl) benzamide <b>10a</b></h3><div class="NLM_p last">To a solution of <b>9a</b> (7.50g, 17.2 mmol) in 30 mL of methanol, 0.75g Pd/C was added, and the reaction flask was evacuated and backfilled with hydrogen twice. The reaction mixture was stirred at room temperature under a hydrogen balloon for 5 h. The reaction mixture was filtered through a pad of Celite and concentrated under vacuum to yield <b>10a</b> (5.20g, yield: 75%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 10.27 (s, 1 H), 8.22 (d, <i>J</i> = 2.0 Hz, 1 H), 8.04 (dd, <i>J</i> = 8.4 Hz, 1.6 Hz, 1 H), 7.66 (d, <i>J</i> = 8.4 Hz, 1 H), 7.22 (d, <i>J</i> = 1.6 Hz, 1 H), 7.13–7.06 (m, 2 H), 5.08 (s, 2 H), 3.54 (s, 2 H), 3.41 (s, 1 H), 2.48–2.21 (m, 7 H), 2.13 (m, 6 H). Compounds <b>10b</b>–<b>d</b> were synthesized by using a similar procedure; yield, 68–92%.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> 3-Amino-4-ethyl-<i>N</i>-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide <b>10c</b></h3><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 10.29 (s, 1H), 8.21 (d, <i>J</i> = 1 Hz, 1H), 8.05 (d, <i>J</i> = 8.5 Hz, 1H), 7.67 (d, <i>J</i> = 8.5 Hz, 1H), 7.16 (s, 1H), 7.11 (d, <i>J</i> = 8.0 Hz, 1H), 7.06 (d, <i>J</i> = 8.0 Hz, 1H), 5.12 (s, 2H), 3.61 (s, 2H), 2.84 −2.49 (m, 8H), 2.51 (q, <i>J</i> = 7.5 Hz, 2H), 1.15 (t, <i>J</i> = 7.5 Hz, 3H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 166.99, 147.41, 146.48, 139.19, 133.27, 131.73, 131.28, 131.18, 128.22, 123.67, 117.51, 115.65, 113.92, 60.15, 57.35, 54.07 (2C), 51.21, 44.07, 23.84, 13.35; MS (ESI), <i>m</i>/<i>z</i> 421 [M + H]<sup>+</sup>.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> <i>N</i>-(2-Methyl-5-((4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl) phenyl)nicotinamide <b>4.</b></h3><div class="NLM_p">To a solution of <b>10a</b> (100.0 mg, 0.25 mmol) in 5 mL of <i>N</i>,<i>N</i>-dimethylformamide (DMF), 46.4 mg of nicotinic acid (0.38 mmol), (1-[bis(dimethylamino) methylene]-1<i>H</i>-1,2,3-triazolo[4,5-<i>b</i>]pyridinium 3-oxid hexafluorophosphate) (HATU) (140.1 mg, 0.37 mmol), and <i>N</i>,<i>N-</i>diisopropylethylamine (DIPEA) (0.13 mL, 0.75 mmol) were added. The resulting mixture was stirred at room temperature overnight. The reaction was quenched with water and extracted with ethyl acetate (3 × 20 mL). The combined organic layer was dried over anhydrous sodium sulfate, concentrated under vacuum, and then purified by column chromatography over silica gel to afford pure compound <b>4</b> (72.9 mg) (yield: 57%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 10.47 (s, 1 H), 10.27 (s, 1 H), 9.17 (s, 1 H), 8.79 (d, <i>J</i> = 3.6 Hz, 1 H), 8.34 (d, <i>J</i> = 7.6 Hz, 1 H), 8.20 (s, 1 H), 8.06 (d, <i>J</i> = 8.0 Hz, 1 H), 8.01 (s, 1 H), 7.85 (d, <i>J</i> = 8.0 Hz, 1 H), 7.70 (d, <i>J</i> = 4.4 Hz, 1 H), 7.60 (dd, <i>J</i> = 4.8 Hz, 7.6 Hz, 1 H), 7.48 (d, <i>J</i> = 8.0 Hz, 1 H), 3.56 (s, 2H), 2.40–2. 32 (m, 11 H), 2.16 (s, 3 H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 165.10, 164.19, 152.30, 148.70, 138.27, 138.23, 136.17, 135.50, 132.37, 132.03, 131.27, 130.55, 129.94, 127.54, 126.02, 125.51, 123.65, 123.57, 117.38, 117.30, 57.45, 54.68(2C), 52.62(2C), 45.63, 18.00. HRMS (ESI) calcd for C<sub>27</sub>H<sub>28</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 512.2268; found, 512.2272. HPLC purity = 97.06%, Rt 5.82 min.</div><div class="NLM_p last">Compounds <b>5a</b>–<b>o</b> and <b>6a</b>–<b>f</b> were synthesized by using a similar procedure.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> <i>N</i>-(2-Methyl-5-((4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl) carbamoyl) phenyl)picolinamide <b>5a</b></h3><div class="NLM_p last">Yield: 52%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 10.47 (s, 1 H), 10.27 (s, 1 H), 9.17 (d, <i>J</i> = 1.5 Hz, 1 H), 8.79 (dd, <i>J</i> = 4.8, 1.5 Hz, 1 H), 8.34 (d, <i>J</i> = 8.0 Hz, 1 H), 8.20 (d, <i>J</i> = 1.8 Hz, 1 H), 8.07 (d, <i>J</i> = 8.4 Hz, 1 H), 8.01 (s, 1 H), 7.85 (dd, <i>J</i> = 8.0 Hz, 1.5 Hz, 1 H), 7.70 (d, <i>J</i> = 8.5 Hz, 1 H), 7.60 (dd, <i>J</i> = 7.7 Hz, 4.8 Hz, 1 H), 7.48 (d, <i>J</i> = 8.1 Hz, 1 H), 3.56 (s, 2 H), 2.39–2.33 (m, 11 H), 2.18 (s, 3 H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 165.16, 164.25, 152.34, 148.72, 138.32, 138.26, 136.20, 135.55, 132.40, 132.04, 131.32, 130.61, 129.97, 126.05, 125.56, 123.71(2C), 123.62, 117.19, 117.08, 57.45, 54.66(2C), 52.55(2C), 45.56, 18.03. HRMS (ESI) calcd for C<sub>27</sub>H<sub>28</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 512.2268; found, 512.2266. HPLC purity = 95.01%, Rt 6.16 min.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> <i>N</i>-(2-Methyl-5-((4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl) carbamoyl) phenyl)isonicotinamide <b>5b.</b></h3><div class="NLM_p last">Yield: 61%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 10.46 (s, 1 H), 10.34 (s, 1 H), 8.81 (dd, <i>J</i> = 4.4 Hz, 1.6 Hz, 2 H), 8.20 (d, <i>J</i> = 2.0 Hz, 1 H), 8.07 (dd, <i>J</i> = 8.8 Hz, 1.8 Hz, 1 H), 8.01 (d, <i>J</i> = 1.2 Hz, 1 H), 7.92–7.90 (m, 2 H), 7.86 (dd, <i>J</i> = 8.0 Hz, 1.8 Hz, 1 H), 7.70 (d, <i>J</i> = 8.8 Hz, 1 H), 7.47 (d, <i>J</i> = 8.0 Hz, 1 H), 3.56 (s, 2 H), 2.50–2.33 (m, 11 H), 2.16 (s, 3 H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 164.96, 164.03, 150.35(2C), 141.25, 138.22, 135.93, 132.36, 131.97, 131.17, 130.50, 127,48, 127.25, 126.00, 125.62, 123.49, 121.53(2C), 117.28, 117.23, 57.41, 54.67(2C), 52.62(2C), 45.63, 17.91. HRMS (ESI) calcd for C<sub>27</sub>H<sub>28</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 512.2268; found, 512.2269. HPLC purity = 97.9%, Rt 5.82 min.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> 3-Benzamido-4-methyl-<i>N</i>-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl) phenyl) benzamide <b>5c</b></h3><div class="NLM_p last">Yield: 65%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 10.48 (s, 1 H), 10.08 (s, 1 H), 8.21 (s, 1 H), 8.7 (d, <i>J</i> = 8.5 Hz, 1 H), 8.03 (s, 1 H), 8.01 (s, 2 H), 7.83 (d, <i>J</i> = 8 Hz, 1 H), 7.70 (d, <i>J</i> = 8.5 Hz, 1 H), 7.63–7.53 (m, 3 H), 7.46 (d, <i>J</i> = 8.0 Hz, 1 H), 3.56 (s, 2 H), 2.50–2.31 (m, 11 H), 2.15 (s, 3 H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 165.46, 165.06, 138.23, 136.58, 134.25, 132.25, 131.93, 131.63, 131.16, 130.37, 128.42, 127.61, 127.47, 127.23, 126.02, 125.40, 125.23, 123.48, 123.22, 117.26, 117.21, 57.41, 54.67(2C), 52.64(2C), 45.64, 17.96. HRMS (ESI) calcd for C<sub>28</sub>H<sub>29</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 511.2316; found, 511.2314. HPLC purity = 98.6%, Rt 7.23 min.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> <i>N</i>-(2-Methyl-5-((4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl) carbamoyl) phenyl)pyrazine-2-carboxamide <b>5d</b></h3><div class="NLM_p last">Yield: 47%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 10.48 (s, 2 H), 9.33 (s, 1 H), 8.97 (d, <i>J</i> = 2.3 Hz, 1 H), 8.85 (s, 1 H), 8.24 (s, 1 H), 8.20 (s, 1 H), 8.07 (d, <i>J</i> = 8.5 Hz, 1 H), 7.83 (d, <i>J</i> = 7.9 Hz, 1 H), 7.70 (d, <i>J</i> = 8.0 Hz, 1 H), 7.47 (d, <i>J</i> = 8.0 Hz, 1 H), 3.56 (s, 2 H), 2.48–2.25 (m, 11 H), 2.17 (s, 3 H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 165.23, 161.80, 148.03, 144.62, 143.92, 143.52, 138.27, 136.77, 135.84, 132.53, 132.02, 131.30, 130.50, 127.58, 125.47, 125.13, 124.54, 123.59, 117.32, 57.46, 54.67(2C), 52.57(2C), 45.59, 17.78. HRMS (ESI) calcd for C<sub>26</sub>H<sub>27</sub>F<sub>3</sub>N<sub>6</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 513.2221; found, 513.2228. HPLC purity = 99.64%, Rt 7.01 min.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> <i>N</i>-(2-Methyl-5-((4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl) carbamoyl) phenyl)pyrimidine-5-carboxamid <b>5e</b></h3><div class="NLM_p last">Yield: 45%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 10.48(s, 1 H), 10.42 (s, 1 H), 9.40 (s, 1 H), 9.32 (s, 2 H), 8.20 (s, 1 H), 8.19–8.03 (m, 2 H), 7.86 (dd, <i>J</i> = 8.0 Hz, 1.8 Hz, 1 H), 7.70 (d, <i>J</i> = 8.4 Hz, 1 H), 7.48 (d, <i>J</i> = 8.0 Hz, 1 H), 3.56 (s, 2 H), 2.39–2.35 (m, 11 H), 2.15 (s, 3 H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 164.98, 162.34, 160.27, 156.23(2C), 138.18, 138.00, 135.74, 132.40, 131.99, 131.19, 130.54, 127.96, 127.24, 125.81, 125.54, 123.50, 117.28, 117.23, 57.42, 54.68(2C), 52.65(2C), 45.66, 17.96. HRMS (ESI) calcd for C<sub>26</sub>H<sub>27</sub>F<sub>3</sub>N<sub>6</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 513.2221; found, 513.2229. HPLC purity = 98.70%, Rt 5.90 min.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> 2-Amino-<i>N</i>-(2-methyl-5-((4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl) phenyl) carbamoyl)phenyl)pyrimidine-5-carboxamide <b>5f</b></h3><div class="NLM_p last">Yield: 38%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 10.47 (s, 1 H), 9.88 (s, 1 H), 8.83 (s, 2 H), 8.20 (s, 1 H), 8.06 (d, <i>J</i> = 8.4 Hz, 1 H), 7.98 (s, 1 H), 7.81 (d, <i>J</i> = 7.6 Hz, 1 H), 7.69 (d, <i>J</i> = 8.4 Hz, 1 H), 7.44 (d, <i>J</i> = 8.0 Hz,1 H) 7.34 (s, 2 H), 3.56 (s, 2 H), 2.49–2.30 (m, 11 H), 2.20 (s, 3 H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 165.73, 164.74, 163.64, 158.81(2C), 138.67, 138.50, 136.61, 132.59, 132.35, 131.73, 128.00, 127.77, 126.29, 125.76, 125.64, 124.02, 123.58, 117.79, 116.69, 57.69, 54.78(2C), 52.57(2C), 45.59, 18.33; HRMS (ESI) calcd for C<sub>26</sub>H<sub>28</sub>F<sub>3</sub>N<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 528.2330; found, 528.2332. HPLC purity = 97.80%, Rt 5.15 min.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> 6-Hydroxy-<i>N</i>-(2-methyl-5-((4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl) carbamoyl) phenyl)nicotinamide <b>5g</b></h3><div class="NLM_p last">Yield: 56%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 12.10 (s, 1 H), 10.47 (s, 1 H), 9.82 (s, 1 H), 8.21–8.19 (m, 2 H), 8.11 (d, <i>J</i> = 8.4 Hz, 1 H), 7.97 (dd, <i>J</i> = 9.6, 2.8 Hz, 1 H), 7.94 (d, <i>J</i> = 1.6 Hz, 1 H), 7.81 (dd, <i>J</i> = 8.0, 1.6 Hz, 1 H), 7.70 (d, <i>J</i> = 8.8 Hz, 1 H), 7.44 (d, <i>J</i> = 8.4 Hz, 1 H), 6.43 (d, <i>J</i> = 9.6 Hz, 1 H), 3.65 (s, 2 H), 3.30–2.50 (br, 8 H), 2.73 (s, 3 H), 2.29 (s, 3 H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 165.49, 163.15, 162.77, 139.61, 138.65, 138.58, 138.55, 136.85, 132.66, 132.38, 131.61, 130.81, 127.91, 127.67, 126.40, 125.85, 125.55, 123.92, 123.67, 119.45, 117.65, 112.49, 57.87, 55.13(2C), 53.10(2C), 46.12, 18.43; HRMS (ESI) calcd for C<sub>27</sub>H<sub>28</sub>F<sub>3</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 528.2217; found, 528.2220. HPLC purity = 97.72%, Rt 4.43 min.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> <i>N</i>-(2-Methyl-5-((4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl) phenyl)-2-(methylamino)pyrimidine-5-carboxamide <b>5h</b></h3><div class="NLM_p last">Yield: 55%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 10.45 (s, 1 H), 9.86 (s, 1 H), 8.90 (s, 1 H), 8.83 (s, 1 H), 8.20 (s, 1 H), 8.06 (d, <i>J</i> = 8.4 Hz, 1 H), 7.99 (s, 1 H), 7.82–7.80 (m, 2 H), 7.70 (d, <i>J</i> = 8.5 Hz, 1 H), 7.44 (d, <i>J</i> = 7.9 Hz, 1 H), 3.56 (s, 2 H), 2.88 (d, <i>J</i> = 4.6 Hz, 3 H), 2.39–2.30 (m, 11 H), 2.16 (s, 3 H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 165.06, 163.34, 162.98, 158.13 (2C), 138.21, 138.05, 136.37, 132.21, 131.92, 131.17, 130.39, 127.38, 125.84, 125.11, 123.48, 117.25, 117.21, 115.85, 57.40, 54.67 (2C), 52.62 (2C), 45.63, 27.86, 18.01. HRMS (ESI) calcd for C<sub>27</sub>H<sub>30</sub>F<sub>3</sub>N<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 542.2486; found, 542.2486. HPLC purity = 95.62%, Rt 6.35 min.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> 2-(Ethylamino)-<i>N</i>-(2-methyl-5-((4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl) carbamoyl)phenyl)pyrimidine-5-carboxamide <b>5i</b></h3><div class="NLM_p last">Yield: 30%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 10.46 (s, 1 H), 9.85 (s, 1 H), 8.88 (s, 1 H), 8.83 (s, 1 H), 8.20 (s, 1 H), 8.07 (d, <i>J</i> = 8.1 Hz, 1 H), 7.98 (s, 1 H), 7.89 (t, <i>J</i> = 5.7 Hz, 1 H), 7.81 (d, <i>J</i> = 7.9 Hz, 1 H), 7.73–7. 65 (m, 2 H), 7.44 (d, <i>J</i> = 8.1 Hz, 1 H), 3.57 (s, 2 H), 3.38 (q, <i>J</i> = 7.0 Hz, 2 H), 2.40 (s, 7 H), 2.31 (s, 4 H), 2.20 (s, 3 H), 1.15 (t, <i>J</i> = 7.1 Hz, 3 H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 167.02, 165.21, 163.13, 162.84, 158.24, 138.29, 138.15, 136.44, 132.28, 131.94, 131.30, 130.49, 128.69, 125.92, 125.18, 123.59, 123.29, 117.33, 115.91, 57.41, 54.58(2C), 52.41(2C), 45.42, 35.60, 18.06, 14.51. HRMS (ESI) calcd for C<sub>28</sub>H<sub>32</sub>F<sub>3</sub>N<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 556.2643; found, 556.2644. HPLC purity = 99.38%, Rt 6.73 min.</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> 2-(Iisopropylamino)-<i>N</i>-(2-methyl-5-((4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl) phenyl)carbamoyl)phenyl)pyrimidine-5-carboxamide <b>5j</b></h3><div class="NLM_p last">Yield: 52%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 10.46 (s, 1 H), 9.84 (s, 1 H), 8.84 (s, 2 H), 8.20 (s, 1 H), 8.06 (d, <i>J</i> = 8.2 Hz, 1 H), 7.98 (s, 1 H), 7.80 (t, <i>J</i> = 7.8 Hz, 2 H), 7.70 (d, <i>J</i> = 8.5 Hz, 1 H), 7.44 (d, <i>J</i> = 7.8 Hz, 1 H), 4.17–4.11 (m, 1 H), 3.56 (s, 2 H), 2.41–2. 30 (m, 11 H), 2.16 (s, 3 H), 1.18 (d, <i>J</i> = 6.3 Hz, 6 H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 165.07, 162.97, 162.19, 158.16, 158.14, 138.22, 138.01, 136.40, 132.22, 131.92, 131.17, 130.37, 125.82, 125.05, 123.48, 123.22, 117.25, 117.20, 115.72, 57.41, 54.66 (2C), 52.61 (2C), 45.63, 42.25, 22.13 (2C), 18.00. HRMS (ESI) calcd for C<sub>29</sub>H<sub>34</sub>F<sub>3</sub>N<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 570.2799; found, 570.2798. HPLC purity = 98.64%, Rt 7.63 min.</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> 2-(Cyclopropylamino)-<i>N</i>-(2-methyl-5-((4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl) phenyl)carbamoyl)phenyl)pyrimidine-5-carboxamide <b>5k</b></h3><div class="NLM_p last">Yield: 48%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 10.46 (s, 1 H), 9.88 (s, 1 H), 8.88 (s, 2 H), 8.20 (d, <i>J</i> = 2.0 Hz, 1 H), 8.08–8.04 (m, 2 H), 7.99 (d, <i>J</i> = 1.6 Hz, 1 H), 7.82 (dd, <i>J</i> = 7.9, 1.6 Hz, 1 H), 7.70 (d, <i>J</i> = 8.6 Hz, 1 H), 7.45 (d, <i>J</i> = 8.1 Hz, 1 H), 3.56 (s, 2 H), 2.82 (tq, <i>J</i> = 7.5, 3.9 Hz, 1 H), 2.40–2.31 (m, 11 H), 2.15 (s, 3 H), 0.75–0.70 (m, 2 H), 0.55–0.51 (m, 2 H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 165.06, 164.03, 162.96, 158.05, 158.03, 138.21, 138.01, 136.36, 132.23, 131.93, 131.17, 130.38, 125.81, 125.09, 123.48, 117.26, 117.21, 116.50, 57.41, 54.68 (2C), 52.65 (2C), 45.66, 23.95, 17.99, 6.24 (2C). HRMS (ESI) calcd for C<sub>29</sub>H<sub>32</sub>F<sub>3</sub>N<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 528.2643; found, 528.2640. HPLC purity = 96.68%, Rt 6.80 min.</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> 2-(Cyclopentylamino)-<i>N</i>-(2-methyl-5-((4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl) phenyl)carbamoyl)phenyl)pyrimidine-5-carboxamide <b>5l</b></h3><div class="NLM_p last">Yield: 52%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 10.45 (s, 1 H), 9.84 (s, 1 H), 8.85 (s, 2 H), 8.20 (s, 1 H), 8.06 (d, <i>J</i> = 8.0 Hz, 1 H), 7.99 (s, 1 H), 7.90 (d, <i>J</i> = 7.2 Hz, 1 H), 7.81 (d, <i>J</i> = 7.6 Hz, 1 H), 7.69 (d, <i>J</i> = 8.4 Hz, 1 H), 7.43 (d, <i>J</i> = 8.0 Hz, 1 H), 4.27 (t, <i>J</i> = 6.6 Hz, 1 H), 3.56 (s, 2 H), 2.50–2.31 (m, 11 H), 2.18 (s, 3 H), 1.92 (d, <i>J</i> = 3.6 Hz, 2 H), 1.70 (s, 2 H), 1.54 (s, 4 H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 165.09, 163.01, 162.56, 158.08, 138.24, 138.02, 136.41, 132.23, 131.88, 131.17, 130.36, 127.48, 125.84, 125.06, 123.48, 123.22, 117.26, 117.22, 115.75, 57.39, 54.61(2C), 52.53(2C), 52.34, 45.53, 32.04(2C), 23.38(2C), 18.00. HRMS (ESI) calcd for C<sub>31</sub>H<sub>36</sub>F<sub>3</sub>N<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 596.2956; found, 596.2959. HPLC purity = 96.00%, Rt 9.32 min.</div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> 2-(Cyclohexylamino)-<i>N</i>-(2-methyl-5-((4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl) phenyl)carbamoyl)phenyl)pyrimidine-5-carboxamide <b>5m</b></h3><div class="NLM_p last">Yield: 66%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 10.45 (s, 1 H), 9.83 (s, 1 H), 8.84 (s, 2 H), 8.20 (d, <i>J</i> = 1.8 Hz, 1 H), 8.06 (d, <i>J</i> = 8.4 Hz, 1 H), 7.99 (d, <i>J</i> = 1.2 Hz, 1 H), 7.82 (s, 1 H), 7.80 (s, 1 H), 7.70 (d, <i>J</i> = 8.6 Hz, 1 H), 7.44 (d, <i>J</i> = 8.1 Hz, 1 H), 3.82–3.79 (m, 1 H), 3.56 (s, 2 H), 2.47–2. 30 (m, 11 H), 2.15 (s, 3 H), 1.89 (s, 2 H), 1.73 (s, 2 H), 1.60 (d, <i>J</i> = 12.0 Hz, 1 H), 1.30 (dd, <i>J</i> = 16.0, 7.9 Hz, 4 H), 1.18–1.12 (m, 1 H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 165.06, 162.95, 162.19, 158.17, 138.20, 137.99, 136.39, 132.21, 131.92, 131.16, 130.36, 127.22, 125.80, 125.39, 125.05, 123.47, 117.25, 117.20, 115.72, 57.41, 54.68 (2C), 52.65 (2C), 49.45, 45.66, 32.17 (2C), 25.23, 24.68 (2C), 17.98. HRMS (ESI) calcd for C<sub>32</sub>H<sub>38</sub>F<sub>3</sub>N<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 610.3112; found, 610.3114. HPLC purity = 99.42%, Rt 11.84 min.</div></div><div id="sec4_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> <i>N</i>-(2-Methyl-5-((4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl) phenyl)-2-(phenylamino)pyrimidine-5-carboxamide <b>5n</b></h3><div class="NLM_p last">Yield: 81%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 10.48 (s, 1 H), 10.20 (s, 1 H), 10.04 (s, 1 H), 9.04 (s, 2 H), 8.20 (s, 1 H), 8.05–8.02 (m, 2 H), 7.80–7.78 (m, 3 H), 7.71 (s, 1 H), 7.46 (d, <i>J</i> = 6.4 Hz, 1 H), 7.34 (s, 2 H), 7.03 (s, 1 H), 3.56 (s, 2 H), 2.49–2.33 (m, 11 H), 2.18 (s, 3 H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 165.61, 163.17, 161.27, 158.48(2C), 139.84, 138.58, 138.55, 136.58, 132.68, 132.37, 131.69, 130.95, 129.02(2C), 126.26, 125.70, 123.99, 123.02, 120.21(2C), 118.69, 117.71, 57.77, 54.93(2C), 52.78(2C), 45.79, 18.40; HRMS (ESI) calcd for C<sub>32</sub>H<sub>32</sub>F<sub>3</sub>N<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 604.2643; found, 604.2642. HPLC purity = 99.42%, Rt 8.29 min.</div></div><div id="sec4_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> 2-(Dimethylamino)-<i>N</i>-(2-methyl-5-((4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl) phenyl)carbamoyl)phenyl)pyrimidine-5-carboxamide <b>5o</b></h3><div class="NLM_p last">Yield: 71%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 10.47 (s, 1 H), 9.90 (s, 1 H), 8.91 (s, 2 H), 8.20 (s, 1 H), 8.06 (d, <i>J</i> = 7.6 Hz, 1 H), 7.99 (s, 1 H), 7.81 (d, <i>J</i> = 7.6 Hz, 1 H), 7.69 (d, <i>J</i> = 7.6 Hz, 1 H), 7.40 (d, <i>J</i> = 7.6 Hz, 1 H), 3.56 (s, 2 H), 3.21 (s, 6 H), 2.50–2.31 (m, 11 H), 2.19 (s, 3 H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 165.63, 163.58, 162.54(2C), 138.58, 136.69, 132.62, 132.29, 131.70, 130.91, 126.27, 125.61, 123.98, 117.72, 115.47, 57.72, 54.83(2C), 52.61(2C), 45.61, 37.21(2C), 18.37; HRMS (ESI) calcd for C<sub>28</sub>H<sub>32</sub>F<sub>3</sub>N<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 556.2643; found, 556.2641. HPLC purity = 97.80%, Rt 7.51 min.</div></div><div id="sec4_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> <i>N</i>-(2-Methyl-5-((4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl) phenyl)-1<i>H</i>-pyrrolo[2,3-b]pyridine-5-carboxamide <b>6a</b></h3><div class="NLM_p last">Yield: 63%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 11.99 (s, 1 H), 10.47 (s, 1 H), 10.09 (s, 1 H), 8.88 (d, <i>J</i> = 2.4 Hz, 1 H), 8.61 (d, <i>J</i> = 1.6 Hz, 1 H), 8.21 (d, <i>J</i> = 2.0 Hz, 1 H), 8.07 (d, <i>J</i> = 8.4 Hz, 1 H), 8.04 (d, <i>J</i> = 1.3 Hz, 1 H), 7.83 (dd, <i>J</i> = 7.9, 1.6 Hz, 1 H), 7.70 (d, <i>J</i> = 8.5 Hz, 1 H), 7.62–7.60 (m, 1 H), 7.47 (d, <i>J</i> = 8.0 Hz, 1 H), 6.62 (dd, <i>J</i> = 3.4, 1.6 Hz, 1 H), 3.57 (s, 2 H), 2.40–2.34 (m, 11 H), 2.19 (s, 3 H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 165.29, 165.11, 160.91, 149.69, 142.77, 138.24, 138.13, 136.72, 132.22, 131.86, 131.18, 130.37, 128.02, 127.74, 127.47, 125.96, 125.09, 123.48, 122.04, 118.71, 117.26, 117.21, 100.97, 57.37, 54.59 (2C), 52.49 (2C), 45.49, 18.02. HRMS (ESI) calcd for C<sub>29</sub>H<sub>29</sub>F<sub>3</sub>N<sub>6</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 551.2377; found, 551.2375. HPLC purity = 96.06%, Rt 6.60 min.</div></div><div id="sec4_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> <i>N</i>-(2-Methyl-5-((4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl) phenyl)-1<i>H</i>-pyrazolo[3,4-b]pyridine-5-carboxamide <b>6b</b></h3><div class="NLM_p last">Yield: 42%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 13.98 (s, 1 H), 10.48 (s, 1 H), 10.25 (s, 1 H), 9.12 (d, <i>J</i> = 1.9 Hz, 1 H), 8.88 (d, <i>J</i> = 1.9 Hz, 1 H), 8.35 (s, 1 H), 8.20 (s, 1 H), 8.08–8.03 (m, 2 H), 7.84 (d, <i>J</i> = 7.9 Hz, 1 H), 7.70 (d, <i>J</i> = 8.5 Hz, 1 H), 7.48 (d, <i>J</i> = 8.1 Hz, 1 H), 3.56 (s, 2 H), 2.48–2.23 (m, 11 H), 2.15 (s, 3 H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 165.09, 164.52, 152.57, 148.71, 138.26, 138.13, 136.46, 134.65, 132.32, 131.87, 131.20, 130.46, 130.37, 127.51, 127.27, 125.95, 125.41, 123.50, 123.23, 117.29, 117.24, 113.62, 57.36, 54.55(2C), 52.41(2C), 45.40, 18.03. HRMS (ESI) calcd for C<sub>28</sub>H<sub>28</sub>F<sub>3</sub>N<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 552.2330; found, 552.2331. HPLC purity = 97.48%, Rt 5.97 min.</div></div><div id="sec4_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> <i>N</i>-(2-Methyl-5-((4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl) phenyl)-1<i>H</i>-indole-5-carboxamide <b>6c</b></h3><div class="NLM_p last">Yield: 57%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 13.36 (s, 1 H), 10.47 (s, 1 H), 10.07 (s, 1 H), 8.53 (s, 1 H), 8.28 (s, 1 H), 8.21 (d, <i>J</i> = 1.6 Hz, 1 H), 8.07 (dd, <i>J</i> = 8.4 Hz, 1.6 Hz, 1 H), 8.03 (d, <i>J</i> = 1.2 Hz, 1 H), 8.00 (dd, <i>J</i> = 8.8 Hz, 1.2 Hz, 1 H), 7.83 (dd, <i>J</i> = 8.0 Hz, 1.6 Hz, 1 H), 7.70 (d, <i>J</i> = 8.4 Hz, 1 H), 7.66 (d, <i>J</i> = 8.8 Hz, 1 H), 7.46 (d, <i>J</i> = 8.0 Hz, 1 H), 3.57 (s, 2 H), 2.50–2.34 (m, 11 H), 2.20 (s, 3 H). <sup>13</sup>C NMR (125 MHz, DMSO) δ 165.77, 165.13, 160.92, 141.06, 138.26, 138.16, 136.88, 134.92, 132.22, 131.84, 131.19, 130.35, 127.48, 126.66, 125.98, 125.48, 125.05, 123.48, 122.37, 121.24, 117.27, 109.95, 57.36, 54.56(2C), 52.43(2C), 45.42, 18.02. HRMS (ESI) calcd for C<sub>30</sub>H<sub>30</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 550.2425; found, 550.2425. HPLC purity = 98.24%, Rt 6.12 min.</div></div><div id="sec4_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> <i>N</i>-(3-((4-((4-Methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)-1<i>H</i>-pyrrolo[2,3-b]pyridine-5-carboxamide <b>6d</b></h3><div class="NLM_p last">Yield: 85%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 12.02 (s, 1 H), 10.58 (s, 1 H), 10.52 (s, 1 H), 8.87 (d, <i>J</i> = 1.2 Hz, 1 H), 8.62 (s, 1 H), 8.39 (s, 1 H), 8.22 (s, 1 H), 8.08–8.04 (m, 2 H), 7.72 (s, 1 H), 7.70 (s, 1 H), 7.61 (t, <i>J</i> = 2.8 Hz, 1 H), 7.54 (t, <i>J</i> = 8.0 Hz, 1 H), 6.63 (d, <i>J</i> = 1.6 Hz, 1 H), 3.57 (s, 2 H), 2.39 (s, 8 H), 2.17 (s, 3 H). <sup>13</sup>C NMR (125 MHz, DMSO) δ 166.28, 165.92, 150.13, 143.28, 140.01, 138.66, 135.56, 132.46, 131.65, 129.11, 128.52, 128.23, 127.88(q, <i>J</i> = 30 Hz), 124.77(q, <i>J</i> = 274 Hz), 123.94, 120.28, 119.12, 117.64, 101.47, 57.87, 55.13(2C), 53.09(2C), 46.10; HRMS (ESI) calcd for C<sub>28</sub>H<sub>27</sub>F<sub>3</sub>N<sub>6</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 537.2221; found, 537.2220. HPLC purity = 99.14%, Rt 6.66 min.</div></div><div id="sec4_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> <i>N</i>-(2-Ethyl-5-((4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)-1<i>H</i>-pyrrolo[2,3-b]pyridine-5-carboxamide <b>6e</b></h3><div class="NLM_p last">Yield: 42%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 12.00 (s, 1 H), 10.49 (s, 1 H), 10.10 (s, 1 H), 8.88 (s, 1 H), 8.60 (s, 1 H), 8.21 (s, 1 H), 8.07 (d, <i>J</i> = 8.4 Hz, 1 H), 7.99 (s, 1 H), 7.89 (d, <i>J</i> = 7.6 Hz, 1 H), 7.70 (d, <i>J</i> = 8.4 Hz, 1 H), 7.61 (s, 1 H), 7.49 (d, <i>J</i> = 8.0 Hz, 1 H), 6.63 (s, 1 H), 3.56 (s, 2 H), 2.74 (dd, <i>J</i> = 14.4 Hz, 7.2 Hz, 2 H), 2.50–2.38 (m, 8 H), 2.16 (s, 3 H), 1.19 (t, <i>J</i> = 7.2 Hz, 3 H). <sup>13</sup>C NMR (125 MHz, DMSO) δ 166.32, 165.66, 150.04, 144.66, 143.12, 138.57, 136.41, 132.63, 132.39, 131.70, 129.17, 128.50, 128.23, 127.97, 127.74, 127.35, 126.20, 124.00, 123.63, 119.24, 117.72, 101.54, 57.77, 54.93(2C), 52.80(2C), 45.82, 24.47, 14.26; HRMS (ESI) calcd for C<sub>30</sub>H<sub>31</sub>F<sub>3</sub>N<sub>6</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 565.2534; found, 565.2533. HPLC purity = 95.37%, Rt 6.60 min.</div></div><div id="sec4_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> <i>N</i>-(2-Isopropyl-5-((4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl) phenyl)-1<i>H</i>-pyrrolo[2,3-b]pyridine-5-carboxamide <b>6f</b></h3><div class="NLM_p last">Yield: 28%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 12.00 (s, 1 H), 10.48 (s, 1 H), 10.13 (s, 1 H), 8.89 (d, <i>J</i> = 2.0 Hz, 1 H), 8.62 (d, <i>J</i> = 1.6 Hz, 1 H), 8.21 (d, <i>J</i> = 1.6 Hz, 1 H), 8.07 (d, <i>J</i> = 8.4 Hz, 1 H), 7.94–7.92 (m, 2 H), 7.70 (d, <i>J</i> = 8.4 Hz, 1 H), 7.61 (t, <i>J</i> = 2.8 Hz, 1 H), 7.56 (d, <i>J</i> = 8.8 Hz, 1 H), 6.63 (dd, <i>J</i> = 3.2 Hz, 1.6 Hz, 1 H), 3.56 (s, 2 H), 3.33–3.27 (m, 1 H), 2.50–2.38 (m, 8 H), 2.16 (s, 3 H), 2.21 (d, <i>J</i> = 6.8 Hz, 6 H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 165.96, 165.04, 149.70, 149.11, 142.75, 138.23, 135.31, 132.05, 131.92, 131.18, 127.96, 127.74, 127.51, 127.24, 126.19, 125.91, 123.48, 121.97, 118.73, 117.25, 117.20, 100.98, 57.40, 54.65(2C), 52.60(2C), 45.60, 27.76, 22.89(2C). HRMS (ESI) calcd for C<sub>31</sub>H<sub>33</sub>F<sub>3</sub>N<sub>6</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 579.2690; found, 579.2689. HPLC purity = 97.27%, Rt 7.10 min.</div></div><div id="sec4_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> Methyl 2-(methylamino)pyrimidine-5-carboxylate <b>12b</b></h3><div class="NLM_p last">To a solution of <b>11b</b> (1.05g, 5.58 mmol) in 6 mL of DMF, Pd(OAc)<sub>2</sub> (62.0 mg, 0.28 mmol), Xantphos (194.3 mg, 0.34 mmol), triethylamine (1.4 mL, 10.0 mmol), and 1.0 mL og methanol were added. The reaction flask was evacuated and backfilled with CO twice. The mixture was heated to 100 °C and stirred overnight under a CO balloon. Then, the reaction mixture was cooled to room temperature and diluted with water and extracted with ethyl acetate (3 × 50 mL). The combined organic layer was dried over anhydrous sodium sulfate, concentrated under vacuum, and was used in the next step without further purification. Compounds <b>12c</b>–<b>i</b> were synthesized by a similar procedure.</div></div><div id="sec4_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> Methyl 2-(methylamino)pyrimidine-5-carboxylate <b>13b</b></h3><div class="NLM_p last">To a solution of <b>12b</b> (446.0 mg, 0.27 mmol) in 15 mL of mixture solvent (MeOH/THF/H<sub>2</sub>O = 3:3:9), LiOH (224.2 mg, 5.34 mmol) was added, and the resulting mixture was stirred at room temperature for 3 h. The organic solvent was removed under vacuum, and the resulting residue was diluted with water and extracted with ethyl acetate (2 × 50 mL). Then, the aqueous solution was acidified with dilute hydrochloric acid (pH about.4), and the precipitate was filtered and washed with water and petroleum ether to give the pure product <b>13b</b> (297.4 mg; yield, 73%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 8.74 (d, <i>J</i> = 2.0 Hz, 1 H), 8.65 (d, <i>J</i> = 2.4 Hz, 1 H), 7.90 (d, <i>J</i> = 4.8 Hz, 1 H), 2.86 (d, <i>J</i> = 4.8 Hz, 3 H). MS (ESI), <i>m</i>/<i>z</i> 154 [M + H]<sup>+</sup>.</div></div><div id="sec4_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> 2-(Ethylamino)pyrimidine-5-carboxylic Acid <b>13c</b></h3><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 12.68 (s, 1 H), 8.72 (s, 1 H), 8.66 (s, 1 H), 7,99 (t, <i>J</i> = 5 Hz, 1 H), 3.38–3.32 (m, 2 H), 1.12 (t, <i>J</i> = 7 Hz, 3 H). MS (ESI), <i>m</i>/<i>z</i> 168 [M + H]<sup>+</sup>.</div></div><div id="sec600" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> 2-(Cyclopropylamino)pyrimidine-5-carboxylic Acid <b>13e</b></h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 12.74 (s, 1 H), 8.77 (s, 1 H), 8.67 (s, 1 H) 8.16 (d, <i>J</i> = 3.6 Hz, 1 H), 2.83–2.78 (m, 1 H), 0.73–0.68 (m, 2 H), 0.54 −0.50(m, 2 H); MS (ESI), <i>m</i>/<i>z</i> 180 [M + H]<sup>+</sup>.</div></div><div id="sec601" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> 2-(Cyclopentylamino)pyrimidine-5-carboxylic Acid <b>13f</b></h3><div class="NLM_p"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 12.67 (s, 1 H), 8.71 (s, 1 H), 8.65 (s, 1 H), 8.03 (d, <i>J</i> = 7.5 Hz, 1 H), 4.25–4.21 (m, 1 H), 1.91–1.86 (m, 2 H), 1.71–1.1.65 (m, 2 H), 1.57–1.50 (m, 4 H); MS (ESI), <i>m</i>/<i>z</i> 208 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Compounds <b>13a</b>–<b>i</b> and <b>16a</b>–<b>c</b><a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> were synthesized by the same procedure; yield, 44–89%.</div></div><div id="sec602" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> 1<i>H</i>-Pyrrolo[2,3-<i>b</i>]pyridine-5-carboxylic Acid <b>16a</b></h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 12.01 (s, 1 H), 8.78 (d, <i>J</i> = 1.8 Hz, 1 H), 8.50 (d, <i>J</i> = 1.8 Hz, 1 H), 7.58 (dd, <i>J</i> = 3.2 Hz, 1.8 Hz, 1 H), 6.60 (dd, <i>J</i> = 3.2 Hz, 1.8 Hz, 1 H); MS (ESI), <i>m</i>/<i>z</i> 163 [M + H]<sup>+</sup>.</div></div><div id="sec603" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> 1<i>H</i>-Pyrazolo[3,4-<i>b</i>]pyridine-5-carboxylic Acid <b>16b</b></h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 13.99 (s, 1H), 9.02 (d, <i>J</i> = 2.0 Hz, 1 H), 8.79 (d, <i>J</i> = 2.0 Hz, 1 H), 8.30 (s, 1 H); MS (ESI), <i>m</i>/<i>z</i> 164 [M + H]<sup>+</sup>.</div></div><div id="sec4_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> Cell Culture</h3><div class="NLM_p last">The human colorectal adenocarcinoma cell lines HT-29, HCT-116, Colo205, LOVO, and WiDr and malignant melanoma cell lines A375 and SK-MEL-28 were purchased from ATCC. HT-29 and HCT116 were maintained in McCoy’s 5a with 10% FBS, Colo205, LOVO, and A375 were maintained in RPMI-1640, F12K, and DMEM with 10% FBS, respectively, while WiDr and SK-MEL-28 were grown in Eagle’s minimum essential medium with 10% FBS. The drug <b>1</b> resistant cell line SK-MEL-28-PR30 was selected in our laboratory by exposing the parental SK-MEL-28 cells to increasing concentrations of drug <b>1</b> for 2 months (<a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>).</div></div><div id="sec4_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> <i>In Vitro</i> Enzymatic Activity Assay</h3><div class="NLM_p">EGFR, B-Raf<sup>V600E</sup> (as B-Raf<sup>V599E</sup> in supplier’s catalogue), and the Z′-Lyte Kinase Assay Kit were purchased from Invitrogen. The experiments were performed according to the instructions of the manufacturer. The concentrations of different kinases were determined by optimization experiments, and the respective concentrations were EGFR (PV3872, Invitrogen), 0.43 μg/μL; and BRAF<sup>V600E</sup> (PV4173, Invitrogen), 0.22 μg/μL. First, the compounds were diluted 3-fold from 5.1 × 10<sup>–9</sup> M to 1 × 10<sup>–4</sup> M in DMSO, and a 4× compound solution was prepared (4 μL of compound dissolved in 96 μL of water). Second, a 40 μM ATP solution in 1.33× kinase buffer was prepared. Third, a kinase/peptide mixture containing 2× kinase and 4 μM Tyr 4 peptide (Invitrogen, PV3193) was prepared right before use.</div><div class="NLM_p">For both EGFR and B-Raf assays, 10 μL of kinase reactions were made at first (including 2.5 μL of compound solution, 5 μL of kinase/peptide mixture, and 2.5 μL of ATP solution). The plate was mixed thoroughly and incubated for 1 h at room temperature. Then 5 μL of development solution was added to each well, and the plate was incubated for 1 h at room temperature; the nonphospho-peptides were cleaved at this time. In the end, 5 μL of stop reagent was loaded to stop the reaction. For the control setting, 5 μL of phospho-peptide solution instead of the kinase/peptide mixture was used as 100% of the phosphorylation control. 2.5 μL of 1.33 × kinase buffer instead of ATP solution was used as 100% inhibition control, and 2.5 μL of 4% DMSO instead of compound solution was used as the 0% inhibitor control. The plate was measured on an EnVision Multilabel Reader (Perkin-Elmer). Curve fitting and data presentations were performed using Graph Pad Prism, version 5.0. Every experiment was repeated at least 2 times.</div><div class="NLM_p last">For the B-Raf<sup>V600E</sup> assay, the kinase/peptide mixture was prepared by diluting the Z′-LYTE Ser/Thr3 peptide (Invitrogen, PV3176) and three kinases (B-Raf, MAP2K1/MEK1 (Invitrogen, P3093), MAPK1/ERK2 (Invitrogen, PV3314)) in 1× kinase buffer, and a 0.2 μM Ser/Thr3 phospho-peptide solution was made by adding Z′-LYTE Ser/Thr3 Phospho-peptide to 1× kinase buffer. The final 10 μL reaction consists of 0.002 ng of B-Raf, 10 ng of inactive MAP2K1 (MEK1),100 ng of inactive MAPK1 (ERK2), and 2 μM Ser/Thr3 peptide in 1× kinase buffer.</div></div><div id="sec4_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> Cell Proliferation and Growth Inhibition Assay</h3><div class="NLM_p last">WiDr, A375, HT-29, SK-MEL-28, SK-MEL-28-PR30, HCT-116, and LOVO cells were cultured with the respective growth medium. Cells of log phase were used. One thousand to 3000 cells/well were seeded in 96-well plates with a 100 μL volume, and 6 parallels and 8 rows were designed. Compounds were dissolved to 10 μM with DMSO, and a 5-fold serial dilution of the compounds from 1 × 10<sup>–5</sup> M to 0.64 × 10<sup>–9</sup> M was performed. Two microliters of compound solution was added to 998 μL of growth medium, the mixture was vortexed sufficiently. One hundred microliters of the mixture was correspondingly added to the 96-well plate. Two microliters of DMSO instead of compound solution was used as the 0% inhibitor control. After coincubation for 68 h, 20 μL of MTT (5 mg/mL) was added. Four hours later, the supernatant was discarded completely, and 150 μL of DMSO was added. After shaking for 10 min, the plates were read in the Synergy HT (Bio Tek) at 570 nm. The data was calculated using Graph Pad Prism, version 4.0. The IC<sub>50</sub> were fitted using a nonlinear regression model with a sigmoidal dose–response.</div></div><div id="sec4_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> Western Blot</h3><div class="NLM_p last">Cells (1 ×10<sup>6</sup>) of WiDr, A375, HT-29, SK-MEL-28, and SK-MEL-28-PR30 were seeded into 6-cm dishes overnight. The medium was changed, and 3, 1, 0.3 μM <b>6a</b> was added the next day; medium with 1‰ DMSO was used as the control. Cells were exposed to treatment for different times. The dishes were washed twice using precold PBS, and 400 μL of RIPA was added then. After incubating plates on ice for 15 min, cells were scraped carefully and centrifuged for 10 min at 14,000<i>g</i> at 4 °C immediately, and lysates (the supernantant) were maintained at −70 °C. A BCA protein assay kit (23227, Thermo) was used to quantitate the cell lysates. Proper 5× loading buffer was loaded before use, and the samples were denatured by boiling. The same amount of quantitated sample was loaded, and proteins were transferred to the PVDF membrane (Milipore) then. After blocking for 1.0 h at room temperature, diluted primary antibody EGFR (CST, 2232), phospho-EGFR (Tyr1068) (CST, 2234), ERK (CST, 9102), phospho-ERK (t202/y204) (CST, 9101), and GAPDH (KC-5G5, KangChen) were added. A second antibody with horseradish peroxidase (HRP, sigma) conjugated was used then. Blots were developed by enhanced chemiluminescence (Thermo).</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i46"><a href="/doi/suppl/10.1021/jm500007h">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70558" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70558" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last"><sup>1</sup>H NMR and <sup>13</sup>C NMR for final compounds, biological data, and assay details. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm500007h/suppl_file/jm500007h_si_001.pdf">jm500007h_si_001.pdf (2.16 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm500007h" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20681" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20681" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ke Ding</span> - <span class="hlFld-Affiliation affiliation">Institute of Chemical
Biology, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, #190 Kaiyuan Avenue, Guangzhou 510530, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#8eeae7e0e9d1e5ebcee9e7ece6a0efeda0ede0"><span class="__cf_email__" data-cfemail="b3d7daddd4ecd8d6f3d4dad1db9dd2d09dd0dd">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Huimin Cheng</span> - <span class="hlFld-Affiliation affiliation">Institute of Chemical
Biology, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, #190 Kaiyuan Avenue, Guangzhou 510530, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yu Chang</span> - <span class="hlFld-Affiliation affiliation">University
of Macau, Avenue Padre
Tomás Pereira Taipa, Macau, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lianwen Zhang</span> - <span class="hlFld-Affiliation affiliation">Institute of Chemical
Biology, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, #190 Kaiyuan Avenue, Guangzhou 510530, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jinfeng Luo</span> - <span class="hlFld-Affiliation affiliation">Institute of Chemical
Biology, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, #190 Kaiyuan Avenue, Guangzhou 510530, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhengchao Tu</span> - <span class="hlFld-Affiliation affiliation">Institute of Chemical
Biology, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, #190 Kaiyuan Avenue, Guangzhou 510530, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaoyun Lu</span> - <span class="hlFld-Affiliation affiliation">Institute of Chemical
Biology, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, #190 Kaiyuan Avenue, Guangzhou 510530, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qingwen Zhang</span> - <span class="hlFld-Affiliation affiliation">University
of Macau, Avenue Padre
Tomás Pereira Taipa, Macau, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jibu Lu</span> - <span class="hlFld-Affiliation affiliation">Shenyang
Pharmaceutical University, #103 Wenhua Road, Shenyang 110016, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaomei Ren</span> - <span class="hlFld-Affiliation affiliation">Institute of Chemical
Biology, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, #190 Kaiyuan Avenue, Guangzhou 510530, China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>H.C., Y.C., and L.Z. contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d1991e3385-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i48">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05235" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05235" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank the National Natural Science Foundation (#21302186) and the Key Project on Innovative Drug of Guangdong Province (#2012A080201014) for their financial support.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i49" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i49"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i50" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i50"> Abbreviations Used</h2><tr><td class="NLM_term">MAPK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase signaling pathway</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">Erk</td><td class="NLM_def"><p class="first last">extracellular signal-regulated kinase</p></td></tr><tr><td class="NLM_term">PDGFR</td><td class="NLM_def"><p class="first last">Platelet-derived growth factor</p></td></tr><tr><td class="NLM_term">Val (V)</td><td class="NLM_def"><p class="first last">valine</p></td></tr><tr><td class="NLM_term">Glu (E)</td><td class="NLM_def"><p class="first last">glutamic acid</p></td></tr><tr><td class="NLM_term">rt</td><td class="NLM_def"><p class="first last">room temperature</p></td></tr><tr><td class="NLM_term">DIEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">PyBOP</td><td class="NLM_def"><p class="first last">benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last">1-[bis(dimethylamino)methylene]-1<i>H</i>-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate</p></td></tr><tr><td class="NLM_term">MOA</td><td class="NLM_def"><p class="first last">mechanisms of action</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">Food and Drug Administration</p></td></tr><tr><td class="NLM_term">IC<sub>50</sub></td><td class="NLM_def"><p class="first last">the half maximal (50%) inhibitory concentration (IC) of a substance</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">GAPDH</td><td class="NLM_def"><p class="first last">glyceraldehyde-3-phosphate dehydrogenase</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylformamide</p></td></tr><tr><td class="NLM_term">MTT</td><td class="NLM_def"><p class="first last">3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i51">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74172" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74172" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 45 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Peyssonnaux, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eychene, A.</span><span> </span><span class="NLM_article-title">The Raf/MEK/ERK pathway: new concepts of activation</span> <span class="citation_source-journal">Biol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">53</span><span class="NLM_x">–</span> <span class="NLM_lpage">62</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm500007h&amp;key=10.1016%2FS0248-4900%2801%2901125-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm500007h&amp;key=11730323" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm500007h&amp;key=1%3ACAS%3A528%3ADC%252BD3MXptVOju7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2001&pages=53-62&author=C.+Peyssonnauxauthor=A.+Eychene&title=The+Raf%2FMEK%2FERK+pathway%3A+new+concepts+of+activation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The Raf/MEK/ERK pathway: New concepts of activation</span></div><div class="casAuthors">Peyssonnaux, Carole; Eychene, Alain</div><div class="citationInfo"><span class="NLM_cas:title">Biology of the Cell</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">1/2</span>),
    <span class="NLM_cas:pages">53-62</span>CODEN:
                <span class="NLM_cas:coden">BCELDF</span>;
        ISSN:<span class="NLM_cas:issn">0248-4900</span>.
    
            (<span class="NLM_cas:orgname">Editions Scientifiques et Medicales Elsevier</span>)
        </div><div class="casAbstract">A review.  The Raf/MEK/ERK signaling was the first MAP kinase cascade to be characterized.  It is probably one of the most well known signal transduction pathways among biologists because of its implication in a wide variety of cellular functions as diverse -and occasionally contradictory- as cell proliferation, cell-cycle arrest, terminal differentiation and apoptosis.  Discovery and understanding of this pathway have benefited from the combination of both genetic studies in worms and flies and biochem. studies in mammalian cells.  However, ten years after, this field is still under debate and new mol. partners in the cascade continue to increase the complexity of its regulation.  This review deals with the emergence of new concepts in the activation and regulation of the Raf/MEK/ERK module.  In particular, the preponderant role of B-Raf is underlined, and the role of novel regulators such as KSR is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyjiXSFlBQ6rVg90H21EOLACvtfcHk0liprNuPaJdp8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXptVOju7s%253D&md5=cde3db5b205a1305dc2e6262deea65ec</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS0248-4900%2801%2901125-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0248-4900%252801%252901125-X%26sid%3Dliteratum%253Aachs%26aulast%3DPeyssonnaux%26aufirst%3DC.%26aulast%3DEychene%26aufirst%3DA.%26atitle%3DThe%2520Raf%252FMEK%252FERK%2520pathway%253A%2520new%2520concepts%2520of%2520activation%26jtitle%3DBiol.%2520Cell%26date%3D2001%26volume%3D93%26spage%3D53%26epage%3D62" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Dhillon, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rath, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolch, W.</span><span> </span><span class="NLM_article-title">MAP kinase signalling pathways in cancer</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">3279</span><span class="NLM_x">–</span> <span class="NLM_lpage">3290</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm500007h&amp;key=10.1038%2Fsj.onc.1210421" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm500007h&amp;key=17496922" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm500007h&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlt1WktLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=3279-3290&author=A.+S.+Dhillonauthor=S.+Haganauthor=O.+Rathauthor=W.+Kolch&title=MAP+kinase+signalling+pathways+in+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">MAP kinase signaling pathways in cancer</span></div><div class="casAuthors">Dhillon, A. S.; Hagan, S.; Rath, O.; Kolch, W.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3279-3290</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cancer can be perceived as a disease of communication between and within cells.  The aberrations are pleiotropic, but mitogen-activated protein kinase (MAPK) pathways feature prominently.  Here, we discuss recent findings and hypotheses on the role of MAPK pathways in cancer.  Cancerous mutations in MAPK pathways are frequently mostly affecting Ras and B-Raf in the extracellular signal-regulated kinase pathway.  Stress-activated pathways, such as Jun N-terminal kinase and p38, largely seem to counteract malignant transformation.  The balance and integration between these signals may widely vary in different tumors, but are important for the outcome and the sensitivity to drug therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2AJjwZsw0PbVg90H21EOLACvtfcHk0liprNuPaJdp8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlt1WktLc%253D&md5=510709dcee2bbe62c7d48dbd8f270130</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1210421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1210421%26sid%3Dliteratum%253Aachs%26aulast%3DDhillon%26aufirst%3DA.%2BS.%26aulast%3DHagan%26aufirst%3DS.%26aulast%3DRath%26aufirst%3DO.%26aulast%3DKolch%26aufirst%3DW.%26atitle%3DMAP%2520kinase%2520signalling%2520pathways%2520in%2520cancer%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D3279%26epage%3D3290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Marais, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, C. J.</span><span> </span><span class="NLM_article-title">Control of the ERK MAP kinase cascade by Ras and Raf</span> <span class="citation_source-journal">Cancer Surv.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">101</span><span class="NLM_x">–</span> <span class="NLM_lpage">125</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm500007h&amp;key=8909797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm500007h&amp;key=1%3ACAS%3A528%3ADyaK28XntlSns7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1996&pages=101-125&author=R.+Maraisauthor=C.+J.+Marshall&title=Control+of+the+ERK+MAP+kinase+cascade+by+Ras+and+Raf"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Control of the ERK MAP kinase cascade by Ras and Raf</span></div><div class="casAuthors">Marais, R.; Marshall, C. J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Surveys</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">Cell Signalling</span>),
    <span class="NLM_cas:pages">101-125</span>CODEN:
                <span class="NLM_cas:coden">CASUD7</span>;
        ISSN:<span class="NLM_cas:issn">0261-2429</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">A review, with ∼125 refs., on Mek activators, how Raf proteins are activated, and possibilities for therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHudK_EtTwhrVg90H21EOLACvtfcHk0ljhU_SIASSAOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XntlSns7k%253D&md5=e01ca3a4a1e327f46311a04e73e0fa79</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMarais%26aufirst%3DR.%26aulast%3DMarshall%26aufirst%3DC.%2BJ.%26atitle%3DControl%2520of%2520the%2520ERK%2520MAP%2520kinase%2520cascade%2520by%2520Ras%2520and%2520Raf%26jtitle%3DCancer%2520Surv.%26date%3D1996%26volume%3D27%26spage%3D101%26epage%3D125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Garnett, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marais, R.</span><span> </span><span class="NLM_article-title">Guilty as charged: B-RAF is a human oncogene</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">313</span><span class="NLM_x">–</span> <span class="NLM_lpage">319</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2004&pages=313-319&author=M.+J.+Garnettauthor=R.+Marais&title=Guilty+as+charged%3A+B-RAF+is+a+human+oncogene"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGarnett%26aufirst%3DM.%2BJ.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DGuilty%2520as%2520charged%253A%2520B-RAF%2520is%2520a%2520human%2520oncogene%26jtitle%3DCancer%2520Cell%26date%3D2004%26volume%3D6%26spage%3D313%26epage%3D319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Davies, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bignell, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephens, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edkins, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clegg, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teague, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woffendin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garnett, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bottomley, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dicks, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ewing, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawes, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosmidou, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menzies, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mould, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hooper, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayatilake, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gusterson, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shipley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hargrave, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard-Jones, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maitland, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chenevix-Trench, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riggins, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bigner, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmieri, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cossu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flanagan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, J. W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuen, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegler, H. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darrow, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paterson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marais, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wooster, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stratton, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Futreal, P. A.</span><span> </span><span class="NLM_article-title">Mutations of the BRAF gene in human cancer</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">417</span><span class="NLM_x">, </span> <span class="NLM_fpage">949</span><span class="NLM_x">–</span> <span class="NLM_lpage">954</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm500007h&amp;key=10.1038%2Fnature00766" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm500007h&amp;key=12068308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm500007h&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvVagsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=417&publication_year=2002&pages=949-954&author=H.+Daviesauthor=G.+R.+Bignellauthor=C.+Coxauthor=P.+Stephensauthor=S.+Edkinsauthor=S.+Cleggauthor=J.+Teagueauthor=H.+Woffendinauthor=M.+J.+Garnettauthor=W.+Bottomleyauthor=N.+Davisauthor=N.+Dicksauthor=R.+Ewingauthor=Y.+Floydauthor=K.+Grayauthor=S.+Hallauthor=R.+Hawesauthor=J.+Hughesauthor=V.+Kosmidouauthor=A.+Menziesauthor=C.+Mouldauthor=A.+Parkerauthor=C.+Stevensauthor=S.+Wattauthor=S.+Hooperauthor=R.+Wilsonauthor=H.+Jayatilakeauthor=B.+A.+Gustersonauthor=C.+Cooperauthor=J.+Shipleyauthor=D.+Hargraveauthor=K.+Pritchard-Jonesauthor=N.+Maitlandauthor=G.+Chenevix-Trenchauthor=G.+J.+Rigginsauthor=D.+D.+Bignerauthor=G.+Palmieriauthor=A.+Cossuauthor=A.+Flanaganauthor=A.+Nicholsonauthor=J.+W.+C.+Hoauthor=S.+Y.+Leungauthor=S.+T.+Yuenauthor=B.+L.+Weberauthor=H.+F.+Sieglerauthor=T.+L.+Darrowauthor=H.+Patersonauthor=R.+Maraisauthor=C.+J.+Marshallauthor=R.+Woosterauthor=M.+R.+Strattonauthor=P.+A.+Futreal&title=Mutations+of+the+BRAF+gene+in+human+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations of the BRAF gene in human cancer</span></div><div class="casAuthors">Davies, Helen; Bignell, Graham R.; Cox, Charles; Stephens, Philip; Edkins, Sarah; Clegg, Sheila; Teague, Jon; Woffendin, Hayley; Garnett, Mathew J.; Bottomley, William; Davis, Neil; Dicks, Ed; Ewing, Rebecca; Floyd, Yvonne; Gray, Kristian; Hall, Sarah; Hawes, Rachel; Hughes, Jaime; Kosmidou, Vivian; Menzies, Andrew; Mould, Catherine; Parker, Adrian; Stevens, Claire; Watt, Stephen; Hooper, Steven; Wilson, Rebecca; Jayatilake, Hiran; Gusterson, Barry A.; Cooper, Colin; Shipley, Janet; Hargrave, Darren; Pritchard-Jones, Katherine; Maitland, Norman; Chenevix-Trench, Georgia; Riggins, Gregory J.; Bigner, Darell D.; Palmieri, Giuseppe; Cossu, Antonio; Flanagan, Adrienne; Nicholson, Andrew; Ho, Judy W. C.; Leung, Suet Y.; Yuen, Siu T.; Weber, Barbara L.; Seigler, Hilliard F.; Darrow, Timothy L.; Paterson, Hugh; Marais, Richard; Marshall, Christopher J.; Wooster, Richard; Stratton, Michael R.; Futreal, P. Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">417</span>
        (<span class="NLM_cas:issue">6892</span>),
    <span class="NLM_cas:pages">949-954</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cancers arise owing to the accumulation of mutations in crit. genes that alter normal programs of cell proliferation, differentiation and death.  As the first stage of a systematic genome-wide screen for these genes, we have prioritized for anal. signalling pathways in which at least one gene is mutated in human cancer.  The RAS-RAF-MEK-ERK-MAP kinase pathway mediates cellular responses to growth signals.  RAS is mutated to an oncogenic form in about 15% of human cancer.  The three RAF genes code for cytoplasmic serine/threonine kinases that are regulated by binding RAS.  Here we report BRAF somatic missense mutations in 66% of malignant melanomas and at lower frequency in a wide range of human cancers.  All mutations are within the kinase domain, with a single substitution (V599E) accounting for 80%.  Mutated BRAF proteins have elevated kinase activity and are transforming in NIH3T3 cells.  Furthermore, RAS function is not required for the growth of cancer cell lines with the V599E mutation.  As BRAF is a serine/threonine kinase that is commonly activated by somatic point mutation in human cancer, it may provide new therapeutic opportunities in malignant melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPBmhJC0GAjrVg90H21EOLACvtfcHk0ljhU_SIASSAOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvVagsLo%253D&md5=4625be53ad9a382d51b6ee753d0c17e8</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnature00766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature00766%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DH.%26aulast%3DBignell%26aufirst%3DG.%2BR.%26aulast%3DCox%26aufirst%3DC.%26aulast%3DStephens%26aufirst%3DP.%26aulast%3DEdkins%26aufirst%3DS.%26aulast%3DClegg%26aufirst%3DS.%26aulast%3DTeague%26aufirst%3DJ.%26aulast%3DWoffendin%26aufirst%3DH.%26aulast%3DGarnett%26aufirst%3DM.%2BJ.%26aulast%3DBottomley%26aufirst%3DW.%26aulast%3DDavis%26aufirst%3DN.%26aulast%3DDicks%26aufirst%3DN.%26aulast%3DEwing%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DY.%26aulast%3DGray%26aufirst%3DK.%26aulast%3DHall%26aufirst%3DS.%26aulast%3DHawes%26aufirst%3DR.%26aulast%3DHughes%26aufirst%3DJ.%26aulast%3DKosmidou%26aufirst%3DV.%26aulast%3DMenzies%26aufirst%3DA.%26aulast%3DMould%26aufirst%3DC.%26aulast%3DParker%26aufirst%3DA.%26aulast%3DStevens%26aufirst%3DC.%26aulast%3DWatt%26aufirst%3DS.%26aulast%3DHooper%26aufirst%3DS.%26aulast%3DWilson%26aufirst%3DR.%26aulast%3DJayatilake%26aufirst%3DH.%26aulast%3DGusterson%26aufirst%3DB.%2BA.%26aulast%3DCooper%26aufirst%3DC.%26aulast%3DShipley%26aufirst%3DJ.%26aulast%3DHargrave%26aufirst%3DD.%26aulast%3DPritchard-Jones%26aufirst%3DK.%26aulast%3DMaitland%26aufirst%3DN.%26aulast%3DChenevix-Trench%26aufirst%3DG.%26aulast%3DRiggins%26aufirst%3DG.%2BJ.%26aulast%3DBigner%26aufirst%3DD.%2BD.%26aulast%3DPalmieri%26aufirst%3DG.%26aulast%3DCossu%26aufirst%3DA.%26aulast%3DFlanagan%26aufirst%3DA.%26aulast%3DNicholson%26aufirst%3DA.%26aulast%3DHo%26aufirst%3DJ.%2BW.%2BC.%26aulast%3DLeung%26aufirst%3DS.%2BY.%26aulast%3DYuen%26aufirst%3DS.%2BT.%26aulast%3DWeber%26aufirst%3DB.%2BL.%26aulast%3DSiegler%26aufirst%3DH.%2BF.%26aulast%3DDarrow%26aufirst%3DT.%2BL.%26aulast%3DPaterson%26aufirst%3DH.%26aulast%3DMarais%26aufirst%3DR.%26aulast%3DMarshall%26aufirst%3DC.%2BJ.%26aulast%3DWooster%26aufirst%3DR.%26aulast%3DStratton%26aufirst%3DM.%2BR.%26aulast%3DFutreal%26aufirst%3DP.%2BA.%26atitle%3DMutations%2520of%2520the%2520BRAF%2520gene%2520in%2520human%2520cancer%26jtitle%3DNature%26date%3D2002%26volume%3D417%26spage%3D949%26epage%3D954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Yuen, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bignell, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephens, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edkins, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsui, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Futreal, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stratton, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wooster, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, S. Y.</span><span> </span><span class="NLM_article-title">Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">6451</span><span class="NLM_x">–</span> <span class="NLM_lpage">6455</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=6451-6455&author=S.+T.+Yuenauthor=H.+Daviesauthor=T.+L.+Chanauthor=J.+W.+Hoauthor=G.+R.+Bignellauthor=C.+Coxauthor=P.+Stephensauthor=S.+Edkinsauthor=W.+W.+Tsuiauthor=A.+S.+Chanauthor=P.+A.+Futrealauthor=M.+R.+Strattonauthor=R.+Woosterauthor=S.+Y.+Leung&title=Similarity+of+the+phenotypic+patterns+associated+with+BRAF+and+KRAS+mutations+in+colorectal+neoplasia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYuen%26aufirst%3DS.%2BT.%26aulast%3DDavies%26aufirst%3DH.%26aulast%3DChan%26aufirst%3DT.%2BL.%26aulast%3DHo%26aufirst%3DJ.%2BW.%26aulast%3DBignell%26aufirst%3DG.%2BR.%26aulast%3DCox%26aufirst%3DC.%26aulast%3DStephens%26aufirst%3DP.%26aulast%3DEdkins%26aufirst%3DS.%26aulast%3DTsui%26aufirst%3DW.%2BW.%26aulast%3DChan%26aufirst%3DA.%2BS.%26aulast%3DFutreal%26aufirst%3DP.%2BA.%26aulast%3DStratton%26aufirst%3DM.%2BR.%26aulast%3DWooster%26aufirst%3DR.%26aulast%3DLeung%26aufirst%3DS.%2BY.%26atitle%3DSimilarity%2520of%2520the%2520phenotypic%2520patterns%2520associated%2520with%2520BRAF%2520and%2520KRAS%2520mutations%2520in%2520colorectal%2520neoplasia%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26spage%3D6451%26epage%3D6455" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Kimura, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nikiforova, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knauf, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nikiforov, Y. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fagin, J. A.</span><span> </span><span class="NLM_article-title">High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">1454</span><span class="NLM_x">–</span> <span class="NLM_lpage">1457</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=1454-1457&author=E.+T.+Kimuraauthor=M.+N.+Nikiforovaauthor=Z.+W.+Zhuauthor=J.+A.+Knaufauthor=Y.+E.+Nikiforovauthor=J.+A.+Fagin&title=High+prevalence+of+BRAF+mutations+in+thyroid+cancer%3A+genetic+evidence+for+constitutive+activation+of+the+RET%2FPTC-RAS-BRAF+signaling+pathway+in+papillary+thyroid+carcinoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKimura%26aufirst%3DE.%2BT.%26aulast%3DNikiforova%26aufirst%3DM.%2BN.%26aulast%3DZhu%26aufirst%3DZ.%2BW.%26aulast%3DKnauf%26aufirst%3DJ.%2BA.%26aulast%3DNikiforov%26aufirst%3DY.%2BE.%26aulast%3DFagin%26aufirst%3DJ.%2BA.%26atitle%3DHigh%2520prevalence%2520of%2520BRAF%2520mutations%2520in%2520thyroid%2520cancer%253A%2520genetic%2520evidence%2520for%2520constitutive%2520activation%2520of%2520the%2520RET%252FPTC-RAS-BRAF%2520signaling%2520pathway%2520in%2520papillary%2520thyroid%2520carcinoma%26jtitle%3DCancer%2520Res.%26date%3D2003%26volume%3D63%26spage%3D1454%26epage%3D1457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Wellbrock, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurlstone, A.</span><span> </span><span class="NLM_article-title">BRAF as therapeutic target in melanoma</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">80</span><span class="NLM_x">, </span> <span class="NLM_fpage">561</span><span class="NLM_x">–</span> <span class="NLM_lpage">567</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2010&pages=561-567&author=C.+Wellbrockauthor=A.+Hurlstone&title=BRAF+as+therapeutic+target+in+melanoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWellbrock%26aufirst%3DC.%26aulast%3DHurlstone%26aufirst%3DA.%26atitle%3DBRAF%2520as%2520therapeutic%2520target%2520in%2520melanoma%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2010%26volume%3D80%26spage%3D561%26epage%3D567" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Tuveson, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herlyn, M.</span><span> </span><span class="NLM_article-title">BRAF as a potential therapeutic target in melanoma and other malignancies</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">95</span><span class="NLM_x">–</span> <span class="NLM_lpage">98</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2003&pages=95-98&author=D.+A.+Tuvesonauthor=B.+L.+Weberauthor=M.+Herlyn&title=BRAF+as+a+potential+therapeutic+target+in+melanoma+and+other+malignancies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTuveson%26aufirst%3DD.%2BA.%26aulast%3DWeber%26aufirst%3DB.%2BL.%26aulast%3DHerlyn%26aufirst%3DM.%26atitle%3DBRAF%2520as%2520a%2520potential%2520therapeutic%2520target%2520in%2520melanoma%2520and%2520other%2520malignancies%26jtitle%3DCancer%2520Cell%26date%3D2003%26volume%3D4%26spage%3D95%26epage%3D98" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Tsai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mamo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bremer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillette, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haass, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sproesser, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smalley, K. S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fong, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marimuthu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settachatgul, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shellooe, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantwell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlessinger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, K. Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habets, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ibrahim, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirth, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Artis, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herlyn, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bollag, G.</span><span> </span><span class="NLM_article-title">Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">3041</span><span class="NLM_x">–</span> <span class="NLM_lpage">3046</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm500007h&amp;key=10.1073%2Fpnas.0711741105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm500007h&amp;key=18287029" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm500007h&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjtVSitrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=3041-3046&author=J.+Tsaiauthor=J.+T.+Leeauthor=W.+Wangauthor=J.+Zhangauthor=H.+Choauthor=S.+Mamoauthor=R.+Bremerauthor=S.+Gilletteauthor=J.+Kongauthor=N.+K.+Haassauthor=K.+Sproesserauthor=L.+Liauthor=K.+S.+M.+Smalleyauthor=D.+Fongauthor=Y.+L.+Zhuauthor=A.+Marimuthuauthor=H.+Nguyenauthor=B.+Lamauthor=J.+Liuauthor=I.+Cheungauthor=J.+Riceauthor=Y.+Suzukiauthor=C.+Luuauthor=C.+Settachatgulauthor=R.+Shellooeauthor=J.+Cantwellauthor=S.+H.+Kimauthor=J.+Schlessingerauthor=K.+Y.+J.+Zhangauthor=B.+L.+Westauthor=B.+Powellauthor=G.+Habetsauthor=C.+Zhangauthor=P.+N.+Ibrahimauthor=P.+Hirthauthor=D.+R.+Artisauthor=M.+Herlynauthor=G.+Bollag&title=Discovery+of+a+selective+inhibitor+of+oncogenic+B-Raf+kinase+with+potent+antimelanoma+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity</span></div><div class="casAuthors">Tsai, James; Lee, John T.; Wang, Weiru; Zhang, Jiazhong; Cho, Hanna; Mamo, Shumeye; Bremer, Ryan; Gillette, Sam; Kong, Jun; Haass, Nikolas K.; Sproesser, Katrin; Li, Ling; Smalley, Keiran S. M.; Fong, Daniel; Zhu, Yong-Liang; Marimuthu, Adhirai; Nguyen, Hoa; Lam, Billy; Liu, Jennifer; Cheung, Ivana; Rice, Julie; Suzuki, Yoshihisa; Luu, Catherine; Settachatgul, Calvin; Shellooe, Rafe; Cantwell, John; Kim, Sung-Hou; Schlessinger, Joseph; Zhang, Kam Y. J.; West, Brian L.; Powell, Ben; Habets, Gaston; Zhang, Chao; Ibrahim, Prabha N.; Hirth, Peter; Artis, Dean R.; Herlyn, Meenhard; Bollag, Gideon</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3041-3046</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">BRAFV600E is the most frequent oncogenic protein kinase mutation known.  Furthermore, inhibitors targeting "active" protein kinases have demonstrated significant utility in the therapeutic repertoire against cancer.  Therefore, the authors pursued the development of specific kinase inhibitors targeting B-Raf, and the V600E allele in particular.  By using a structure-guided discovery approach, a potent and selective inhibitor of active B-Raf has been discovered.  PLX4720, a 7-azaindole deriv. that inhibits B-RafV600E with an IC50 of 13 nM, defines a class of kinase inhibitor with marked selectivity in both biochem. and cellular assays.  PLX4720 preferentially inhibits the active B-RafV600E kinase compared with a broad spectrum of other kinases, and potent cytotoxic effects are also exclusive to cells bearing the V600E allele.  Consistent with the high degree of selectivity, ERK phosphorylation is potently inhibited by PLX4720 in B-RafV600E-bearing tumor cell lines but not in cells lacking oncogenic B-Raf.  In melanoma models, PLX4720 induces cell cycle arrest and apoptosis exclusively in B-RafV600E-pos. cells.  In B-RafV600E-dependent tumor xenograft models, orally dosed PLX4720 causes significant tumor growth delays, including tumor regressions, without evidence of toxicity.  The work described here represents the entire discovery process, from initial identification through structural and biol. studies in animal models to a promising therapeutic for testing in cancer patients bearing B-RafV600E-driven tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPX53IQCbDJ7Vg90H21EOLACvtfcHk0lgYUSicSyCm8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjtVSitrk%253D&md5=273b94202f99984e6eb24723d0c6141f</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0711741105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0711741105%26sid%3Dliteratum%253Aachs%26aulast%3DTsai%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DJ.%2BT.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DCho%26aufirst%3DH.%26aulast%3DMamo%26aufirst%3DS.%26aulast%3DBremer%26aufirst%3DR.%26aulast%3DGillette%26aufirst%3DS.%26aulast%3DKong%26aufirst%3DJ.%26aulast%3DHaass%26aufirst%3DN.%2BK.%26aulast%3DSproesser%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DSmalley%26aufirst%3DK.%2BS.%2BM.%26aulast%3DFong%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DY.%2BL.%26aulast%3DMarimuthu%26aufirst%3DA.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DLam%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DCheung%26aufirst%3DI.%26aulast%3DRice%26aufirst%3DJ.%26aulast%3DSuzuki%26aufirst%3DY.%26aulast%3DLuu%26aufirst%3DC.%26aulast%3DSettachatgul%26aufirst%3DC.%26aulast%3DShellooe%26aufirst%3DR.%26aulast%3DCantwell%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DK.%2BY.%2BJ.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DHabets%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DIbrahim%26aufirst%3DP.%2BN.%26aulast%3DHirth%26aufirst%3DP.%26aulast%3DArtis%26aufirst%3DD.%2BR.%26aulast%3DHerlyn%26aufirst%3DM.%26aulast%3DBollag%26aufirst%3DG.%26atitle%3DDiscovery%2520of%2520a%2520selective%2520inhibitor%2520of%2520oncogenic%2520B-Raf%2520kinase%2520with%2520potent%2520antimelanoma%2520activity%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2008%26volume%3D105%26spage%3D3041%26epage%3D3046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Rheault, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stellwagen, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adjabeng, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hornberger, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrov, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waterson, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickerson, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mook, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laquerre, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossanese, O. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnone, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smitheman, K. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kane-Carson, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moorthy, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moss, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uehling, D. E.</span><span> </span><span class="NLM_article-title">Discovery of dabrafenib: a selective inhibitor of Raf kinases with antitumor activity against B-Raf-driven tumors</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">358</span><span class="NLM_x">–</span> <span class="NLM_lpage">362</span></span><div class="citationLinks">[<a href="/doi/10.1021/ml4000063" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=358-362&author=T.+R.+Rheaultauthor=J.+C.+Stellwagenauthor=G.+M.+Adjabengauthor=K.+R.+Hornbergerauthor=K.+G.+Petrovauthor=A.+G.+Watersonauthor=S.+H.+Dickersonauthor=R.+A.+Mookauthor=S.+G.+Laquerreauthor=A.+J.+Kingauthor=O.+W.+Rossaneseauthor=M.+R.+Arnoneauthor=K.+N.+Smithemanauthor=L.+S.+Kane-Carsonauthor=C.+Hanauthor=G.+S.+Moorthyauthor=K.+G.+Mossauthor=D.+E.+Uehling&title=Discovery+of+dabrafenib%3A+a+selective+inhibitor+of+Raf+kinases+with+antitumor+activity+against+B-Raf-driven+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Fml4000063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml4000063%26sid%3Dliteratum%253Aachs%26aulast%3DRheault%26aufirst%3DT.%2BR.%26aulast%3DStellwagen%26aufirst%3DJ.%2BC.%26aulast%3DAdjabeng%26aufirst%3DG.%2BM.%26aulast%3DHornberger%26aufirst%3DK.%2BR.%26aulast%3DPetrov%26aufirst%3DK.%2BG.%26aulast%3DWaterson%26aufirst%3DA.%2BG.%26aulast%3DDickerson%26aufirst%3DS.%2BH.%26aulast%3DMook%26aufirst%3DR.%2BA.%26aulast%3DLaquerre%26aufirst%3DS.%2BG.%26aulast%3DKing%26aufirst%3DA.%2BJ.%26aulast%3DRossanese%26aufirst%3DO.%2BW.%26aulast%3DArnone%26aufirst%3DM.%2BR.%26aulast%3DSmitheman%26aufirst%3DK.%2BN.%26aulast%3DKane-Carson%26aufirst%3DL.%2BS.%26aulast%3DHan%26aufirst%3DC.%26aulast%3DMoorthy%26aufirst%3DG.%2BS.%26aulast%3DMoss%26aufirst%3DK.%2BG.%26aulast%3DUehling%26aufirst%3DD.%2BE.%26atitle%3DDiscovery%2520of%2520dabrafenib%253A%2520a%2520selective%2520inhibitor%2520of%2520Raf%2520kinases%2520with%2520antitumor%2520activity%2520against%2520B-Raf-driven%2520tumors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D358%26epage%3D362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Bollag, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ibrahim, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolop, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirth, P.</span><span> </span><span class="NLM_article-title">Vemurafenib: the first drug approved for BRAF-mutant cancer</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">873</span><span class="NLM_x">–</span> <span class="NLM_lpage">886</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=873-886&author=G.+Bollagauthor=J.+Tsaiauthor=J.+Z.+Zhangauthor=C.+Zhangauthor=P.+Ibrahimauthor=K.+Nolopauthor=P.+Hirth&title=Vemurafenib%3A+the+first+drug+approved+for+BRAF-mutant+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DTsai%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%2BZ.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DIbrahim%26aufirst%3DP.%26aulast%3DNolop%26aufirst%3DK.%26aulast%3DHirth%26aufirst%3DP.%26atitle%3DVemurafenib%253A%2520the%2520first%2520drug%2520approved%2520for%2520BRAF-mutant%2520cancer%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26spage%3D873%26epage%3D886" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Ballantyne, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garnock-Jones, K. P.</span><span> </span><span class="NLM_article-title">Dabrafenib: first global approval</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">1367</span><span class="NLM_x">–</span> <span class="NLM_lpage">1376</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=1367-1376&author=A.+D.+Ballantyneauthor=K.+P.+Garnock-Jones&title=Dabrafenib%3A+first+global+approval"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBallantyne%26aufirst%3DA.%2BD.%26aulast%3DGarnock-Jones%26aufirst%3DK.%2BP.%26atitle%3DDabrafenib%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2013%26volume%3D73%26spage%3D1367%26epage%3D1376" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Chapman, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hauschild, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haanen, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ascierto, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larkin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dummer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garbe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Testori, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorigan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebbe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jouary, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schadendorf, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Day, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkwood, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eggermont, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dreno, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolop, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G. A.</span><span> </span><span class="NLM_article-title">Improved survival with vemurafenib in melanoma with BRAF V600E mutation</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">364</span><span class="NLM_x">, </span> <span class="NLM_fpage">2507</span><span class="NLM_x">–</span> <span class="NLM_lpage">2516</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm500007h&amp;key=10.1056%2FNEJMoa1103782" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm500007h&amp;key=21639808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm500007h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosVeitbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=2507-2516&author=P.+B.+Chapmanauthor=A.+Hauschildauthor=C.+Robertauthor=J.+B.+Haanenauthor=P.+Asciertoauthor=J.+Larkinauthor=R.+Dummerauthor=C.+Garbeauthor=A.+Testoriauthor=M.+Maioauthor=D.+Hoggauthor=P.+Loriganauthor=C.+Lebbeauthor=T.+Jouaryauthor=D.+Schadendorfauthor=A.+Ribasauthor=S.+J.+O%E2%80%99Dayauthor=J.+A.+Sosmanauthor=J.+M.+Kirkwoodauthor=A.+M.+Eggermontauthor=B.+Drenoauthor=K.+Nolopauthor=J.+Liauthor=B.+Nelsonauthor=J.+Houauthor=R.+J.+Leeauthor=K.+T.+Flahertyauthor=G.+A.+McArthur&title=Improved+survival+with+vemurafenib+in+melanoma+with+BRAF+V600E+mutation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Improved survival with vemurafenib in melanoma with BRAF V600E mutation</span></div><div class="casAuthors">Chapman, Paul B.; Hauschild, Axel; Robert, Caroline; Haanen, John B.; Ascierto, Paolo; Larkin, James; Dummer, Reinhard; Garbe, Claus; Testori, Alessandro; Maio, Michele; Hogg, David; Lorigan, Paul; Lebbe, Celeste; Jouary, Thomas; Schadendorf, Dirk; Ribas, Antoni; O'Day, Steven J.; Sosman, Jeffrey A.; Kirkwood, John M.; Eggermont, Alexander M. M.; Dreno, Brigitte; Nolop, Keith; Li, Jiang; Nelson, Betty; Hou, Jeannie; Lee, Richard J.; Flaherty, Keith T.; McArthur, Grant A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">2507-2516</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Phase 1 and 2 clin. trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E mutation.  METHODS: We conducted a phase 3 randomized clin. trial comparing vemurafenib with dacarbazine in 675 patients with previously untreated, metastatic melanoma with the BRAF V600E mutation.  Patients were randomly assigned to receive either vemurafenib (960 mg orally twice daily) or dacarbazine (1000 mg per square meter of body-surface area i.v. every 3 wk).  Coprimary end points were rates of overall and progression-free survival.  Secondary end points included the response rate, response duration, and safety.  A final anal. was planned after 196 deaths and an interim anal. after 98 deaths.  RESULTS: At 6 mo, overall survival was 840/ (95% confidence interval [CI], 78 to 89) in the vemurafenib group and 64% (95% CI, 56 to 73) in the dacarbazine group.  In the interim anal. for overall survival and final anal. for progression-free survival, vemurafenib was assocd. with a relative redn. of 63% in the risk of death and of 74% in the risk of either death or disease progression, as compared with dacarbazine (P < 0.001 for both comparisons).  After review of the interim anal. by an independent data and safety monitoring board, crossover from dacarbazine to vemurafenib was recommended.  Response rates were 48% for vemurafenib and 5% for dacarbazine.  Common adverse events assocd. with vemurafenib were arthralgia, rash, fatigue, alopecia, keratoacanthoma or squamous-cell carcinoma, photosensitivity, nausea, and diarrhea; 38% of patients required dose modification because of toxic effects.  CONCLUSIONS: Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4NFxmTaDz97Vg90H21EOLACvtfcHk0lhSMp_oQJNHGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosVeitbs%253D&md5=1a4b4f963221888dc63f620e87408070</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1103782&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1103782%26sid%3Dliteratum%253Aachs%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DHauschild%26aufirst%3DA.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DHaanen%26aufirst%3DJ.%2BB.%26aulast%3DAscierto%26aufirst%3DP.%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DDummer%26aufirst%3DR.%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DTestori%26aufirst%3DA.%26aulast%3DMaio%26aufirst%3DM.%26aulast%3DHogg%26aufirst%3DD.%26aulast%3DLorigan%26aufirst%3DP.%26aulast%3DLebbe%26aufirst%3DC.%26aulast%3DJouary%26aufirst%3DT.%26aulast%3DSchadendorf%26aufirst%3DD.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Day%26aufirst%3DS.%2BJ.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DKirkwood%26aufirst%3DJ.%2BM.%26aulast%3DEggermont%26aufirst%3DA.%2BM.%26aulast%3DDreno%26aufirst%3DB.%26aulast%3DNolop%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DNelson%26aufirst%3DB.%26aulast%3DHou%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26atitle%3DImproved%2520survival%2520with%2520vemurafenib%2520in%2520melanoma%2520with%2520BRAF%2520V600E%2520mutation%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D2507%26epage%3D2516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puzanov, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Dwyer, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grippo, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolop, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, P. B.</span><span> </span><span class="NLM_article-title">Inhibition of mutated, activated BRAF in metastatic melanoma</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x">, </span> <span class="NLM_fpage">809</span><span class="NLM_x">–</span> <span class="NLM_lpage">819</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm500007h&amp;key=10.1056%2FNEJMoa1002011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm500007h&amp;key=20818844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm500007h&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVyksb3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=809-819&author=K.+T.+Flahertyauthor=I.+Puzanovauthor=K.+B.+Kimauthor=A.+Ribasauthor=G.+A.+McArthurauthor=J.+A.+Sosmanauthor=P.+J.+O%E2%80%99Dwyerauthor=R.+J.+Leeauthor=J.+F.+Grippoauthor=K.+Nolopauthor=P.+B.+Chapman&title=Inhibition+of+mutated%2C+activated+BRAF+in+metastatic+melanoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of mutated, activated BRAF in metastatic melanoma</span></div><div class="casAuthors">Flaherty, Keith T.; Puzanov, Igor; Kim, Kevin B.; Ribas, Antoni; McArthur, Grant A.; Sosman, Jeffrey A.; O'dwyer, Peter J.; Lee, Richard J.; Grippo, Joseph F.; Nolop, Keith; Chapman, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">809-819</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: The identification of somatic mutations in the gene encoding the serine-threonine protein kinase B-RAF (BRAF) in the majority of melanomas offers an opportunity to test oncogene-targeted therapy for this disease.  Methods: We conducted a multicenter, phase 1, dose-escalation trial of PLX4032 (also known as RG7204), an orally available inhibitor of mutated BRAF, followed by an extension phase involving the max. dose that could be administered without adverse effects (the recommended phase 2 dose).  Patients received PLX4032 twice daily until they had disease progression.  Pharmacokinetic anal. and tumor-response assessments were conducted in all patients.  In selected patients, tumor biopsy was performed before and during treatment to validate BRAF inhibition.  Results: A total of 55 patients (49 of whom had melanoma) were enrolled in the dose-escalation phase, and 32 addnl. patients with metastatic melanoma who had BRAF with the V600E mutation were enrolled in the extension phase.  The recommended phase 2 dose was 960 mg twice daily, with increases in the dose limited by grade 2 or 3 rash, fatigue, and arthralgia.  In the dose-escalation cohort, among the 16 patients with melanoma whose tumors carried the V600E BRAF mutation and who were receiving 240 mg or more of PLX4032 twice daily, 10 had a partial response and 1 had a complete response.  Among the 32 patients in the extension cohort, 24 had a partial response and 2 had a complete response.  The estd. median progression-free survival among all patients was more than 7 mo.  Conclusions: Treatment of metastatic melanoma with PLX4032 in patients with tumors that carry the V600E BRAF mutation resulted in complete or partial tumor regression in the majority of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwq1fkvEjfyLVg90H21EOLACvtfcHk0lhSMp_oQJNHGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVyksb3M&md5=80f70df0ac490828a42e6c7c0b40067f</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1002011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1002011%26sid%3Dliteratum%253Aachs%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DO%25E2%2580%2599Dwyer%26aufirst%3DP.%2BJ.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DGrippo%26aufirst%3DJ.%2BF.%26aulast%3DNolop%26aufirst%3DK.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26atitle%3DInhibition%2520of%2520mutated%252C%2520activated%2520BRAF%2520in%2520metastatic%2520melanoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D809%26epage%3D819" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuchter, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pavlick, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutson, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moschos, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hersey, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kefford, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawrence, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puzanov, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amaravadi, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chmielowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawrence, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shyr, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolop, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joe, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span> </span><span class="NLM_article-title">Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">366</span><span class="NLM_x">, </span> <span class="NLM_fpage">707</span><span class="NLM_x">–</span> <span class="NLM_lpage">714</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm500007h&amp;key=10.1056%2FNEJMoa1112302" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm500007h&amp;key=22356324" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm500007h&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtFOqtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2012&pages=707-714&author=J.+A.+Sosmanauthor=K.+B.+Kimauthor=L.+Schuchterauthor=R.+Gonzalezauthor=A.+C.+Pavlickauthor=J.+S.+Weberauthor=G.+A.+McArthurauthor=T.+E.+Hutsonauthor=S.+J.+Moschosauthor=K.+T.+Flahertyauthor=P.+Herseyauthor=R.+Keffordauthor=D.+Lawrenceauthor=I.+Puzanovauthor=K.+D.+Lewisauthor=R.+K.+Amaravadiauthor=B.+Chmielowskiauthor=H.+J.+Lawrenceauthor=Y.+Shyrauthor=F.+Yeauthor=J.+Liauthor=K.+B.+Nolopauthor=R.+J.+Leeauthor=A.+K.+Joeauthor=A.+Ribas&title=Survival+in+BRAF+V600-mutant+advanced+melanoma+treated+with+vemurafenib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib</span></div><div class="casAuthors">Sosman, Jeffrey A.; Kim, Kevin B.; Schuchter, Lynn; Gonzalez, Rene; Pavlick, Anna C.; Weber, Jeffrey S.; McArthur, Grant A.; Hutson, Thomas E.; Moschos, Stergios J.; Flaherty, Keith T.; Hersey, Peter; Kefford, Richard; Lawrence, Donald; Puzanov, Igor; Lewis, Karl D.; Amaravadi, Ravi K.; Chmielowski, Bartosz; Lawrence, H. Jeffrey; Shyr, Yu; Ye, Fei; Li, Jiang; Nolop, Keith B.; Lee, Richard J.; Joe, Andrew K.; Ribas, Antoni</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">366</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">707-714</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Approx. 50% of melanomas harbor activating (V600) mutations in the serine-threonine protein kinase B-RAF (BRAF).  The oral BRAF inhibitor vemurafenib (PLX4032) frequently produced tumor regressions in patients with BRAF V600-mutant metastatic melanoma in a phase 1 trial and improved overall survival in a phase 3 trial.  METHODS We designed a multicenter phase 2 trial of vemurafenib in patients with previously treated BRAF V600-mutant metastatic melanoma to investigate the efficacy of vem urafenib with respect to overall response rate (percentage of treated patients with a tumor response), duration of response, and overall survival.  The primary end point was the overall response rate as ascertained by the independent review committee; overall survival was a secondary end point.  RESULTS A total of 132 patients had a median follow-up of 12.9 mo (range, 0.6 to 20.1).  The confirmed overall response rate was 53% (95% confidence interval [CI], 44 to 62; 6% with a complete response and 47% with a partial response), the median duration of response was 6.7 mo (95% CI, 5.6 to 8.6), and the median progression-free survival was 6.8 mo (95% CI, 5.6 to 8.1).  Primary progression was obsd.,in only 14% of patients.  Some patients had a response after receiving vemurafenib for more than 6' months.  The median overall survival was 15.9 mo (95% CI, 11.6 to 18.3).  The most common adverse events were grade 1 or 2 arthralgia, rash, photosensitivity, fatigue, and alopecia.  Cutaneous squamous-cell carcinomas (the majority, keratoacanthoma type) were diagnosed in 26% of patients.  CONCLUSIONS Vemurafenib induces clin. responses in more than half of patients with previously treated BRAF V600-mutant metastatic melanoma.  In this study with a long follow-up, the median overall survival was approx. 16 mo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0-17UBZyghrVg90H21EOLACvtfcHk0lhSMp_oQJNHGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtFOqtr0%253D&md5=74da93cc5ac6497207f12dd0461d9414</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1112302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1112302%26sid%3Dliteratum%253Aachs%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DSchuchter%26aufirst%3DL.%26aulast%3DGonzalez%26aufirst%3DR.%26aulast%3DPavlick%26aufirst%3DA.%2BC.%26aulast%3DWeber%26aufirst%3DJ.%2BS.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DHutson%26aufirst%3DT.%2BE.%26aulast%3DMoschos%26aufirst%3DS.%2BJ.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DHersey%26aufirst%3DP.%26aulast%3DKefford%26aufirst%3DR.%26aulast%3DLawrence%26aufirst%3DD.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DLewis%26aufirst%3DK.%2BD.%26aulast%3DAmaravadi%26aufirst%3DR.%2BK.%26aulast%3DChmielowski%26aufirst%3DB.%26aulast%3DLawrence%26aufirst%3DH.%2BJ.%26aulast%3DShyr%26aufirst%3DY.%26aulast%3DYe%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DNolop%26aufirst%3DK.%2BB.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DJoe%26aufirst%3DA.%2BK.%26aulast%3DRibas%26aufirst%3DA.%26atitle%3DSurvival%2520in%2520BRAF%2520V600-mutant%2520advanced%2520melanoma%2520treated%2520with%2520vemurafenib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D366%26spage%3D707%26epage%3D714" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Falchook, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, G. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurzrock, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arkenau, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamid, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Infante, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Millward, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pavlick, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Day, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackman, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtis, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebowitz, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ouellet, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kefford, R. F.</span><span> </span><span class="NLM_article-title">Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">379</span><span class="NLM_x">, </span> <span class="NLM_fpage">1893</span><span class="NLM_x">–</span> <span class="NLM_lpage">1901</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm500007h&amp;key=10.1016%2FS0140-6736%2812%2960398-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm500007h&amp;key=22608338" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm500007h&amp;key=1%3ACAS%3A528%3ADC%252BC38Xnt1Kmtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=379&publication_year=2012&pages=1893-1901&author=G.+S.+Falchookauthor=G.+V.+Longauthor=R.+Kurzrockauthor=K.+B.+Kimauthor=T.+H.+Arkenauauthor=M.+P.+Brownauthor=O.+Hamidauthor=J.+R.+Infanteauthor=M.+Millwardauthor=A.+C.+Pavlickauthor=S.+J.+O%E2%80%99Dayauthor=S.+C.+Blackmanauthor=C.+M.+Curtisauthor=P.+Lebowitzauthor=B.+Maauthor=D.+Ouelletauthor=R.+F.+Kefford&title=Dabrafenib+in+patients+with+melanoma%2C+untreated+brain+metastases%2C+and+other+solid+tumours%3A+a+phase+1+dose-escalation+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial</span></div><div class="casAuthors">Falchook, Gerald S.; Long, Georgina V.; Kurzrock, Razelle; Kim, Kevin B.; Arkenau, Tobias H.; Brown, Michael P.; Hamid, Omid; Infante, Jeffrey R.; Millward, Michael; Pavlick, Anna C.; O'Day, Steven J.; Blackman, Samuel C.; Curtis, C. Martin; Lebowitz, Peter; Ma, Bo; Ouellet, Daniele; Kefford, Richard F.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">379</span>
        (<span class="NLM_cas:issue">9829</span>),
    <span class="NLM_cas:pages">1893-1901</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Dabrafenib is an inhibitor of BRAF kinase that is selective for mutant BRAF.  We aimed to assess its safety and tolerability and to establish a recommended phase 2 dose in patients with incurable solid tumors, esp. those with melanoma and untreated, asymptomatic brain metastases.  We undertook a phase 1 trial between May 27, 2009, and March 20, 2012, at eight study centers in Australia and the USA.  Eligible patients had incurable solid tumors, were 18 years or older, and had adequate organ function.  BRAF mutations were mandatory for inclusion later in the study because of an absence of activity in patients with wild-type BRAF.  We used an accelerated dose titrn. method, with the first dose cohort receiving 12 mg dabrafenib daily in a 21-day cycle.  Once doses had been established, we expanded the cohorts to include up to 20 patients.  On the basis of initial data, we chose a recommended phase 2 dose.  Efficacy at the recommended phase 2 dose was studied in patients with BRAF-mutant tumors, including those with non-Val600Glu mutations, in three cohorts: metastatic melanoma, melanoma with untreated brain metastases, and non-melanoma solid tumors.  This study is registered with ClinicalTrials.gov, no. NCT00880321.  We enrolled 184 patients, of whom 156 had metastatic melanoma.  The most common treatment-related adverse events of grade 2 or worse were cutaneous squamous-cell carcinoma (20 patients, 11%), fatigue (14, 8%), and pyrexia (11, 6%).  Dose redns. were necessary in 13 (7%) patients.  No deaths or discontinuations resulted from adverse events, and 140 (76%) patients had no treatment-related adverse events worse than grade 2.  Doses were increased to 300 mg twice daily, with no max. tolerated dose recorded.  On the basis of safety, pharmacokinetic, and response data, we selected a recommended phase 2 dose of 150 mg twice daily.  At the recommended phase 2 dose in 36 patients with Val600 BRAF-mutant melanoma, responses were reported in 25 (69%, 95% CI 51·9-83·7) and confirmed responses in 18 (50%, 32·9-67·1). 21 (78%, 57·7-91·4) of 27 patients with Val600Glu BRAF-mutant melanoma responded and 15 (56%, 35·3-74·5) had a confirmed response.  In Val600 BRAF-mutant melanoma, responses were durable, with 17 patients (47%) on treatment for more than 6 mo.  Responses were recorded in patients with non-Val600Glu BRAF mutations.  In patients with melanoma and untreated brain metastases, nine of ten patients had redns. in size of brain lesions.  In 28 patients with BRAF-mutant non-melanoma solid tumors, apparent antitumor activity was noted in a gastrointestinal stromal tumor, papillary thyroid cancers, non-small-cell lung cancer, ovarian cancer, and colorectal cancer.  Dabrafenib is safe in patients with solid tumors, and an active inhibitor of Val600-mutant BRAF with responses noted in patients with melanoma, brain metastases, and other solid tumors.GlaxoSmithKline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLh2oSdpl4mrVg90H21EOLACvtfcHk0ljCZ4jS5a2GBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xnt1Kmtbo%253D&md5=f2d104a308316cf613ed8639491a3acf</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2812%2960398-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252812%252960398-5%26sid%3Dliteratum%253Aachs%26aulast%3DFalchook%26aufirst%3DG.%2BS.%26aulast%3DLong%26aufirst%3DG.%2BV.%26aulast%3DKurzrock%26aufirst%3DR.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DArkenau%26aufirst%3DT.%2BH.%26aulast%3DBrown%26aufirst%3DM.%2BP.%26aulast%3DHamid%26aufirst%3DO.%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26aulast%3DMillward%26aufirst%3DM.%26aulast%3DPavlick%26aufirst%3DA.%2BC.%26aulast%3DO%25E2%2580%2599Day%26aufirst%3DS.%2BJ.%26aulast%3DBlackman%26aufirst%3DS.%2BC.%26aulast%3DCurtis%26aufirst%3DC.%2BM.%26aulast%3DLebowitz%26aufirst%3DP.%26aulast%3DMa%26aufirst%3DB.%26aulast%3DOuellet%26aufirst%3DD.%26aulast%3DKefford%26aufirst%3DR.%2BF.%26atitle%3DDabrafenib%2520in%2520patients%2520with%2520melanoma%252C%2520untreated%2520brain%2520metastases%252C%2520and%2520other%2520solid%2520tumours%253A%2520a%2520phase%25201%2520dose-escalation%2520trial%26jtitle%3DLancet%26date%3D2012%26volume%3D379%26spage%3D1893%26epage%3D1901" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Hauschild, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grob, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demidov, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jouary, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gutzmer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Millward, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rutkowski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blank, C. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, W. H.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaempgen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin-Algarra, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karaszewska, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mauch, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiarion-Sileni, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swann, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haney, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mirakhur, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guckert, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodman, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, P. B.</span><span> </span><span class="NLM_article-title">Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">380</span><span class="NLM_x">, </span> <span class="NLM_fpage">358</span><span class="NLM_x">–</span> <span class="NLM_lpage">365</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm500007h&amp;key=10.1016%2FS0140-6736%2812%2960868-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm500007h&amp;key=22735384" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm500007h&amp;key=1%3ACAS%3A528%3ADC%252BC38Xpt1SgtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=380&publication_year=2012&pages=358-365&author=A.+Hauschildauthor=J.+J.+Grobauthor=L.+V.+Demidovauthor=T.+Jouaryauthor=R.+Gutzmerauthor=M.+Millwardauthor=P.+Rutkowskiauthor=C.+U.+Blankauthor=W.+H.+Millerauthor=E.+Kaempgenauthor=S.+Martin-Algarraauthor=B.+Karaszewskaauthor=C.+Mauchauthor=V.+Chiarion-Sileniauthor=A.+M.+Martinauthor=S.+Swannauthor=P.+Haneyauthor=B.+Mirakhurauthor=M.+E.+Guckertauthor=V.+Goodmanauthor=P.+B.+Chapman&title=Dabrafenib+in+BRAF-mutated+metastatic+melanoma%3A+a+multicentre%2C+open-label%2C+phase+3+randomised+controlled+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial</span></div><div class="casAuthors">Hauschild, Axel; Grob, Jean-Jacques; Demidov, Lev V.; Jouary, Thomas; Gutzmer, Ralf; Millward, Michael; Rutkowski, Piotr; Blank, Christian U.; Miller, Wilson H.; Kaempgen, Eckhart; Martin-Algarra, Salvador; Karaszewska, Boguslawa; Mauch, Cornelia; Chiarion-Sileni, Vanna; Martin, Anne-Marie; Swann, Suzanne; Haney, Patricia; Mirakhur, Beloo; Guckert, Mary E.; Goodman, Vicki; Chapman, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">380</span>
        (<span class="NLM_cas:issue">9839</span>),
    <span class="NLM_cas:pages">358-365</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Dabrafenib, an inhibitor of mutated BRAF, has clin. activity with a manageable safety profile in studies of phase 1 and 2 in patients with BRAFV600-mutated metastatic melanoma.  We studied the efficacy of dabrafenib in patients with BRAFV600E-mutated metastatic melanoma.We enrolled patients in this open-label phase 3 trial between Dec 23, 2010, and Sept 1, 2011.  This report is based on a data cutoff date of Dec 19, 2011.  Patients aged 18 years or older with previously untreated, stage IV or unresectable stage III BRAFV600E mutation-pos. melanoma were randomly assigned (3:1) to receive dabrafenib (150 mg twice daily, orally) or dacarbazine (1000 mg/m2 i.v. every 3 wk).  Patients were stratified according to American Joint Committee on Cancer stage (unresectable III+IVM1a+IVM1b vs IVM1c).  The primary endpoint was investigator-assessed progression-free survival and was analyzed by intention to treat; safety was assessed per protocol.  This study is registered with ClinicalTrials.gov, no. NCT01227889.Of the 733 patients screened, 250 were randomly assigned to receive either dabrafenib (187 patients) or dacarbazine (63 patients).  Median progression-free survival was 5·1 mo for dabrafenib and 2·7 mo for dacarbazine, with a hazard ratio (HR) of 0·30 (95% CI 0·18-0·51; p<0·0001).  At data cutoff, 107 (57%) patients in the dabrafenib group and 14 (22%) in the dacarbazine group remained on randomized treatment.  Treatment-related adverse events (grade 2 or higher) occurred in 100 (53%) of the 187 patients who received dabrafenib and in 26 (44%) of the 59 patients who received dacarbazine.  The most common adverse events with dabrafenib were skin-related toxic effects, fever, fatigue, arthralgia, and headache.  The most common adverse events with dacarbazine were nausea, vomiting, neutropenia, fatigue, and asthenia.  Grade 3-4 adverse events were uncommon in both groups.Dabrafenib significantly improved progression-free survival compared with dacarbazine.GlaxoSmithKline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEDYPJULE5c7Vg90H21EOLACvtfcHk0ljCZ4jS5a2GBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xpt1SgtLg%253D&md5=5e8699780f47bd37e075d39636e0d809</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2812%2960868-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252812%252960868-X%26sid%3Dliteratum%253Aachs%26aulast%3DHauschild%26aufirst%3DA.%26aulast%3DGrob%26aufirst%3DJ.%2BJ.%26aulast%3DDemidov%26aufirst%3DL.%2BV.%26aulast%3DJouary%26aufirst%3DT.%26aulast%3DGutzmer%26aufirst%3DR.%26aulast%3DMillward%26aufirst%3DM.%26aulast%3DRutkowski%26aufirst%3DP.%26aulast%3DBlank%26aufirst%3DC.%2BU.%26aulast%3DMiller%26aufirst%3DW.%2BH.%26aulast%3DKaempgen%26aufirst%3DE.%26aulast%3DMartin-Algarra%26aufirst%3DS.%26aulast%3DKaraszewska%26aufirst%3DB.%26aulast%3DMauch%26aufirst%3DC.%26aulast%3DChiarion-Sileni%26aufirst%3DV.%26aulast%3DMartin%26aufirst%3DA.%2BM.%26aulast%3DSwann%26aufirst%3DS.%26aulast%3DHaney%26aufirst%3DP.%26aulast%3DMirakhur%26aufirst%3DB.%26aulast%3DGuckert%26aufirst%3DM.%2BE.%26aulast%3DGoodman%26aufirst%3DV.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26atitle%3DDabrafenib%2520in%2520BRAF-mutated%2520metastatic%2520melanoma%253A%2520a%2520multicentre%252C%2520open-label%252C%2520phase%25203%2520randomised%2520controlled%2520trial%26jtitle%3DLancet%26date%3D2012%26volume%3D380%26spage%3D358%26epage%3D365" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Johannessen, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boehm, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardwell, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emery, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stransky, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cogdill, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barretina, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caponigro, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hieronymus, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salehi-Ashtiani, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vidal, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, X. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alkan, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myer, V. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finan, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Root, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golub, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dummer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlegel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wargo, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hahn, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garraway, L. A.</span><span> </span><span class="NLM_article-title">COT drives resistance to RAF inhibition through MAP kinase pathway reactivation</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">468</span><span class="NLM_x">, </span> <span class="NLM_fpage">968</span><span class="NLM_x">–</span> <span class="NLM_lpage">972</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=468&publication_year=2010&pages=968-972&author=C.+M.+Johannessenauthor=J.+S.+Boehmauthor=S.+Y.+Kimauthor=S.+R.+Thomasauthor=L.+Wardwellauthor=L.+A.+Johnsonauthor=C.+M.+Emeryauthor=N.+Stranskyauthor=A.+P.+Cogdillauthor=J.+Barretinaauthor=G.+Caponigroauthor=H.+Hieronymusauthor=R.+R.+Murrayauthor=K.+Salehi-Ashtianiauthor=D.+E.+Hillauthor=M.+Vidalauthor=J.+J.+Zhaoauthor=X.+P.+Yangauthor=O.+Alkanauthor=S.+Kimauthor=J.+L.+Harrisauthor=C.+J.+Wilsonauthor=V.+E.+Myerauthor=P.+M.+Finanauthor=D.+E.+Rootauthor=T.+M.+Robertsauthor=T.+Golubauthor=K.+T.+Flahertyauthor=R.+Dummerauthor=B.+L.+Weberauthor=W.+R.+Sellersauthor=R.+Schlegelauthor=J.+A.+Wargoauthor=W.+C.+Hahnauthor=L.+A.+Garraway&title=COT+drives+resistance+to+RAF+inhibition+through+MAP+kinase+pathway+reactivation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJohannessen%26aufirst%3DC.%2BM.%26aulast%3DBoehm%26aufirst%3DJ.%2BS.%26aulast%3DKim%26aufirst%3DS.%2BY.%26aulast%3DThomas%26aufirst%3DS.%2BR.%26aulast%3DWardwell%26aufirst%3DL.%26aulast%3DJohnson%26aufirst%3DL.%2BA.%26aulast%3DEmery%26aufirst%3DC.%2BM.%26aulast%3DStransky%26aufirst%3DN.%26aulast%3DCogdill%26aufirst%3DA.%2BP.%26aulast%3DBarretina%26aufirst%3DJ.%26aulast%3DCaponigro%26aufirst%3DG.%26aulast%3DHieronymus%26aufirst%3DH.%26aulast%3DMurray%26aufirst%3DR.%2BR.%26aulast%3DSalehi-Ashtiani%26aufirst%3DK.%26aulast%3DHill%26aufirst%3DD.%2BE.%26aulast%3DVidal%26aufirst%3DM.%26aulast%3DZhao%26aufirst%3DJ.%2BJ.%26aulast%3DYang%26aufirst%3DX.%2BP.%26aulast%3DAlkan%26aufirst%3DO.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DHarris%26aufirst%3DJ.%2BL.%26aulast%3DWilson%26aufirst%3DC.%2BJ.%26aulast%3DMyer%26aufirst%3DV.%2BE.%26aulast%3DFinan%26aufirst%3DP.%2BM.%26aulast%3DRoot%26aufirst%3DD.%2BE.%26aulast%3DRoberts%26aufirst%3DT.%2BM.%26aulast%3DGolub%26aufirst%3DT.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DDummer%26aufirst%3DR.%26aulast%3DWeber%26aufirst%3DB.%2BL.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DSchlegel%26aufirst%3DR.%26aulast%3DWargo%26aufirst%3DJ.%2BA.%26aulast%3DHahn%26aufirst%3DW.%2BC.%26aulast%3DGarraway%26aufirst%3DL.%2BA.%26atitle%3DCOT%2520drives%2520resistance%2520to%2520RAF%2520inhibition%2520through%2520MAP%2520kinase%2520pathway%2520reactivation%26jtitle%3DNature%26date%3D2010%26volume%3D468%26spage%3D968%26epage%3D972" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Nazarian, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, X. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koya, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Attar, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sazegar, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chodon, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo, R. S.</span><span> </span><span class="NLM_article-title">Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">468</span><span class="NLM_x">, </span> <span class="NLM_fpage">973</span><span class="NLM_x">–</span> <span class="NLM_lpage">977</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm500007h&amp;key=10.1038%2Fnature09626" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm500007h&amp;key=21107323" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm500007h&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsbjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=468&publication_year=2010&pages=973-977&author=R.+Nazarianauthor=H.+B.+Shiauthor=Q.+Wangauthor=X.+J.+Kongauthor=R.+C.+Koyaauthor=H.+Leeauthor=Z.+G.+Chenauthor=M.+K.+Leeauthor=N.+Attarauthor=H.+Sazegarauthor=T.+Chodonauthor=S.+F.+Nelsonauthor=G.+McArthurauthor=J.+A.+Sosmanauthor=A.+Ribasauthor=R.+S.+Lo&title=Melanomas+acquire+resistance+to+B-RAF%28V600E%29+inhibition+by+RTK+or+N-RAS+upregulation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation</span></div><div class="casAuthors">Nazarian, Ramin; Shi, Hubing; Wang, Qi; Kong, Xiangju; Koya, Richard C.; Lee, Hane; Chen, Zugen; Lee, Mi-Kyung; Attar, Narsis; Sazegar, Hooman; Chodon, Thinle; Nelson, Stanley F.; McArthur, Grant; Sosman, Jeffrey A.; Ribas, Antoni; Lo, Roger S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">468</span>
        (<span class="NLM_cas:issue">7326</span>),
    <span class="NLM_cas:pages">973-977</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Activating B-RAF(V600E) (also known as BRAF) kinase mutations occur in ∼7% of human malignancies and ∼60% of melanomas.  Early clin. experience with a novel class I RAF-selective inhibitor, PLX4032, demonstrated an unprecedented 80% anti-tumor response rate among patients with B-RAF(V600E)-pos. melanomas, but acquired drug resistance frequently develops after initial responses.  Hypotheses for mechanisms of acquired resistance to B-RAF inhibition include secondary mutations in B-RAF(V600E), MAPK reactivation, and activation of alternative survival pathways.  Here we show that acquired resistance to PLX4032 develops by mutually exclusive PDGFRβ (also known as PDGFRB) upregulation or N-RAS (also known as NRAS) mutations but not through secondary mutations in B-RAF(V600E).  We used PLX4032-resistant sub-lines artificially derived from B-RAF(V600E)-pos. melanoma cell lines and validated key findings in PLX4032-resistant tumors and tumor-matched, short-term cultures from clin. trial patients.  Induction of PDGFRβ RNA, protein and tyrosine phosphorylation emerged as a dominant feature of acquired PLX4032 resistance in a subset of melanoma sub-lines, patient-derived biopsies and short-term cultures.  PDGFRβ-upregulated tumor cells have low activated RAS levels and, when treated with PLX4032, do not reactivate the MAPK pathway significantly.  In another subset, high levels of activated N-RAS resulting from mutations lead to significant MAPK pathway reactivation upon PLX4032 treatment.  Knockdown of PDGFRβ or N-RAS reduced growth of the resp. PLX4032-resistant subsets.  Overexpression of PDGFRβ or N-RAS(Q61K) conferred PLX4032 resistance to PLX4032-sensitive parental cell lines.  Importantly, MAPK reactivation predicts MEK inhibitor sensitivity.  Thus, melanomas escape B-RAF(V600E) targeting not through secondary B-RAF(V600E) mutations but via receptor tyrosine kinase (RTK)-mediated activation of alternative survival pathway(s) or activated RAS-mediated reactivation of the MAPK pathway, suggesting addnl. therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMqxhHr_chLbVg90H21EOLACvtfcHk0ljvOpRaWx7juA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsbjI&md5=a591f224d5e36fe1d350394bbd49b3a7</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fnature09626&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09626%26sid%3Dliteratum%253Aachs%26aulast%3DNazarian%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DH.%2BB.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DKong%26aufirst%3DX.%2BJ.%26aulast%3DKoya%26aufirst%3DR.%2BC.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DZ.%2BG.%26aulast%3DLee%26aufirst%3DM.%2BK.%26aulast%3DAttar%26aufirst%3DN.%26aulast%3DSazegar%26aufirst%3DH.%26aulast%3DChodon%26aufirst%3DT.%26aulast%3DNelson%26aufirst%3DS.%2BF.%26aulast%3DMcArthur%26aufirst%3DG.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DLo%26aufirst%3DR.%2BS.%26atitle%3DMelanomas%2520acquire%2520resistance%2520to%2520B-RAF%2528V600E%2529%2520inhibition%2520by%2520RTK%2520or%2520N-RAS%2520upregulation%26jtitle%3DNature%26date%3D2010%26volume%3D468%26spage%3D973%26epage%3D977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Villanueva, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vultur, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somasundaram, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukunaga-Kalabis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cipolla, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wubbenhorst, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, X. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gimotty, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kee, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santiago-Walker, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Letrero, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Andrea, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pushparajan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayden, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laquerre, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nathanson, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herlyn, M.</span><span> </span><span class="NLM_article-title">Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">683</span><span class="NLM_x">–</span> <span class="NLM_lpage">695</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm500007h&amp;key=10.1016%2Fj.ccr.2010.11.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm500007h&amp;key=21156289" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm500007h&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFGhsbjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=683-695&author=J.+Villanuevaauthor=A.+Vulturauthor=J.+T.+Leeauthor=R.+Somasundaramauthor=M.+Fukunaga-Kalabisauthor=A.+K.+Cipollaauthor=B.+Wubbenhorstauthor=X.+W.+Xuauthor=P.+A.+Gimottyauthor=D.+Keeauthor=A.+E.+Santiago-Walkerauthor=R.+Letreroauthor=K.+D%E2%80%99Andreaauthor=A.+Pushparajanauthor=J.+E.+Haydenauthor=K.+D.+Brownauthor=S.+Laquerreauthor=G.+A.+McArthurauthor=J.+A.+Sosmanauthor=K.+L.+Nathansonauthor=M.+Herlyn&title=Acquired+resistance+to+BRAF+inhibitors+mediated+by+a+RAF+kinase+switch+in+melanoma+can+be+overcome+by+cotargeting+MEK+and+IGF-1R%2FPI3K"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K</span></div><div class="casAuthors">Villanueva, Jessie; Vultur, Adina; Lee, John T.; Somasundaram, Rajasekharan; Fukunaga-Kalabis, Mizuho; Cipolla, Angela K.; Wubbenhorst, Bradley; Xu, Xiaowei; Gimotty, Phyllis A.; Kee, Damien; Santiago-Walker, Ademi E.; Letrero, Richard; D'Andrea, Kurt; Pushparajan, Anitha; Hayden, James E.; Brown, Kimberly Dahlman; Laquerre, Sylvie; McArthur, Grant A.; Sosman, Jeffrey A.; Nathanson, Katherine L.; Herlyn, Meenhard</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">683-695</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">BRAF is an attractive target for melanoma drug development.  However, resistance to BRAF inhibitors is a significant clin. challenge.  We describe a model of resistance to BRAF inhibitors developed by chronic treatment of BRAFV600E melanoma cells with the BRAF inhibitor SB-590885; these cells are cross-resistant to other BRAF-selective inhibitors.  Resistance involves flexible switching among the three RAF isoforms, underscoring the ability of melanoma cells to adapt to pharmacol. challenges.  IGF-1R/PI3K signaling was enhanced in resistant melanomas, and combined treatment with IGF-1R/PI3K and MEK inhibitors induced death of BRAF inhibitor-resistant cells.  Increased IGF-1R and pAKT levels in a post-relapse human tumor sample are consistent with a role for IGF-1R/PI3K-dependent survival in the development of resistance to BRAF inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgKfw2MUtmLLVg90H21EOLACvtfcHk0ljh4gHl_O9WEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFGhsbjJ&md5=c535681201c592cd8941b68e8a936d0e</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2010.11.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2010.11.023%26sid%3Dliteratum%253Aachs%26aulast%3DVillanueva%26aufirst%3DJ.%26aulast%3DVultur%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DJ.%2BT.%26aulast%3DSomasundaram%26aufirst%3DR.%26aulast%3DFukunaga-Kalabis%26aufirst%3DM.%26aulast%3DCipolla%26aufirst%3DA.%2BK.%26aulast%3DWubbenhorst%26aufirst%3DB.%26aulast%3DXu%26aufirst%3DX.%2BW.%26aulast%3DGimotty%26aufirst%3DP.%2BA.%26aulast%3DKee%26aufirst%3DD.%26aulast%3DSantiago-Walker%26aufirst%3DA.%2BE.%26aulast%3DLetrero%26aufirst%3DR.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DK.%26aulast%3DPushparajan%26aufirst%3DA.%26aulast%3DHayden%26aufirst%3DJ.%2BE.%26aulast%3DBrown%26aufirst%3DK.%2BD.%26aulast%3DLaquerre%26aufirst%3DS.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DNathanson%26aufirst%3DK.%2BL.%26aulast%3DHerlyn%26aufirst%3DM.%26atitle%3DAcquired%2520resistance%2520to%2520BRAF%2520inhibitors%2520mediated%2520by%2520a%2520RAF%2520kinase%2520switch%2520in%2520melanoma%2520can%2520be%2520overcome%2520by%2520cotargeting%2520MEK%2520and%2520IGF-1R%252FPI3K%26jtitle%3DCancer%2520Cell%26date%3D2010%26volume%3D18%26spage%3D683%26epage%3D695" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Poulikakos, P. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Persaud, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janakiraman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, X. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moriceau, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atefi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Titz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabay, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahlman, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tadi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wargo, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelley, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Misteli, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graeber, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solit, D. B.</span><span> </span><span class="NLM_article-title">RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">480</span><span class="NLM_x">, </span> <span class="NLM_fpage">387</span><span class="NLM_x">–</span> <span class="NLM_lpage">390</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm500007h&amp;key=10.1038%2Fnature10662" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm500007h&amp;key=22113612" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm500007h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFWqtL%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=480&publication_year=2011&pages=387-390&author=P.+I.+Poulikakosauthor=Y.+Persaudauthor=M.+Janakiramanauthor=X.+J.+Kongauthor=C.+Ngauthor=G.+Moriceauauthor=H.+B.+Shiauthor=M.+Atefiauthor=B.+Titzauthor=M.+T.+Gabayauthor=M.+Saltonauthor=K.+B.+Dahlmanauthor=M.+Tadiauthor=J.+A.+Wargoauthor=K.+T.+Flahertyauthor=M.+C.+Kelleyauthor=T.+Misteliauthor=P.+B.+Chapmanauthor=J.+A.+Sosmanauthor=T.+G.+Graeberauthor=A.+Ribasauthor=R.+S.+Loauthor=N.+Rosenauthor=D.+B.+Solit&title=RAF+inhibitor+resistance+is+mediated+by+dimerization+of+aberrantly+spliced+BRAF%28V600E%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)</span></div><div class="casAuthors">Poulikakos, Poulikos I.; Persaud, Yogindra; Janakiraman, Manickam; Kong, Xiangju; Ng, Charles; Moriceau, Gatien; Shi, Hubing; Atefi, Mohammad; Titz, Bjoern; Gabay, May Tal; Salton, Maayan; Dahlman, Kimberly B.; Tadi, Madhavi; Wargo, Jennifer A.; Flaherty, Keith T.; Kelley, Mark C.; Misteli, Tom; Chapman, Paul B.; Sosman, Jeffrey A.; Graeber, Thomas G.; Ribas, Antoni; Lo, Roger S.; Rosen, Neal; Solit, David B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">480</span>
        (<span class="NLM_cas:issue">7377</span>),
    <span class="NLM_cas:pages">387-390</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Although clin. trials have shown that RAF inhibitors prolong the survival of patients with BRAF-mutant melanoma, resistance inevitably develops; resistance is shown here to be frequently mediated by the expression of splicing variants of mutant BRAF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0XPUFDxeK5rVg90H21EOLACvtfcHk0ljh4gHl_O9WEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFWqtL%252FN&md5=b239591d5efd1d965deabf0527c3b9a6</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnature10662&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature10662%26sid%3Dliteratum%253Aachs%26aulast%3DPoulikakos%26aufirst%3DP.%2BI.%26aulast%3DPersaud%26aufirst%3DY.%26aulast%3DJanakiraman%26aufirst%3DM.%26aulast%3DKong%26aufirst%3DX.%2BJ.%26aulast%3DNg%26aufirst%3DC.%26aulast%3DMoriceau%26aufirst%3DG.%26aulast%3DShi%26aufirst%3DH.%2BB.%26aulast%3DAtefi%26aufirst%3DM.%26aulast%3DTitz%26aufirst%3DB.%26aulast%3DGabay%26aufirst%3DM.%2BT.%26aulast%3DSalton%26aufirst%3DM.%26aulast%3DDahlman%26aufirst%3DK.%2BB.%26aulast%3DTadi%26aufirst%3DM.%26aulast%3DWargo%26aufirst%3DJ.%2BA.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DKelley%26aufirst%3DM.%2BC.%26aulast%3DMisteli%26aufirst%3DT.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DGraeber%26aufirst%3DT.%2BG.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DLo%26aufirst%3DR.%2BS.%26aulast%3DRosen%26aufirst%3DN.%26aulast%3DSolit%26aufirst%3DD.%2BB.%26atitle%3DRAF%2520inhibitor%2520resistance%2520is%2520mediated%2520by%2520dimerization%2520of%2520aberrantly%2520spliced%2520BRAF%2528V600E%2529%26jtitle%3DNature%26date%3D2011%26volume%3D480%26spage%3D387%26epage%3D390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Shi, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, X. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo, R. S.</span><span> </span><span class="NLM_article-title">Combinatorial treatments that overcome PDGFR beta-driven resistance of melanoma cells to B-V600E-RAF inhibition</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">5067</span><span class="NLM_x">–</span> <span class="NLM_lpage">5074</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=5067-5074&author=H.+B.+Shiauthor=X.+J.+Kongauthor=A.+Ribasauthor=R.+S.+Lo&title=Combinatorial+treatments+that+overcome+PDGFR+beta-driven+resistance+of+melanoma+cells+to+B-V600E-RAF+inhibition"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DH.%2BB.%26aulast%3DKong%26aufirst%3DX.%2BJ.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DLo%26aufirst%3DR.%2BS.%26atitle%3DCombinatorial%2520treatments%2520that%2520overcome%2520PDGFR%2520beta-driven%2520resistance%2520of%2520melanoma%2520cells%2520to%2520B-V600E-RAF%2520inhibition%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D5067%26epage%3D5074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Wagle, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emery, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pochanard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kehoe, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johannessen, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macconaill, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hahn, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garraway, L. A.</span><span> </span><span class="NLM_article-title">Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">3085</span><span class="NLM_x">–</span> <span class="NLM_lpage">3096</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm500007h&amp;key=10.1200%2FJCO.2010.33.2312" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm500007h&amp;key=21383288" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm500007h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFCqtLfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=3085-3096&author=N.+Wagleauthor=C.+Emeryauthor=M.+F.+Bergerauthor=M.+J.+Davisauthor=A.+Sawyerauthor=P.+Pochanardauthor=S.+M.+Kehoeauthor=C.+M.+Johannessenauthor=L.+E.+Macconaillauthor=W.+C.+Hahnauthor=M.+Meyersonauthor=L.+A.+Garraway&title=Dissecting+therapeutic+resistance+to+RAF+inhibition+in+melanoma+by+tumor+genomic+profiling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling</span></div><div class="casAuthors">Wagle, Nikhil; Emery, Caroline; Berger, Michael F.; Davis, Matthew J.; Sawyer, Allison; Pochanard, Panisa; Kehoe, Sarah M.; Johannessen, Cory M.; MacConaill, Laura E.; Hahn, William C.; Meyerson, Matthew; Garraway, Levi A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3085-3096</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A detailed understanding of the mechanisms by which tumors acquire resistance to targeted anticancer agents should speed the development of treatment strategies with lasting clin. efficacy.  RAF inhibition in BRAF-mutant melanoma exemplifies the promise and challenge of many targeted drugs; although response rates are high, resistance invariably develops.  Here, we articulate overarching principles of resistance to kinase inhibitors, as well as a translational approach to characterize resistance in the clin. setting through tumor mutation profiling.  As a proof of principle, we performed targeted, massively parallel sequencing of 138 cancer genes in a tumor obtained from a patient with melanoma who developed resistance to PLX4032 after an initial dramatic response.  The resulting profile identified an activating mutation at codon 121 in the downstream kinase MEK1 that was absent in the corresponding pretreatment tumor.  The MEK1C121S mutation was shown to increase kinase activity and confer robust resistance to both RAF and MEK inhibition in vitro.  Thus, MEK1C121S or functionally similar mutations are predicted to confer resistance to combined MEK/RAF inhibition.  These results provide an instructive framework for assessing mechanisms of acquired resistance to kinase inhibition and illustrate the use of emerging technologies in a manner that may accelerate personalized cancer medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpK-2C4fs22UbVg90H21EOLACvtfcHk0lhvVN-ABsFFJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFCqtLfO&md5=d872acb5ba41d7eccc2717e31d856dd3</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1200%2FJCO.2010.33.2312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2010.33.2312%26sid%3Dliteratum%253Aachs%26aulast%3DWagle%26aufirst%3DN.%26aulast%3DEmery%26aufirst%3DC.%26aulast%3DBerger%26aufirst%3DM.%2BF.%26aulast%3DDavis%26aufirst%3DM.%2BJ.%26aulast%3DSawyer%26aufirst%3DA.%26aulast%3DPochanard%26aufirst%3DP.%26aulast%3DKehoe%26aufirst%3DS.%2BM.%26aulast%3DJohannessen%26aufirst%3DC.%2BM.%26aulast%3DMacconaill%26aufirst%3DL.%2BE.%26aulast%3DHahn%26aufirst%3DW.%2BC.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DGarraway%26aufirst%3DL.%2BA.%26atitle%3DDissecting%2520therapeutic%2520resistance%2520to%2520RAF%2520inhibition%2520in%2520melanoma%2520by%2520tumor%2520genomic%2520profiling%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D29%26spage%3D3085%26epage%3D3096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Corcoran, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turke, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coffee, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishino, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cogdill, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Della Pelle, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dias-Santagata, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hung, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piris, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wargo, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mino-Kenudson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span> </span><span class="NLM_article-title">EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">227</span><span class="NLM_x">–</span> <span class="NLM_lpage">235</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=227-235&author=R.+B.+Corcoranauthor=H.+Ebiauthor=A.+B.+Turkeauthor=E.+M.+Coffeeauthor=M.+Nishinoauthor=A.+P.+Cogdillauthor=R.+D.+Brownauthor=P.+Della+Pelleauthor=D.+Dias-Santagataauthor=K.+E.+Hungauthor=K.+T.+Flahertyauthor=A.+Pirisauthor=J.+A.+Wargoauthor=J.+Settlemanauthor=M.+Mino-Kenudsonauthor=J.+A.+Engelman&title=EGFR-mediated+re-activation+of+MAPK+signaling+contributes+to+insensitivity+of+BRAF+mutant+colorectal+cancers+to+RAF+inhibition+with+vemurafenib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCorcoran%26aufirst%3DR.%2BB.%26aulast%3DEbi%26aufirst%3DH.%26aulast%3DTurke%26aufirst%3DA.%2BB.%26aulast%3DCoffee%26aufirst%3DE.%2BM.%26aulast%3DNishino%26aufirst%3DM.%26aulast%3DCogdill%26aufirst%3DA.%2BP.%26aulast%3DBrown%26aufirst%3DR.%2BD.%26aulast%3DDella%2BPelle%26aufirst%3DP.%26aulast%3DDias-Santagata%26aufirst%3DD.%26aulast%3DHung%26aufirst%3DK.%2BE.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DPiris%26aufirst%3DA.%26aulast%3DWargo%26aufirst%3DJ.%2BA.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DEGFR-mediated%2520re-activation%2520of%2520MAPK%2520signaling%2520contributes%2520to%2520insensitivity%2520of%2520BRAF%2520mutant%2520colorectal%2520cancers%2520to%2520RAF%2520inhibition%2520with%2520vemurafenib%26jtitle%3DCancer%2520Discovery%26date%3D2012%26volume%3D2%26spage%3D227%26epage%3D235" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Prahallad, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Nicolantonio, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salazar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zecchin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beijersbergen, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bardelli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernards, R.</span><span> </span><span class="NLM_article-title">Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">483</span><span class="NLM_x">, </span> <span class="NLM_fpage">100</span><span class="NLM_x">–</span> <span class="NLM_lpage">103</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm500007h&amp;key=10.1038%2Fnature10868" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Fjm500007h&amp;key=22281684" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm500007h&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtFOktb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=483&publication_year=2012&pages=100-103&author=A.+Prahalladauthor=C.+Sunauthor=S.+D.+Huangauthor=F.+Di+Nicolantonioauthor=R.+Salazarauthor=D.+Zecchinauthor=R.+L.+Beijersbergenauthor=A.+Bardelliauthor=R.+Bernards&title=Unresponsiveness+of+colon+cancer+to+BRAF%28V600E%29+inhibition+through+feedback+activation+of+EGFR"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR</span></div><div class="casAuthors">Prahallad, Anirudh; Sun, Chong; Huang, Sidong; Di Nicolantonio, Federica; Salazar, Ramon; Zecchin, Davide; Beijersbergen, Roderick L.; Bardelli, Alberto; Bernards, Rene</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">483</span>
        (<span class="NLM_cas:issue">7387</span>),
    <span class="NLM_cas:pages">100-103</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Inhibition of the BRAF(V600E) oncoprotein by the small-mol. drug PLX4032 (vemurafenib) is highly effective in the treatment of melanoma.  However, colon cancer patients harbouring the same BRAF(V600E) oncogenic lesion have poor prognosis and show only a very limited response to this drug.  To investigate the cause of the limited therapeutic effect of PLX4032 in BRAF(V600E) mutant colon tumors, here we performed an RNA-interference-based genetic screen in human cells to search for kinases whose knockdown synergizes with BRAF(V600E) inhibition.  We report that blockade of the epidermal growth factor receptor (EGFR) shows strong synergy with BRAF(V600E) inhibition.  We find in multiple BRAF(V600E) mutant colon cancers that inhibition of EGFR by the antibody drug cetuximab or the small-mol. drugs gefitinib or erlotinib is strongly synergistic with BRAF(V600E) inhibition, both in vitro and in vivo.  Mechanistically, we find that BRAF(V600E) inhibition causes a rapid feedback activation of EGFR, which supports continued proliferation in the presence of BRAF(V600E) inhibition.  Melanoma cells express low levels of EGFR and are therefore not subject to this feedback activation.  Consistent with this, we find that ectopic expression of EGFR in melanoma cells is sufficient to cause resistance to PLX4032.  Our data suggest that BRAF(V600E) mutant colon cancers (approx. 8-10% of all colon cancers), for which there are currently no targeted treatment options available, might benefit from combination therapy consisting of BRAF and EGFR inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT_L3CIRBzo7Vg90H21EOLACvtfcHk0lhvVN-ABsFFJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtFOktb4%253D&md5=439e08cc65e43eb82188becb960b9943</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnature10868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature10868%26sid%3Dliteratum%253Aachs%26aulast%3DPrahallad%26aufirst%3DA.%26aulast%3DSun%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DS.%2BD.%26aulast%3DDi%2BNicolantonio%26aufirst%3DF.%26aulast%3DSalazar%26aufirst%3DR.%26aulast%3DZecchin%26aufirst%3DD.%26aulast%3DBeijersbergen%26aufirst%3DR.%2BL.%26aulast%3DBardelli%26aufirst%3DA.%26aulast%3DBernards%26aufirst%3DR.%26atitle%3DUnresponsiveness%2520of%2520colon%2520cancer%2520to%2520BRAF%2528V600E%2529%2520inhibition%2520through%2520feedback%2520activation%2520of%2520EGFR%26jtitle%3DNature%26date%3D2012%26volume%3D483%26spage%3D100%26epage%3D103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Shi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moriceau, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koya, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nazarian, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pupo, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bacchiocchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahlman, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chmielowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halaban, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kefford, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, G. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo, R. S.</span><span> </span><span class="NLM_article-title">Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">414</span><span class="NLM_x">–</span> <span class="NLM_lpage">424</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=414-424&author=H.+Shiauthor=G.+Moriceauauthor=X.+Kongauthor=R.+C.+Koyaauthor=R.+Nazarianauthor=G.+M.+Pupoauthor=A.+Bacchiocchiauthor=K.+B.+Dahlmanauthor=B.+Chmielowskiauthor=J.+A.+Sosmanauthor=R.+Halabanauthor=R.+F.+Keffordauthor=G.+V.+Longauthor=A.+Ribasauthor=R.+S.+Lo&title=Preexisting+MEK1+exon+3+mutations+in+V600E%2FKBRAF+melanomas+do+not+confer+resistance+to+BRAF+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DH.%26aulast%3DMoriceau%26aufirst%3DG.%26aulast%3DKong%26aufirst%3DX.%26aulast%3DKoya%26aufirst%3DR.%2BC.%26aulast%3DNazarian%26aufirst%3DR.%26aulast%3DPupo%26aufirst%3DG.%2BM.%26aulast%3DBacchiocchi%26aufirst%3DA.%26aulast%3DDahlman%26aufirst%3DK.%2BB.%26aulast%3DChmielowski%26aufirst%3DB.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DHalaban%26aufirst%3DR.%26aulast%3DKefford%26aufirst%3DR.%2BF.%26aulast%3DLong%26aufirst%3DG.%2BV.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DLo%26aufirst%3DR.%2BS.%26atitle%3DPreexisting%2520MEK1%2520exon%25203%2520mutations%2520in%2520V600E%252FKBRAF%2520melanomas%2520do%2520not%2520confer%2520resistance%2520to%2520BRAF%2520inhibitors%26jtitle%3DCancer%2520Discovery%26date%3D2012%26volume%3D2%26spage%3D414%26epage%3D424" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Shi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moriceau, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koya, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chodon, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scolyer, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahlman, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kefford, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, G. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo, R. S.</span><span> </span><span class="NLM_article-title">Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance</span> <span class="citation_source-journal">Nat. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">724</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Fjm500007h&amp;key=10.1038%2Fncomms1727" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Fjm500007h&amp;key=22395615" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm500007h&amp;key=1%3ACAS%3A280%3ADC%252BC383ptFKqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=724&author=H.+Shiauthor=G.+Moriceauauthor=X.+Kongauthor=M.+K.+Leeauthor=H.+Leeauthor=R.+C.+Koyaauthor=C.+Ngauthor=T.+Chodonauthor=R.+A.+Scolyerauthor=K.+B.+Dahlmanauthor=J.+A.+Sosmanauthor=R.+F.+Keffordauthor=G.+V.+Longauthor=S.+F.+Nelsonauthor=A.+Ribasauthor=R.+S.+Lo&title=Melanoma+whole-exome+sequencing+identifies+%28V600E%29B-RAF+amplification-mediated+acquired+B-RAF+inhibitor+resistance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance</span></div><div class="casAuthors">Shi Hubing; Moriceau Gatien; Kong Xiangju; Lee Mi-Kyung; Lee Hane; Koya Richard C; Ng Charles; Chodon Thinle; Scolyer Richard A; Dahlman Kimberly B; Sosman Jeffrey A; Kefford Richard F; Long Georgina V; Nelson Stanley F; Ribas Antoni; Lo Roger S</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">724</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The development of acquired drug resistance hampers the long-term success of B-RAF inhibitor therapy for melanoma patients.  Here we show (V600E)B-RAF copy-number gain as a mechanism of acquired B-RAF inhibitor resistance in 4 out of 20 (20%) patients treated with B-RAF inhibitor.  In cell lines, (V600E)B-RAF overexpression and knockdown conferred B-RAF inhibitor resistance and sensitivity, respectively.  In (V600E)B-RAF amplification-driven (versus mutant N-RAS-driven) B-RAF inhibitor resistance, extracellular signal-regulated kinase reactivation is saturable, with higher doses of vemurafenib down-regulating phosho-extracellular signal-regulated kinase and re-sensitizing melanoma cells to B-RAF inhibitor.  These two mechanisms of extracellular signal-regulated kinase reactivation are sensitive to the MEK1/2 inhibitor AZD6244/selumetinib or its combination with the B-RAF inhibitor vemurafenib.  In contrast to mutant N-RAS-mediated (V600E)B-RAF bypass, which is sensitive to C-RAF knockdown, (V600E)B-RAF amplification-mediated resistance functions largely independently of C-RAF.  Thus, alternative clinical strategies may potentially overcome distinct modes of extracellular signal-regulated kinase reactivation underlying acquired B-RAF inhibitor resistance in melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSE43gvtkJkR8K3uFsUIZtkfW6udTcc2ebsWIbqZTliAbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC383ptFKqsw%253D%253D&md5=1bf7d0cdb4dccbef8da9397f23f39ee3</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fncomms1727&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms1727%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DH.%26aulast%3DMoriceau%26aufirst%3DG.%26aulast%3DKong%26aufirst%3DX.%26aulast%3DLee%26aufirst%3DM.%2BK.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DKoya%26aufirst%3DR.%2BC.%26aulast%3DNg%26aufirst%3DC.%26aulast%3DChodon%26aufirst%3DT.%26aulast%3DScolyer%26aufirst%3DR.%2BA.%26aulast%3DDahlman%26aufirst%3DK.%2BB.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DKefford%26aufirst%3DR.%2BF.%26aulast%3DLong%26aufirst%3DG.%2BV.%26aulast%3DNelson%26aufirst%3DS.%2BF.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DLo%26aufirst%3DR.%2BS.%26atitle%3DMelanoma%2520whole-exome%2520sequencing%2520identifies%2520%2528V600E%2529B-RAF%2520amplification-mediated%2520acquired%2520B-RAF%2520inhibitor%2520resistance%26jtitle%3DNat.%2520Commun.%26date%3D2012%26volume%3D3%26spage%3D724" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Straussman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morikawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barzily-Rokni, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, Z. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mongare, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gould, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frederick, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, Z. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solit, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogino, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wargo, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golub, T. R.</span><span> </span><span class="NLM_article-title">Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">487</span><span class="NLM_x">, </span> <span class="NLM_fpage">500</span><span class="NLM_x">–</span> <span class="NLM_lpage">504</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Fjm500007h&amp;key=10.1038%2Fnature11183" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Fjm500007h&amp;key=22763439" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm500007h&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFWjtL3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=487&publication_year=2012&pages=500-504&author=R.+Straussmanauthor=T.+Morikawaauthor=K.+Sheeauthor=M.+Barzily-Rokniauthor=Z.+R.+Qianauthor=J.+Y.+Duauthor=A.+Davisauthor=M.+M.+Mongareauthor=J.+Gouldauthor=D.+T.+Frederickauthor=Z.+A.+Cooperauthor=P.+B.+Chapmanauthor=D.+B.+Solitauthor=A.+Ribasauthor=R.+S.+Loauthor=K.+T.+Flahertyauthor=S.+Oginoauthor=J.+A.+Wargoauthor=T.+R.+Golub&title=Tumour+micro-environment+elicits+innate+resistance+to+RAF+inhibitors+through+HGF+secretion"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion</span></div><div class="casAuthors">Straussman, Ravid; Morikawa, Teppei; Shee, Kevin; Barzily-Rokni, Michal; Qian, Zhi Rong; Du, Jinyan; Davis, Ashli; Mongare, Margaret M.; Gould, Joshua; Frederick, Dennie T.; Cooper, Zachary A.; Chapman, Paul B.; Solit, David B.; Ribas, Antoni; Lo, Roger S.; Flaherty, Keith T.; Ogino, Shuji; Wargo, Jennifer A.; Golub, Todd R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">487</span>
        (<span class="NLM_cas:issue">7408</span>),
    <span class="NLM_cas:pages">500-504</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Drug resistance presents a challenge to the treatment of cancer patients.  Many studies have focused on cell-autonomous mechanisms of drug resistance.  By contrast, the authors proposed that the tumor micro-environment confers innate resistance to therapy.  Here the authors developed a co-culture system to systematically assay the ability of 23 stromal cell types to influence the innate resistance of 45 cancer cell lines to 35 anticancer drugs.  The authors found that stroma-mediated resistance is common, particularly to targeted agents.  The authors characterized further the stroma-mediated resistance of BRAF-mutant melanoma to RAF inhibitors because most patients with this type of cancer show some degree of innate resistance.  Proteomic anal. showed that stromal cell secretion of hepatocyte growth factor (HGF) resulted in activation of the HGF receptor MET, reactivation of the mitogen-activated protein kinase (MAPK), and phosphatidylinositol-3-OH kinase (PI(3)K)-AKT signaling pathways, and immediate resistance to RAF inhibition.  Immunohistochem. expts. confirmed stromal cell expression of HGF in patients with BRAF-mutant melanoma and showed a significant correlation between HGF expression by stromal cells and innate resistance to RAF inhibitor treatment.  Dual inhibition of RAF and either HGF or MET resulted in reversal of drug resistance, suggesting RAF plus HGF or MET inhibitory combination therapy as a potential therapeutic strategy for BRAF-mutant melanoma.  A similar resistance mechanism was uncovered in a subset of BRAF-mutant colorectal and glioblastoma cell lines.  More generally, this study indicates that the systematic dissection of interactions between tumors and their micro-environment can uncover important mechanisms underlying drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwanlhJUTP4LVg90H21EOLACvtfcHk0lg8jqbL-Q97JA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFWjtL3J&md5=0616b5feed3c5dc2a53ee2ee382a6c33</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fnature11183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11183%26sid%3Dliteratum%253Aachs%26aulast%3DStraussman%26aufirst%3DR.%26aulast%3DMorikawa%26aufirst%3DT.%26aulast%3DShee%26aufirst%3DK.%26aulast%3DBarzily-Rokni%26aufirst%3DM.%26aulast%3DQian%26aufirst%3DZ.%2BR.%26aulast%3DDu%26aufirst%3DJ.%2BY.%26aulast%3DDavis%26aufirst%3DA.%26aulast%3DMongare%26aufirst%3DM.%2BM.%26aulast%3DGould%26aufirst%3DJ.%26aulast%3DFrederick%26aufirst%3DD.%2BT.%26aulast%3DCooper%26aufirst%3DZ.%2BA.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DSolit%26aufirst%3DD.%2BB.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DLo%26aufirst%3DR.%2BS.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DOgino%26aufirst%3DS.%26aulast%3DWargo%26aufirst%3DJ.%2BA.%26aulast%3DGolub%26aufirst%3DT.%2BR.%26atitle%3DTumour%2520micro-environment%2520elicits%2520innate%2520resistance%2520to%2520RAF%2520inhibitors%2520through%2520HGF%2520secretion%26jtitle%3DNature%26date%3D2012%26volume%3D487%26spage%3D500%26epage%3D504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Antony, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emery, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garraway, L. A.</span><span> </span><span class="NLM_article-title">C-RAF mutations confer resistance to RAF inhibitors</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">4840</span><span class="NLM_x">–</span> <span class="NLM_lpage">4851</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=4840-4851&author=R.+Antonyauthor=C.+M.+Emeryauthor=A.+M.+Sawyerauthor=L.+A.+Garraway&title=C-RAF+mutations+confer+resistance+to+RAF+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAntony%26aufirst%3DR.%26aulast%3DEmery%26aufirst%3DC.%2BM.%26aulast%3DSawyer%26aufirst%3DA.%2BM.%26aulast%3DGarraway%26aufirst%3DL.%2BA.%26atitle%3DC-RAF%2520mutations%2520confer%2520resistance%2520to%2520RAF%2520inhibitors%26jtitle%3DCancer%2520Res.%26date%3D2013%26volume%3D73%26spage%3D4840%26epage%3D4851" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Lito, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solit, D. B.</span><span> </span><span class="NLM_article-title">Tumor adaptation and resistance to RAF inhibitors</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1401</span><span class="NLM_x">–</span> <span class="NLM_lpage">1409</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Fjm500007h&amp;key=10.1038%2Fnm.3392" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Fjm500007h&amp;key=24202393" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm500007h&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslCntbvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=1401-1409&author=P.+Litoauthor=N.+Rosenauthor=D.+B.+Solit&title=Tumor+adaptation+and+resistance+to+RAF+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor adaptation and resistance to RAF inhibitors</span></div><div class="casAuthors">Lito, Piro; Rosen, Neal; Solit, David B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1401-1409</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  RAF kinase inhibitors have substantial therapeutic effects in patients with BRAF-mutant melanoma.  However, only rarely do tumors regress completely, and the therapeutic effects are often temporary.  Several mechanisms of resistance to RAF inhibitors have been proposed.  The majority of these cause ERK signaling to become insensitive to treatment with RAF inhibitors by increasing the amt. of RAF dimers in cells, whereas others bypass the dependence of the tumor on mutant RAF.  One motivation for studying mechanisms of drug resistance is that such efforts may suggest new therapeutic targets or rational combination strategies that delay or prevent the emergence of drug-resistant clones.  Here, we review the current model of RAF inhibitor resistance with a focus on the implications of this model on ongoing lab. and clin. efforts to develop more effective therapeutic strategies for patients with BRAF-mutant tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpApldbPW5lXLVg90H21EOLACvtfcHk0lg8jqbL-Q97JA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslCntbvN&md5=32718ee0a8ea50be5d6412ce0086cf3d</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fnm.3392&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3392%26sid%3Dliteratum%253Aachs%26aulast%3DLito%26aufirst%3DP.%26aulast%3DRosen%26aufirst%3DN.%26aulast%3DSolit%26aufirst%3DD.%2BB.%26atitle%3DTumor%2520adaptation%2520and%2520resistance%2520to%2520RAF%2520inhibitors%26jtitle%3DNat.%2520Med.%26date%3D2013%26volume%3D19%26spage%3D1401%26epage%3D1409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Kopetz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hecht, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Dwyer, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolop, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saltz, L.</span><span> </span><span class="NLM_article-title">PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl</span><span class="NLM_x">) </span> <span class="NLM_fpage">a3534</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=a3534&issue=Suppl&author=S.+Kopetzauthor=J.+Desaiauthor=E.+Chanauthor=J.+R.+Hechtauthor=P.+J.+O%E2%80%99Dwyerauthor=R.+J.+Leeauthor=K.+B.+Nolopauthor=L.+Saltz&title=PLX4032+in+metastatic+colorectal+cancer+patients+with+mutant+BRAF+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKopetz%26aufirst%3DS.%26aulast%3DDesai%26aufirst%3DJ.%26aulast%3DChan%26aufirst%3DE.%26aulast%3DHecht%26aufirst%3DJ.%2BR.%26aulast%3DO%25E2%2580%2599Dwyer%26aufirst%3DP.%2BJ.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DNolop%26aufirst%3DK.%2BB.%26aulast%3DSaltz%26aufirst%3DL.%26atitle%3DPLX4032%2520in%2520metastatic%2520colorectal%2520cancer%2520patients%2520with%2520mutant%2520BRAF%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26issue%3DSuppl%26spage%3Da3534" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Al-Marrawi, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saroya, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brennan, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dykes, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El-Deiry, W. S.</span><span> </span><span class="NLM_article-title">Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer</span> <span class="citation_source-journal">Cancer Biol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">703</span><span class="NLM_x">–</span> <span class="NLM_lpage">710</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Fjm500007h&amp;key=10.4161%2Fcbt.25191" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Fjm500007h&amp;key=23792568" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm500007h&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjs1yit7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=703-710&author=M.+Y.+Al-Marrawiauthor=B.+S.+Saroyaauthor=M.+C.+Brennanauthor=Z.+Yangauthor=T.+M.+Dykesauthor=W.+S.+El-Deiry&title=Off-label+use+of+cetuximab+plus+sorafenib+and+panitumumab+plus+regorafenib+to+personalize+therapy+for+a+patient+with+V600E+BRAF-mutant+metastatic+colon+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer</span></div><div class="casAuthors">Al-Marrawi, Mhd. Yaser; Saroya, Bikramajit Singh; Brennan, Matthew C.; Yang, Zhaohai; Dykes, Thomas M.; El-Deiry, Wafik S.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biology & Therapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">703-710</span>CODEN:
                <span class="NLM_cas:coden">CBTAAO</span>;
        ISSN:<span class="NLM_cas:issn">1538-4047</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">Sorafenib, the first agent developed to target BRAF mutant melanoma, is a multi-kinase inhibitor that was approved by the FDA for therapy of kidney and subsequently liver cancer, and is currently in clin. trials for thyroid, lung and brain cancer.  Colorectal cancer with V600E BRAF mutation has shown relative resistance to std. chemotherapy regimens, as well as lack of efficacy to vemurafenib in clin. trials.  New treatments are needed for BRAF-mutant colorectal cancer.  We report a case of a patient with BRAF-mutant metastatic colon cancer whose disease had progressed on FOLFOX plus bevacizumab and subsequent FOLFIRI plus cetuximab.  Based on preclin. data published in Nature in 2012 suggesting that successful therapeutic targeting of BRAF in colorectal cancer may require concomitant targeting of the EGFR, we offered this patient without other attractive options the combination of sorafenib plus cetuximab, in off-label use with informed consent.  Sorafenib and cetuximab therapy led to a mixed radiog. response with some areas showing dramatic improvement and other areas showing stable disease over a 7 mo period which is a notably long period of progression-free survival for V600E BRAF mutated colon cancer.  The cetuximab plus sorafenib therapy was very well-tolerated by the patient who remained on it long enough until another therapy option, regorafenib, was approved in Sept. 2012.  The patient was offered single agent regorafenib at the time of progression.  At the time of progression on single agent regorafenib, panitumumab was combined with regorafenib and this was also well-tolerated and appeared to slow disease progression.  Further study of these approaches in the clinic as personalized treatment of BRAF-mutant advanced colorectal cancer is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrW8SBZhzKdGrVg90H21EOLACvtfcHk0lhzZIDonAlrZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjs1yit7k%253D&md5=3f4d41340207576d2d49af3579574f10</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.4161%2Fcbt.25191&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcbt.25191%26sid%3Dliteratum%253Aachs%26aulast%3DAl-Marrawi%26aufirst%3DM.%2BY.%26aulast%3DSaroya%26aufirst%3DB.%2BS.%26aulast%3DBrennan%26aufirst%3DM.%2BC.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DDykes%26aufirst%3DT.%2BM.%26aulast%3DEl-Deiry%26aufirst%3DW.%2BS.%26atitle%3DOff-label%2520use%2520of%2520cetuximab%2520plus%2520sorafenib%2520and%2520panitumumab%2520plus%2520regorafenib%2520to%2520personalize%2520therapy%2520for%2520a%2520patient%2520with%2520V600E%2520BRAF-mutant%2520metastatic%2520colon%2520cancer%26jtitle%3DCancer%2520Biol.%2520Ther.%26date%3D2013%26volume%3D14%26spage%3D703%26epage%3D710" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Abel, E. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basile, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kugell, C. H.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witkiewicz, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amaravadi, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karakousis, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuchter, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ertel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fortina, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aplin, A. E.</span><span> </span><span class="NLM_article-title">Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">123</span><span class="NLM_x">, </span> <span class="NLM_fpage">2155</span><span class="NLM_x">–</span> <span class="NLM_lpage">2168</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2013&pages=2155-2168&author=E.+V.+Abelauthor=K.+J.+Basileauthor=C.+H.+Kugellauthor=A.+K.+Witkiewiczauthor=K.+Leauthor=R.+K.+Amaravadiauthor=G.+C.+Karakousisauthor=X.+Xuauthor=W.+Xuauthor=L.+M.+Schuchterauthor=J.+B.+Leeauthor=A.+Ertelauthor=P.+Fortinaauthor=A.+E.+Aplin&title=Melanoma+adapts+to+RAF%2FMEK+inhibitors+through+FOXD3-mediated+upregulation+of+ERBB3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAbel%26aufirst%3DE.%2BV.%26aulast%3DBasile%26aufirst%3DK.%2BJ.%26aulast%3DKugell%26aufirst%3DC.%2BH.%26aulast%3DWitkiewicz%26aufirst%3DA.%2BK.%26aulast%3DLe%26aufirst%3DK.%26aulast%3DAmaravadi%26aufirst%3DR.%2BK.%26aulast%3DKarakousis%26aufirst%3DG.%2BC.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DSchuchter%26aufirst%3DL.%2BM.%26aulast%3DLee%26aufirst%3DJ.%2BB.%26aulast%3DErtel%26aufirst%3DA.%26aulast%3DFortina%26aufirst%3DP.%26aulast%3DAplin%26aufirst%3DA.%2BE.%26atitle%3DMelanoma%2520adapts%2520to%2520RAF%252FMEK%2520inhibitors%2520through%2520FOXD3-mediated%2520upregulation%2520of%2520ERBB3%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2013%26volume%3D123%26spage%3D2155%26epage%3D2168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">DeVita, V. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schein, P. S.</span><span> </span><span class="NLM_article-title">The Use of drugs in combination for the treatment of cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1973</span><span class="NLM_x">, </span> <span class="NLM_volume">288</span><span class="NLM_x">, </span> <span class="NLM_fpage">998</span><span class="NLM_x">–</span> <span class="NLM_lpage">1006</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Fjm500007h&amp;key=10.1056%2FNEJM197305102881905" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Fjm500007h&amp;key=4348752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm500007h&amp;key=1%3ACAS%3A280%3ADyaE3s7ltlGgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=1973&pages=998-1006&author=V.+T.+DeVitaauthor=P.+S.+Schein&title=The+Use+of+drugs+in+combination+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">The use of drugs in combination for the treatment of cancer: rationale and results</span></div><div class="casAuthors">DeVita V T; Schein P S</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1973</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">998-1006</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRso8dNAqdVHYIRAdBLKY41fW6udTcc2eaQOLeXDisJ6rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaE3s7ltlGgtQ%253D%253D&md5=34ad3e72f5e5668f5cdd5e54829a8bad</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1056%2FNEJM197305102881905&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM197305102881905%26sid%3Dliteratum%253Aachs%26aulast%3DDeVita%26aufirst%3DV.%2BT.%26aulast%3DSchein%26aufirst%3DP.%2BS.%26atitle%3DThe%2520Use%2520of%2520drugs%2520in%2520combination%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1973%26volume%3D288%26spage%3D998%26epage%3D1006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Pegram, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konecny, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Callaghan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beryt, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pietras, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slamon, D. J.</span><span> </span><span class="NLM_article-title">Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">739</span><span class="NLM_x">–</span> <span class="NLM_lpage">749</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Fjm500007h&amp;key=10.1093%2Fjnci%2Fdjh131" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Fjm500007h&amp;key=15150302" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Fjm500007h&amp;key=1%3ACAS%3A528%3ADC%252BD2cXkt1Sqsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2004&pages=739-749&author=M.+D.+Pegramauthor=G.+E.+Konecnyauthor=C.+O%E2%80%99Callaghanauthor=M.+Berytauthor=R.+Pietrasauthor=D.+J.+Slamon&title=Rational+combinations+of+trastuzumab+with+chemotherapeutic+drugs+used+in+the+treatment+of+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Combinations of Trastuzumab With Chemotherapeutic Drugs Used in the Treatment of Breast Cancer</span></div><div class="casAuthors">Pegram, Mark D.; Konecny, Gottfried E.; O'Callaghan, Carminda; Beryt, Malgorzata; Pietras, Richard; Slamon, Dennis J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">739-749</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Trastuzumab, a humanized anti-HER2 antibody, increases the clin. benefit of first-line chemotherapy in patients with metastatic breast cancers that overexpress HER2.  We characterized interactions between trastuzumab and chemotherapeutic agents commonly used in the treatment of breast cancer.  Multiple drug effect/combination index isobologram anal. was used to study the efficacy of chemotherapeutic drug plus trastuzumab combinations tested against four HER2-overexpressing breast cancer cell lines (SK-BR-3, BT-474, MDA-MB-361, and MDA-MB-453).  Combination index values were derived from parameters of the median effect plots, and statistical tests were used to det. whether the mean combination index values at multiple effect levels were statistically significantly different from a combination index value of 1.0.  Values less than 1.0 indicate synergistic interactions, values greater than 1.0 indicate antagonistic interactions, and values equal to 1.0 indicate additive interactions.  At a wide range of clin. achievable drug concns., synergistic interactions were obsd. in all four breast cancer cell lines for trastuzumab plus carboplatin (mean combination index values ranged from 0.32 [P<.001] to 0.53 [P<.001]), 4-hydroxycyclophosphamide (mean combination index values ranged from 0.38 [P<.001] to 0.73 [P = .010]), docetaxel (mean combination index values ranged from 0.30 [P<.001] to 0.62 [P<.001]), and vinorelbine (mean combination index values ranged from 0.24 [P<.001] to 0.78 [P<.034]).  Additive interactions were obsd. in all four cell lines with trastuzumab plus doxorubicin, epirubicin, and paclitaxel.  Interactions between trastuzumab and gemcitabine were synergistic at low concns. of gemcitabine and antagonistic at high concns.  A synergistic interaction was obsd. with a three-drug combination of docetaxel plus carboplatin plus trastuzumab in SK-BR-3 cells (mean combination index value = 0.09; P<.001).  Consistent synergistic interactions of trastuzumab plus carboplatin, 4-hydroxycyclophosphamide, docetaxel, or vinorelbine across a wide range of clin. relevant concns. in HER2-overexpressing breast cancer cells indicate that these are rational combinations to test in human clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZ5NdDhTJwpLVg90H21EOLACvtfcHk0lhefrLfmS9DiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXkt1Sqsbo%253D&md5=1fb831bd3fbb62277de025c4a99f383d</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjh131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjh131%26sid%3Dliteratum%253Aachs%26aulast%3DPegram%26aufirst%3DM.%2BD.%26aulast%3DKonecny%26aufirst%3DG.%2BE.%26aulast%3DO%25E2%2580%2599Callaghan%26aufirst%3DC.%26aulast%3DBeryt%26aufirst%3DM.%26aulast%3DPietras%26aufirst%3DR.%26aulast%3DSlamon%26aufirst%3DD.%2BJ.%26atitle%3DRational%2520combinations%2520of%2520trastuzumab%2520with%2520chemotherapeutic%2520drugs%2520used%2520in%2520the%2520treatment%2520of%2520breast%2520cancer%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2004%26volume%3D96%26spage%3D739%26epage%3D749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodi, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callahan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konto, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolchok, J.</span><span> </span><span class="NLM_article-title">Hepatotoxicity with combination of vemurafenib and ipilimumab</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">368</span><span class="NLM_x">, </span> <span class="NLM_fpage">1365</span><span class="NLM_x">–</span> <span class="NLM_lpage">1366</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Fjm500007h&amp;key=10.1056%2FNEJMc1302338" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Fjm500007h&amp;key=23550685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Fjm500007h&amp;key=1%3ACAS%3A528%3ADC%252BC3sXls1aktbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2013&pages=1365-1366&author=A.+Ribasauthor=F.+S.+Hodiauthor=M.+Callahanauthor=C.+Kontoauthor=J.+Wolchok&title=Hepatotoxicity+with+combination+of+vemurafenib+and+ipilimumab"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatotoxicity with combination of vemurafenib and ipilimumab</span></div><div class="casAuthors">Ribas, Antoni; Hodi, F. Stephen; Callahan, Margaret; Konto, Cyril; Wolchok, Jedd</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">368</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1365-1366</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4C-d0ldXxG7Vg90H21EOLACvtfcHk0lhefrLfmS9DiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXls1aktbg%253D&md5=e903ecac16e34bc5ee83d9d24338d950</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1056%2FNEJMc1302338&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMc1302338%26sid%3Dliteratum%253Aachs%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DHodi%26aufirst%3DF.%2BS.%26aulast%3DCallahan%26aufirst%3DM.%26aulast%3DKonto%26aufirst%3DC.%26aulast%3DWolchok%26aufirst%3DJ.%26atitle%3DHepatotoxicity%2520with%2520combination%2520of%2520vemurafenib%2520and%2520ipilimumab%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D368%26spage%3D1365%26epage%3D1366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Rowbottom, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faraoni, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Setti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ezawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sprankle, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abraham, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Struss, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibney, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armstrong, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunawardane, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nepomuceno, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valenta, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hua, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardner, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cramer, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gitnick, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Apuy, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones-Bolin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghose, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herbertz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ator, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorsey, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhagwat, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holladay, M. W.</span><span> </span><span class="NLM_article-title">Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">1082</span><span class="NLM_x">–</span> <span class="NLM_lpage">1105</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm2009925" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1082-1105&author=M.+W.+Rowbottomauthor=R.+Faraoniauthor=Q.+Chaoauthor=B.+T.+Campbellauthor=A.+G.+Laiauthor=E.+Settiauthor=M.+Ezawaauthor=K.+G.+Sprankleauthor=S.+Abrahamauthor=L.+Tranauthor=B.+Strussauthor=M.+Gibneyauthor=R.+C.+Armstrongauthor=R.+N.+Gunawardaneauthor=R.+R.+Nepomucenoauthor=I.+Valentaauthor=H.+L.+Huaauthor=M.+F.+Gardnerauthor=M.+D.+Cramerauthor=D.+Gitnickauthor=D.+E.+Inskoauthor=J.+L.+Apuyauthor=S.+Jones-Bolinauthor=A.+K.+Ghoseauthor=T.+Herbertzauthor=M.+A.+Atorauthor=B.+D.+Dorseyauthor=B.+Ruggeriauthor=M.+Williamsauthor=S.+Bhagwatauthor=J.+Jamesauthor=M.+W.+Holladay&title=Identification+of+1-%283-%286%2C7-dimethoxyquinazolin-4-yloxy%29phenyl%29-3-%285-%281%2C1%2C1-trifluoro-2-methylpropan-2-yl%29isoxazol-3-yl%29urea+hydrochloride+%28CEP-32496%29%2C+a+highly+potent+and+orally+efficacious+inhibitor+of+V-RAF+murine+sarcoma+viral+oncogene+homologue+B1+%28BRAF%29+V600E"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm2009925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2009925%26sid%3Dliteratum%253Aachs%26aulast%3DRowbottom%26aufirst%3DM.%2BW.%26aulast%3DFaraoni%26aufirst%3DR.%26aulast%3DChao%26aufirst%3DQ.%26aulast%3DCampbell%26aufirst%3DB.%2BT.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DSetti%26aufirst%3DE.%26aulast%3DEzawa%26aufirst%3DM.%26aulast%3DSprankle%26aufirst%3DK.%2BG.%26aulast%3DAbraham%26aufirst%3DS.%26aulast%3DTran%26aufirst%3DL.%26aulast%3DStruss%26aufirst%3DB.%26aulast%3DGibney%26aufirst%3DM.%26aulast%3DArmstrong%26aufirst%3DR.%2BC.%26aulast%3DGunawardane%26aufirst%3DR.%2BN.%26aulast%3DNepomuceno%26aufirst%3DR.%2BR.%26aulast%3DValenta%26aufirst%3DI.%26aulast%3DHua%26aufirst%3DH.%2BL.%26aulast%3DGardner%26aufirst%3DM.%2BF.%26aulast%3DCramer%26aufirst%3DM.%2BD.%26aulast%3DGitnick%26aufirst%3DD.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DApuy%26aufirst%3DJ.%2BL.%26aulast%3DJones-Bolin%26aufirst%3DS.%26aulast%3DGhose%26aufirst%3DA.%2BK.%26aulast%3DHerbertz%26aufirst%3DT.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26aulast%3DRuggeri%26aufirst%3DB.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DBhagwat%26aufirst%3DS.%26aulast%3DJames%26aufirst%3DJ.%26aulast%3DHolladay%26aufirst%3DM.%2BW.%26atitle%3DIdentification%2520of%25201-%25283-%25286%252C7-dimethoxyquinazolin-4-yloxy%2529phenyl%2529-3-%25285-%25281%252C1%252C1-trifluoro-2-methylpropan-2-yl%2529isoxazol-3-yl%2529urea%2520hydrochloride%2520%2528CEP-32496%2529%252C%2520a%2520highly%2520potent%2520and%2520orally%2520efficacious%2520inhibitor%2520of%2520V-RAF%2520murine%2520sarcoma%2520viral%2520oncogene%2520homologue%2520B1%2520%2528BRAF%2529%2520V600E%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D1082%26epage%3D1105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Zhang, Q. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diao, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">You, Q. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, H. Y.</span><span> </span><span class="NLM_article-title">Design and discovery of 4-anilinoquinazoline ureas as multikinase inhibitors targeting BRAF, VEGFR-2 and EGFR</span> <span class="citation_source-journal">MedChemComm</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">979</span><span class="NLM_x">–</span> <span class="NLM_lpage">986</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=979-986&author=Q.+W.+Zhangauthor=Y.+Y.+Diaoauthor=F.+Wangauthor=Y.+Fuauthor=F.+Tangauthor=Q.+D.+Youauthor=H.+Y.+Zhou&title=Design+and+discovery+of+4-anilinoquinazoline+ureas+as+multikinase+inhibitors+targeting+BRAF%2C+VEGFR-2+and+EGFR"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DQ.%2BW.%26aulast%3DDiao%26aufirst%3DY.%2BY.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DFu%26aufirst%3DY.%26aulast%3DTang%26aufirst%3DF.%26aulast%3DYou%26aufirst%3DQ.%2BD.%26aulast%3DZhou%26aufirst%3DH.%2BY.%26atitle%3DDesign%2520and%2520discovery%2520of%25204-anilinoquinazoline%2520ureas%2520as%2520multikinase%2520inhibitors%2520targeting%2520BRAF%252C%2520VEGFR-2%2520and%2520EGFR%26jtitle%3DMedChemComm%26date%3D2013%26volume%3D4%26spage%3D979%26epage%3D986" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Heffron, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, B. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivero, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staben, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsui, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Do, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dotson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Folkes, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldsmith, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldsmith, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunzner, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesnick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathieu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nonomiya, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuttleworth, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutherlin, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, B. Y.</span><span> </span><span class="NLM_article-title">Rational design of phosphoinositide 3-kinase alpha inhibitors that exhibit selectivity over the phosphoinositide 3-kinase beta isoform</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">7815</span><span class="NLM_x">–</span> <span class="NLM_lpage">7833</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm2007084" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7815-7833&author=T.+P.+Heffronauthor=B.+Q.+Weiauthor=A.+Oliveroauthor=S.+T.+Stabenauthor=V.+Tsuiauthor=S.+Doauthor=J.+Dotsonauthor=A.+J.+Folkesauthor=P.+Goldsmithauthor=R.+Goldsmithauthor=J.+Gunznerauthor=J.+Lesnickauthor=C.+Lewisauthor=S.+Mathieuauthor=J.+Nonomiyaauthor=S.+Shuttleworthauthor=D.+P.+Sutherlinauthor=N.+C.+Wanauthor=S.+M.+Wangauthor=C.+Wiesmannauthor=B.+Y.+Zhu&title=Rational+design+of+phosphoinositide+3-kinase+alpha+inhibitors+that+exhibit+selectivity+over+the+phosphoinositide+3-kinase+beta+isoform"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm2007084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2007084%26sid%3Dliteratum%253Aachs%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26aulast%3DWei%26aufirst%3DB.%2BQ.%26aulast%3DOlivero%26aufirst%3DA.%26aulast%3DStaben%26aufirst%3DS.%2BT.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DDo%26aufirst%3DS.%26aulast%3DDotson%26aufirst%3DJ.%26aulast%3DFolkes%26aufirst%3DA.%2BJ.%26aulast%3DGoldsmith%26aufirst%3DP.%26aulast%3DGoldsmith%26aufirst%3DR.%26aulast%3DGunzner%26aufirst%3DJ.%26aulast%3DLesnick%26aufirst%3DJ.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DMathieu%26aufirst%3DS.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DShuttleworth%26aufirst%3DS.%26aulast%3DSutherlin%26aufirst%3DD.%2BP.%26aulast%3DWan%26aufirst%3DN.%2BC.%26aulast%3DWang%26aufirst%3DS.%2BM.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DZhu%26aufirst%3DB.%2BY.%26atitle%3DRational%2520design%2520of%2520phosphoinositide%25203-kinase%2520alpha%2520inhibitors%2520that%2520exhibit%2520selectivity%2520over%2520the%2520phosphoinositide%25203-kinase%2520beta%2520isoform%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7815%26epage%3D7833" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Joseph, E. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pratilas, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poulikakos, P. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tadi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halilovic, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Persaud, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xing, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viale, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bollag, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solit, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, N.</span><span> </span><span class="NLM_article-title">The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">14903</span><span class="NLM_x">–</span> <span class="NLM_lpage">14908</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Fjm500007h&amp;key=10.1073%2Fpnas.1008990107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Fjm500007h&amp;key=20668238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Fjm500007h&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVOjsLrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=14903-14908&author=E.+W.+Josephauthor=C.+A.+Pratilasauthor=P.+I.+Poulikakosauthor=M.+Tadiauthor=W.+Q.+Wangauthor=B.+S.+Taylorauthor=E.+Halilovicauthor=Y.+Persaudauthor=F.+Xingauthor=A.+Vialeauthor=J.+Tsaiauthor=P.+B.+Chapmanauthor=G.+Bollagauthor=D.+B.+Solitauthor=N.+Rosen&title=The+RAF+inhibitor+PLX4032+inhibits+ERK+signaling+and+tumor+cell+proliferation+in+a+V600E+BRAF-selective+manner"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner</span></div><div class="casAuthors">Joseph, Eric W.; Pratilas, Christine A.; Poulikakos, Poulikos I.; Tadi, Madhavi; Wang, Weiqing; Taylor, Barry S.; Halilovic, Ensar; Persaud, Yogindra; Xing, Feng; Viale, Agnes; Tsai, James; Chapman, Paul B.; Bollag, Gideon; Solit, David B.; Rosen, Neal</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">14903-14908, S14903/1-S14903/8</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Tumors with mutant BRAF and some with mutant RAS are dependent upon ERK signaling for proliferation, and their growth is suppressed by MAPK/ERK kinase (MEK) inhibitors.  In contrast, tumor cells with human EGF receptor (HER) kinase activation proliferate in a MEK-independent manner.  These findings have led to the development of RAF and MEK inhibitors as anticancer agents.  Like MEK inhibitors, the RAF inhibitor PLX4032 inhibits the proliferation of BRAFV600E tumor cells but not that of HER kinase-dependent tumors.  However, tumors with RAS mutation that are sensitive to MEK inhibition are insensitive to PLX4032.  MEK inhibitors inhibit ERK phosphorylation in all normal and tumor cells, whereas PLX4032 inhibits ERK signaling only in tumor cells expressing BRAFV600E.  In contrast, the drug activates MEK and ERK phosphorylation in cells with wild-type BRAF.  In BRAFV600E tumor cells, MEK and RAF inhibitors affect the expression of a common set of genes.  PLX4032 inhibits ERK signaling output in mutant BRAF cells, whereas it transiently activates the expression of these genes in tumor cells with wild-type RAF.  Thus, PLX4032 inhibits ERK signaling output in a mutant BRAF-selective manner.  These data explain why the drug selectively inhibits the growth of mutant BRAF tumors and suggest that it will not cause toxicity resulting from the inhibition of ERK signaling in normal cells.  This selectivity may lead to a broader therapeutic index and help explain the greater antitumor activity obsd. with this drug than with MEK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_6Gff4DQiprVg90H21EOLACvtfcHk0ljx_tbSnisrgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVOjsLrP&md5=c5c99b7faca898bd8e4b1d4ae82a5f84</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1008990107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1008990107%26sid%3Dliteratum%253Aachs%26aulast%3DJoseph%26aufirst%3DE.%2BW.%26aulast%3DPratilas%26aufirst%3DC.%2BA.%26aulast%3DPoulikakos%26aufirst%3DP.%2BI.%26aulast%3DTadi%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DW.%2BQ.%26aulast%3DTaylor%26aufirst%3DB.%2BS.%26aulast%3DHalilovic%26aufirst%3DE.%26aulast%3DPersaud%26aufirst%3DY.%26aulast%3DXing%26aufirst%3DF.%26aulast%3DViale%26aufirst%3DA.%26aulast%3DTsai%26aufirst%3DJ.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DSolit%26aufirst%3DD.%2BB.%26aulast%3DRosen%26aufirst%3DN.%26atitle%3DThe%2520RAF%2520inhibitor%2520PLX4032%2520inhibits%2520ERK%2520signaling%2520and%2520tumor%2520cell%2520proliferation%2520in%2520a%2520V600E%2520BRAF-selective%2520manner%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2010%26volume%3D107%26spage%3D14903%26epage%3D14908" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Wakeling, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guy, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodburn, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curry, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barker, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, K. H.</span><span> </span><span class="NLM_article-title">AZD1839 (Iressa): An orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">5749</span><span class="NLM_x">–</span> <span class="NLM_lpage">5754</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=5749-5754&author=A.+E.+Wakelingauthor=S.+P.+Guyauthor=J.+R.+Woodburnauthor=S.+E.+Ashtonauthor=B.+J.+Curryauthor=A.+J.+Barkerauthor=K.+H.+Gibson&title=AZD1839+%28Iressa%29%3A+An+orally+active+inhibitor+of+epidermal+growth+factor+signaling+with+potential+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWakeling%26aufirst%3DA.%2BE.%26aulast%3DGuy%26aufirst%3DS.%2BP.%26aulast%3DWoodburn%26aufirst%3DJ.%2BR.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DCurry%26aufirst%3DB.%2BJ.%26aulast%3DBarker%26aufirst%3DA.%2BJ.%26aulast%3DGibson%26aufirst%3DK.%2BH.%26atitle%3DAZD1839%2520%2528Iressa%2529%253A%2520An%2520orally%2520active%2520inhibitor%2520of%2520epidermal%2520growth%2520factor%2520signaling%2520with%2520potential%2520for%2520cancer%2520therapy%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26spage%3D5749%26epage%3D5754" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Muhsin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkpatrick, P.</span><span> </span><span class="NLM_article-title">Gefitinib</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">515</span><span class="NLM_x">–</span> <span class="NLM_lpage">516</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2003&pages=515-516&author=M.+Muhsinauthor=J.+Grahamauthor=P.+Kirkpatrick&title=Gefitinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMuhsin%26aufirst%3DM.%26aulast%3DGraham%26aufirst%3DJ.%26aulast%3DKirkpatrick%26aufirst%3DP.%26atitle%3DGefitinib%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2003%26volume%3D2%26spage%3D515%26epage%3D516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Jares-Erijman, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jovin, T. M.</span><span> </span><span class="NLM_article-title">FRET imaging</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">1387</span><span class="NLM_x">–</span> <span class="NLM_lpage">1395</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Fjm500007h&amp;key=10.1038%2Fnbt896" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Fjm500007h&amp;key=14595367" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Fjm500007h&amp;key=1%3ACAS%3A528%3ADC%252BD3sXosFOksbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2003&pages=1387-1395&author=E.+A.+Jares-Erijmanauthor=T.+M.+Jovin&title=FRET+imaging"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">FRET imaging</span></div><div class="casAuthors">Jares-Erijman, Elizabeth A.; Jovin, Thomas M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1387-1395</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Foerster (or Fluorescence) Resonance Energy Transfer (FRET) is unique in generating fluorescence signals sensitive to mol. conformation, assocn., and sepn. in the 1-10 nm range.  We introduce a revised photophys. framework for the phenomenon and provide a systematic catalog of FRET techniques adapted to imaging systems, including new approaches proposed as suitable prospects for implementation.  Applications extending from a single mol. to live cells will benefit from multidimensional microscopy techniques, particularly those adapted for optical sectioning and incorporating new algorithms for resolving the component contributions to images of complex mol. systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTN4i2irXbCLVg90H21EOLACvtfcHk0ljZugUaDVknyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXosFOksbo%253D&md5=01814592b10786fdb8f660c4a23dfa78</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Fnbt896&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt896%26sid%3Dliteratum%253Aachs%26aulast%3DJares-Erijman%26aufirst%3DE.%2BA.%26aulast%3DJovin%26aufirst%3DT.%2BM.%26atitle%3DFRET%2520imaging%26jtitle%3DNat.%2520Biotechnol.%26date%3D2003%26volume%3D21%26spage%3D1387%26epage%3D1395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Zheng, X. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bair, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumeister, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowman, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckmelter, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caligiuri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clodfelter, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, Y. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kley, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, X. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liederer, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ly, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oeh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sampath, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skelton, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tremayne, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, G. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuen, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dragovich, P. S.</span><span> </span><span class="NLM_article-title">Identification of amides derived from 1<i>H</i>-pyrazolo [3,4-<i>b</i>]pyridine-5-carboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">5488</span><span class="NLM_x">–</span> <span class="NLM_lpage">5497</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=5488-5497&author=X.+Z.+Zhengauthor=K.+W.+Bairauthor=P.+Bauerauthor=T.+Baumeisterauthor=K.+K.+Bowmanauthor=A.+J.+Buckmelterauthor=M.+Caligiuriauthor=K.+H.+Clodfelterauthor=Y.+Z.+Fengauthor=B.+S.+Hanauthor=Y.+C.+Hoauthor=N.+Kleyauthor=H.+Liauthor=X.+R.+Liangauthor=B.+M.+Liedererauthor=J.+Linauthor=J.+Lyauthor=T.+O%E2%80%99Brienauthor=J.+Oehauthor=A.+Ohauthor=D.+J.+Reynoldsauthor=D.+Sampathauthor=G.+Sharmaauthor=N.+Skeltonauthor=C.+C.+Smithauthor=J.+Tremayneauthor=L.+L.+Wangauthor=W.+R.+Wangauthor=Z.+G.+Wangauthor=H.+X.+Wuauthor=J.+S.+Wuauthor=Y.+Xiaoauthor=G.+X.+Yangauthor=P.+W.+Yuenauthor=M.+Zakauthor=P.+S.+Dragovich&title=Identification+of+amides+derived+from+1H-pyrazolo+%5B3%2C4-b%5Dpyridine-5-carboxylic+acid+as+potent+inhibitors+of+human+nicotinamide+phosphoribosyltransferase+%28NAMPT%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DX.%2BZ.%26aulast%3DBair%26aufirst%3DK.%2BW.%26aulast%3DBauer%26aufirst%3DP.%26aulast%3DBaumeister%26aufirst%3DT.%26aulast%3DBowman%26aufirst%3DK.%2BK.%26aulast%3DBuckmelter%26aufirst%3DA.%2BJ.%26aulast%3DCaligiuri%26aufirst%3DM.%26aulast%3DClodfelter%26aufirst%3DK.%2BH.%26aulast%3DFeng%26aufirst%3DY.%2BZ.%26aulast%3DHan%26aufirst%3DB.%2BS.%26aulast%3DHo%26aufirst%3DY.%2BC.%26aulast%3DKley%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DLiang%26aufirst%3DX.%2BR.%26aulast%3DLiederer%26aufirst%3DB.%2BM.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DLy%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DT.%26aulast%3DOeh%26aufirst%3DJ.%26aulast%3DOh%26aufirst%3DA.%26aulast%3DReynolds%26aufirst%3DD.%2BJ.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DSharma%26aufirst%3DG.%26aulast%3DSkelton%26aufirst%3DN.%26aulast%3DSmith%26aufirst%3DC.%2BC.%26aulast%3DTremayne%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%2BL.%26aulast%3DWang%26aufirst%3DW.%2BR.%26aulast%3DWang%26aufirst%3DZ.%2BG.%26aulast%3DWu%26aufirst%3DH.%2BX.%26aulast%3DWu%26aufirst%3DJ.%2BS.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DG.%2BX.%26aulast%3DYuen%26aufirst%3DP.%2BW.%26aulast%3DZak%26aufirst%3DM.%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26atitle%3DIdentification%2520of%2520amides%2520derived%2520from%25201H-pyrazolo%2520%255B3%252C4-b%255Dpyridine-5-carboxylic%2520acid%2520as%2520potent%2520inhibitors%2520of%2520human%2520nicotinamide%2520phosphoribosyltransferase%2520%2528NAMPT%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D5488%26epage%3D5497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 18 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Wei Yang, Yingjun Li, Yong Ai, Obinna N. Obianom, Dong Guo, Hong Yang, Srilatha Sakamuru, Menghang Xia, Yan Shu, <span class="NLM_string-name hlFld-ContribAuthor">Fengtian Xue</span>. </span><span class="cited-content_cbyCitation_article-title">Pyrazole-4-Carboxamide (YW2065): A Therapeutic Candidate for Colorectal Cancer via Dual Activities of Wnt/β-Catenin Signaling Inhibition and AMP-Activated Protein Kinase (AMPK) Activation. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (24)
                                     , 11151-11164. <a href="https://doi.org/10.1021/acs.jmedchem.9b01252" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01252</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01252&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01252%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPyrazole-4-Carboxamide%252B%252528YW2065%252529%25253A%252BA%252BTherapeutic%252BCandidate%252Bfor%252BColorectal%252BCancer%252Bvia%252BDual%252BActivities%252Bof%252BWnt%25252F%2525CE%2525B2-Catenin%252BSignaling%252BInhibition%252Band%252BAMP-Activated%252BProtein%252BKinase%252B%252528AMPK%252529%252BActivation%26aulast%3DYang%26aufirst%3DWei%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D31072019%26date%3D10122019%26date%3D26112019%26volume%3D62%26issue%3D24%26spage%3D11151%26epage%3D11164" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yingjun  Li</span>, <span class="hlFld-ContribAuthor ">Huimin  Cheng</span>, <span class="hlFld-ContribAuthor ">Zhang  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaoxi  Zhuang</span>, <span class="hlFld-ContribAuthor ">Jinfeng  Luo</span>, <span class="hlFld-ContribAuthor ">Huoyou  Long</span>, <span class="hlFld-ContribAuthor ">Yang  Zhou</span>, <span class="hlFld-ContribAuthor ">Yong  Xu</span>, <span class="hlFld-ContribAuthor ">Rana  Taghipouran</span>, <span class="hlFld-ContribAuthor ">Dan  Li</span>, <span class="hlFld-ContribAuthor ">Adam  Patterson</span>, <span class="hlFld-ContribAuthor ">Jeff  Smaill</span>, <span class="hlFld-ContribAuthor ">Zhengchao  Tu</span>, <span class="hlFld-ContribAuthor ">Donghai  Wu</span>, <span class="hlFld-ContribAuthor ">Xiaomei  Ren</span>, and <span class="hlFld-ContribAuthor ">Ke  Ding</span>  . </span><span class="cited-content_cbyCitation_article-title">N-(3-Ethynyl-2,4-difluorophenyl)sulfonamide Derivatives as Selective Raf Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>6 </em>
                                    (5)
                                     , 543-547. <a href="https://doi.org/10.1021/acsmedchemlett.5b00039" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.5b00039</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.5b00039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.5b00039%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DN-%2525283-Ethynyl-2%25252C4-difluorophenyl%252529sulfonamide%252BDerivatives%252Bas%252BSelective%252BRaf%252BInhibitors%26aulast%3DLi%26aufirst%3DYingjun%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D27012015%26date%3D18032015%26date%3D20032015%26date%3D14052015%26date%3D18032015%26volume%3D6%26issue%3D5%26spage%3D543%26epage%3D547" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cheng-I  Lee</span>, <span class="hlFld-ContribAuthor ">Chu-Bin  Liao</span>, <span class="hlFld-ContribAuthor ">Chih-Shang  Chen</span>, <span class="hlFld-ContribAuthor ">Fen-Ying  Cheng</span>, <span class="hlFld-ContribAuthor ">Yu-Hsuan  Chung</span>, <span class="hlFld-ContribAuthor ">Yu-Chuan  Wang</span>, <span class="hlFld-ContribAuthor ">Sian-Yi  Ciou</span>, <span class="hlFld-ContribAuthor ">Wen-Yun  Hsueh</span>, <span class="hlFld-ContribAuthor ">Tzu-Hao  Lo</span>, <span class="hlFld-ContribAuthor ">Guan-Ru  Huang</span>, <span class="hlFld-ContribAuthor ">Hsin-Yi  Huang</span>, <span class="hlFld-ContribAuthor ">Chia-Shen  Tsai</span>, <span class="hlFld-ContribAuthor ">Yu-Jung  Lu</span>, <span class="hlFld-ContribAuthor ">Shih-Hsien  Chuang</span>, <span class="hlFld-ContribAuthor ">Jiann-Jyh  Huang</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of 4-anilinoquinazolines as Raf kinase inhibitors. Part 1. Selective B-Raf/B-RafV600E and potent EGFR/VEGFR2 inhibitory 4-(3-hydroxyanilino)-6-(1H-1,2,3-triazol-4-yl)quinazolines. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>109 </em>, 104715. <a href="https://doi.org/10.1016/j.bioorg.2021.104715" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.104715</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.104715&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.104715%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252B4-anilinoquinazolines%252Bas%252BRaf%252Bkinase%252Binhibitors.%252BPart%252B1.%252BSelective%252BB-Raf%25252FB-RafV600E%252Band%252Bpotent%252BEGFR%25252FVEGFR2%252Binhibitory%252B4-%2525283-hydroxyanilino%252529-6-%2525281H-1%25252C2%25252C3-triazol-4-yl%252529quinazolines%26aulast%3DLee%26aufirst%3DCheng-I%26date%3D2021%26volume%3D109%26spage%3D104715" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jaydeepsinh  Chavda</span>, <span class="hlFld-ContribAuthor ">Hardik  Bhatt</span>. </span><span class="cited-content_cbyCitation_article-title">Systemic review on B-RafV600E mutation as potential therapeutic target for the treatment of cancer. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>206 </em>, 112675. <a href="https://doi.org/10.1016/j.ejmech.2020.112675" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112675</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112675%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSystemic%252Breview%252Bon%252BB-RafV600E%252Bmutation%252Bas%252Bpotential%252Btherapeutic%252Btarget%252Bfor%252Bthe%252Btreatment%252Bof%252Bcancer%26aulast%3DChavda%26aufirst%3DJaydeepsinh%26date%3D2020%26volume%3D206%26spage%3D112675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ilaria  Proietti</span>, <span class="hlFld-ContribAuthor ">Nevena  Skroza</span>, <span class="hlFld-ContribAuthor ">Nicoletta  Bernardini</span>, <span class="hlFld-ContribAuthor ">Ersilia  Tolino</span>, <span class="hlFld-ContribAuthor ">Veronica  Balduzzi</span>, <span class="hlFld-ContribAuthor ">Anna  Marchesiello</span>, <span class="hlFld-ContribAuthor ">Simone  Michelini</span>, <span class="hlFld-ContribAuthor ">Salvatore  Volpe</span>, <span class="hlFld-ContribAuthor ">Alessandra  Mambrin</span>, <span class="hlFld-ContribAuthor ">Giorgio  Mangino</span>, <span class="hlFld-ContribAuthor ">Giovanna  Romeo</span>, <span class="hlFld-ContribAuthor ">Patrizia  Maddalena</span>, <span class="hlFld-ContribAuthor ">Catherine  Rees</span>, <span class="hlFld-ContribAuthor ">Concetta  Potenza</span>. </span><span class="cited-content_cbyCitation_article-title">Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2020,</strong> <em>12 </em>
                                    (10)
                                     , 2801. <a href="https://doi.org/10.3390/cancers12102801" title="DOI URL">https://doi.org/10.3390/cancers12102801</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers12102801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers12102801%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DMechanisms%252Bof%252BAcquired%252BBRAF%252BInhibitor%252BResistance%252Bin%252BMelanoma%25253A%252BA%252BSystematic%252BReview%26aulast%3DProietti%26aufirst%3DIlaria%26date%3D2020%26date%3D2020%26volume%3D12%26issue%3D10%26spage%3D2801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qing-Shan  Li</span>, <span class="hlFld-ContribAuthor ">Bang-Nian  Shen</span>, <span class="hlFld-ContribAuthor ">Hua-Jian  Xu</span>, <span class="hlFld-ContribAuthor ">Ban-Feng  Ruan</span>. </span><span class="cited-content_cbyCitation_article-title">Promising Strategies for Overcoming BRAF Inhibitor Resistance Based on Known Resistance Mechanisms. </span><span class="cited-content_cbyCitation_journal-name">Anti-Cancer Agents in Medicinal Chemistry</span><span> <strong>2020,</strong> <em>20 </em>
                                    (12)
                                     , 1415-1430. <a href="https://doi.org/10.2174/1871520620666200422073622" title="DOI URL">https://doi.org/10.2174/1871520620666200422073622</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1871520620666200422073622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1871520620666200422073622%26sid%3Dliteratum%253Aachs%26jtitle%3DAnti-Cancer%2520Agents%2520in%2520Medicinal%2520Chemistry%26atitle%3DPromising%252BStrategies%252Bfor%252BOvercoming%252BBRAF%252BInhibitor%252BResistance%252BBased%252Bon%252BKnown%252BResistance%252BMechanisms%26aulast%3DLi%26aufirst%3DQing-Shan%26date%3D2020%26volume%3D20%26issue%3D12%26spage%3D1415%26epage%3D1430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Janos  Sapi</span>, <span class="hlFld-ContribAuthor ">Stéphane  Gérard</span>. </span><span class="cited-content_cbyCitation_article-title">Bicyclic 5-6 Systems: Three Heteroatoms 2:1. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,<a href="https://doi.org/10.1016/B978-0-12-818655-8.00021-4" title="DOI URL">https://doi.org/10.1016/B978-0-12-818655-8.00021-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-818655-8.00021-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-818655-8.00021-4%26sid%3Dliteratum%253Aachs%26atitle%3DBicyclic%252B5-6%252BSystems%25253A%252BThree%252BHeteroatoms%252B2%25253A1%26aulast%3DSapi%26aufirst%3DJanos%26date%3D2020%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BChemistry%25252C%252BMolecular%252BSciences%252Band%252BChemical%252BEngineering%26date%3D2020%26volume%3Dvol.%252010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yu-Shun  Yang</span>, <span class="hlFld-ContribAuthor ">Mi-Mi  Su</span>, <span class="hlFld-ContribAuthor ">Jian-Fei  Xu</span>, <span class="hlFld-ContribAuthor ">Qi-Xing  Liu</span>, <span class="hlFld-ContribAuthor ">Li-Fei  Bai</span>, <span class="hlFld-ContribAuthor ">Xiao-Wei  Hu</span>, <span class="hlFld-ContribAuthor ">Hai-Liang  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel oxoindolin derivatives as atypical dual inhibitors for DNA Gyrase and FabH. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2019,</strong> <em>93 </em>, 103309. <a href="https://doi.org/10.1016/j.bioorg.2019.103309" title="DOI URL">https://doi.org/10.1016/j.bioorg.2019.103309</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2019.103309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2019.103309%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252Boxoindolin%252Bderivatives%252Bas%252Batypical%252Bdual%252Binhibitors%252Bfor%252BDNA%252BGyrase%252Band%252BFabH%26aulast%3DYang%26aufirst%3DYu-Shun%26date%3D2019%26volume%3D93%26spage%3D103309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yi  Ning</span>, <span class="hlFld-ContribAuthor ">Xinwei  He</span>, <span class="hlFld-ContribAuthor ">Youpeng  Zuo</span>, <span class="hlFld-ContribAuthor ">Panyuan  Cai</span>, <span class="hlFld-ContribAuthor ">Mengqing  Xie</span>, <span class="hlFld-ContribAuthor ">Jian  Wang</span>, <span class="hlFld-ContribAuthor ">Yongjia  Shang</span>. </span><span class="cited-content_cbyCitation_article-title">Rhodium(II) Acetate‐Catalysed Cyclization of Pyrazol‐5‐amine and 1,3‐Diketone‐2‐diazo Compounds Using
              N
              ,
              N
              ‐Dimethylformamide as a Carbon‐Hydrogen Source: Access to Pyrazolo[3,4‐
              b
              ]pyridines. </span><span class="cited-content_cbyCitation_journal-name">Advanced Synthesis & Catalysis</span><span> <strong>2019,</strong> <em>361 </em>
                                    (15)
                                     , 3518-3524. <a href="https://doi.org/10.1002/adsc.201900093" title="DOI URL">https://doi.org/10.1002/adsc.201900093</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/adsc.201900093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadsc.201900093%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Synthesis%2520%2526%2520Catalysis%26atitle%3DRhodium%252528II%252529%252BAcetate%2525E2%252580%252590Catalysed%252BCyclization%252Bof%252BPyrazol%2525E2%252580%2525905%2525E2%252580%252590amine%252Band%252B1%25252C3%2525E2%252580%252590Diketone%2525E2%252580%2525902%2525E2%252580%252590diazo%252BCompounds%252BUsing%252BN%252B%25252C%252BN%252B%2525E2%252580%252590Dimethylformamide%252Bas%252Ba%252BCarbon%2525E2%252580%252590Hydrogen%252BSource%25253A%252BAccess%252Bto%252BPyrazolo%25255B3%25252C4%2525E2%252580%252590%252Bb%252B%25255Dpyridines%26aulast%3DNing%26aufirst%3DYi%26date%3D2019%26date%3D2019%26volume%3D361%26issue%3D15%26spage%3D3518%26epage%3D3524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Usama M.  Ammar</span>, <span class="hlFld-ContribAuthor ">Mohammed S.  Abdel-Maksoud</span>, <span class="hlFld-ContribAuthor ">Chang-Hyun  Oh</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances of RAF (rapidly accelerated fibrosarcoma) inhibitors as anti-cancer agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>158 </em>, 144-166. <a href="https://doi.org/10.1016/j.ejmech.2018.09.005" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.09.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.09.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.09.005%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Badvances%252Bof%252BRAF%252B%252528rapidly%252Baccelerated%252Bfibrosarcoma%252529%252Binhibitors%252Bas%252Banti-cancer%252Bagents%26aulast%3DAmmar%26aufirst%3DUsama%2BM.%26date%3D2018%26volume%3D158%26spage%3D144%26epage%3D166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhenhua  Zhai</span>, <span class="hlFld-ContribAuthor ">Xiaohui  Yu</span>, <span class="hlFld-ContribAuthor ">Bin  Yang</span>, <span class="hlFld-ContribAuthor ">Yunjing  Zhang</span>, <span class="hlFld-ContribAuthor ">Long  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaoli  Li</span>, <span class="hlFld-ContribAuthor ">Hongzhi  Sun</span>. </span><span class="cited-content_cbyCitation_article-title">Colorectal cancer heterogeneity and targeted therapy: Clinical implications, challenges and solutions for treatment resistance. </span><span class="cited-content_cbyCitation_journal-name">Seminars in Cell & Developmental Biology</span><span> <strong>2017,</strong> <em>64 </em>, 107-115. <a href="https://doi.org/10.1016/j.semcdb.2016.08.033" title="DOI URL">https://doi.org/10.1016/j.semcdb.2016.08.033</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.semcdb.2016.08.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.semcdb.2016.08.033%26sid%3Dliteratum%253Aachs%26jtitle%3DSeminars%2520in%2520Cell%2520%2526%2520Developmental%2520Biology%26atitle%3DColorectal%252Bcancer%252Bheterogeneity%252Band%252Btargeted%252Btherapy%25253A%252BClinical%252Bimplications%25252C%252Bchallenges%252Band%252Bsolutions%252Bfor%252Btreatment%252Bresistance%26aulast%3DZhai%26aufirst%3DZhenhua%26date%3D2017%26volume%3D64%26spage%3D107%26epage%3D115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jianfei  Sheng</span>, <span class="hlFld-ContribAuthor ">Zhihong  Liu</span>, <span class="hlFld-ContribAuthor ">Ming  Yan</span>, <span class="hlFld-ContribAuthor ">Xuejing  Zhang</span>, <span class="hlFld-ContribAuthor ">Dejian  Wang</span>, <span class="hlFld-ContribAuthor ">Jun  Xu</span>, <span class="hlFld-ContribAuthor ">Ensheng  Zhang</span>, <span class="hlFld-ContribAuthor ">Yong  Zou</span>. </span><span class="cited-content_cbyCitation_article-title">Biomass-involved synthesis of N-substituted benzofuro[2,3-d]pyrimidine-4-amines and biological evaluation as novel EGFR tyrosine kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2017,</strong> <em>15 </em>
                                    (23)
                                     , 4971-4977. <a href="https://doi.org/10.1039/C7OB00793K" title="DOI URL">https://doi.org/10.1039/C7OB00793K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7OB00793K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7OB00793K%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DBiomass-involved%252Bsynthesis%252Bof%252BN-substituted%252Bbenzofuro%25255B2%25252C3-d%25255Dpyrimidine-4-amines%252Band%252Bbiological%252Bevaluation%252Bas%252Bnovel%252BEGFR%252Btyrosine%252Bkinase%252Binhibitors%26aulast%3DSheng%26aufirst%3DJianfei%26date%3D2017%26date%3D2017%26volume%3D15%26issue%3D23%26spage%3D4971%26epage%3D4977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Huazhou  Ying</span>, <span class="hlFld-ContribAuthor ">Jiangfeng  Xie</span>, <span class="hlFld-ContribAuthor ">Xingguo  Liu</span>, <span class="hlFld-ContribAuthor ">Tingting  Yao</span>, <span class="hlFld-ContribAuthor ">Xiaowu  Dong</span>, <span class="hlFld-ContribAuthor ">Chunqi  Hu</span>. </span><span class="cited-content_cbyCitation_article-title">Discriminatory analysis based molecular docking study for in silico identification of epigallocatechin-3-gallate (EGCG) derivatives as B-Raf
              V600E
              inhibitors. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2017,</strong> <em>7 </em>
                                    (71)
                                     , 44820-44826. <a href="https://doi.org/10.1039/C7RA04788F" title="DOI URL">https://doi.org/10.1039/C7RA04788F</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7RA04788F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7RA04788F%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DDiscriminatory%252Banalysis%252Bbased%252Bmolecular%252Bdocking%252Bstudy%252Bfor%252Bin%252Bsilico%252Bidentification%252Bof%252Bepigallocatechin-3-gallate%252B%252528EGCG%252529%252Bderivatives%252Bas%252BB-Raf%252BV600E%252Binhibitors%26aulast%3DYing%26aufirst%3DHuazhou%26date%3D2017%26date%3D2017%26volume%3D7%26issue%3D71%26spage%3D44820%26epage%3D44826" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhi-ling  Zhou</span>, <span class="hlFld-ContribAuthor ">Ji-feng  Deng</span>, <span class="hlFld-ContribAuthor ">Ying-jun  Li</span>, <span class="hlFld-ContribAuthor ">Yu  Chang</span>, <span class="hlFld-ContribAuthor ">Hui-min  Cheng</span>. </span><span class="cited-content_cbyCitation_article-title">Determination of a novel B-Raf V600E and EGFR dual inhibitor in rat plasma by HPLC–MS/MS and its application in a pharmacokinetic study. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmaceutical and Biomedical Analysis</span><span> <strong>2016,</strong> <em>129 </em>, 142-147. <a href="https://doi.org/10.1016/j.jpba.2016.06.049" title="DOI URL">https://doi.org/10.1016/j.jpba.2016.06.049</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jpba.2016.06.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jpba.2016.06.049%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmaceutical%2520and%2520Biomedical%2520Analysis%26atitle%3DDetermination%252Bof%252Ba%252Bnovel%252BB-Raf%252BV600E%252Band%252BEGFR%252Bdual%252Binhibitor%252Bin%252Brat%252Bplasma%252Bby%252BHPLC%2525E2%252580%252593MS%25252FMS%252Band%252Bits%252Bapplication%252Bin%252Ba%252Bpharmacokinetic%252Bstudy%26aulast%3DZhou%26aufirst%3DZhi-ling%26date%3D2016%26volume%3D129%26spage%3D142%26epage%3D147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaokai  Li</span>, <span class="hlFld-ContribAuthor ">Jiayi  Shen</span>, <span class="hlFld-ContribAuthor ">Li  Tan</span>, <span class="hlFld-ContribAuthor ">Zhang  Zhang</span>, <span class="hlFld-ContribAuthor ">Donglin  Gao</span>, <span class="hlFld-ContribAuthor ">Jinfeng  Luo</span>, <span class="hlFld-ContribAuthor ">Huimin  Cheng</span>, <span class="hlFld-ContribAuthor ">Xiaoping  Zhou</span>, <span class="hlFld-ContribAuthor ">Jie  Ma</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>, <span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of  N -(4-aminopyridin-2-yl)amides as B-Raf V600E  inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>26 </em>
                                    (12)
                                     , 2760-2763. <a href="https://doi.org/10.1016/j.bmcl.2016.04.076" title="DOI URL">https://doi.org/10.1016/j.bmcl.2016.04.076</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2016.04.076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2016.04.076%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252BN%252B-%2525284-aminopyridin-2-yl%252529amides%252Bas%252BB-Raf%252BV600E%252Binhibitors%26aulast%3DLi%26aufirst%3DXiaokai%26date%3D2016%26volume%3D26%26issue%3D12%26spage%3D2760%26epage%3D2763" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Biao  Lu</span>, <span class="hlFld-ContribAuthor ">Hu  Cao</span>, <span class="hlFld-ContribAuthor ">Jingsong  Cao</span>, <span class="hlFld-ContribAuthor ">Song  Huang</span>, <span class="hlFld-ContribAuthor ">Qiyue  Hu</span>, <span class="hlFld-ContribAuthor ">Dong  Liu</span>, <span class="hlFld-ContribAuthor ">Ru  Shen</span>, <span class="hlFld-ContribAuthor ">Xiaodong  Shen</span>, <span class="hlFld-ContribAuthor ">Weikang  Tao</span>, <span class="hlFld-ContribAuthor ">Hong  Wan</span>, <span class="hlFld-ContribAuthor ">Dan  Wang</span>, <span class="hlFld-ContribAuthor ">Yinfa  Yan</span>, <span class="hlFld-ContribAuthor ">Liuqing  Yang</span>, <span class="hlFld-ContribAuthor ">Jiayin  Zhang</span>, <span class="hlFld-ContribAuthor ">Lei  Zhang</span>, <span class="hlFld-ContribAuthor ">Lianshan  Zhang</span>, <span class="hlFld-ContribAuthor ">Minsheng  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of EBI-907: A highly potent and orally active B-Raf V600E inhibitor for the treatment of melanoma and associated cancers. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>26 </em>
                                    (3)
                                     , 819-823. <a href="https://doi.org/10.1016/j.bmcl.2015.12.086" title="DOI URL">https://doi.org/10.1016/j.bmcl.2015.12.086</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2015.12.086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2015.12.086%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BEBI-907%25253A%252BA%252Bhighly%252Bpotent%252Band%252Borally%252Bactive%252BB-Raf%252BV600E%252Binhibitor%252Bfor%252Bthe%252Btreatment%252Bof%252Bmelanoma%252Band%252Bassociated%252Bcancers%26aulast%3DLu%26aufirst%3DBiao%26date%3D2016%26volume%3D26%26issue%3D3%26spage%3D819%26epage%3D823" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shihui  Liu</span>, <span class="hlFld-ContribAuthor ">Shaofan  Zhu</span>, <span class="hlFld-ContribAuthor ">Ying  Wu</span>, <span class="hlFld-ContribAuthor ">Jiayu  Gao</span>, <span class="hlFld-ContribAuthor ">Pengfei  Qian</span>, <span class="hlFld-ContribAuthor ">Yanwei  Hu</span>, <span class="hlFld-ContribAuthor ">Linsen  Shi</span>, <span class="hlFld-ContribAuthor ">Shaohua  Chen</span>, <span class="hlFld-ContribAuthor ">Shilei  Zhang</span>, <span class="hlFld-ContribAuthor ">Yinan  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">One-Pot Synthesis of
              N
              -Aryl-Nicotinamides and Diarylamines Based on a Tunable Smiles Rearrangement. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2015,</strong> <em>2015 </em>
                                    (14)
                                     , 3048-3052. <a href="https://doi.org/10.1002/ejoc.201500222" title="DOI URL">https://doi.org/10.1002/ejoc.201500222</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.201500222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.201500222%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DOne-Pot%252BSynthesis%252Bof%252BN%252B-Aryl-Nicotinamides%252Band%252BDiarylamines%252BBased%252Bon%252Ba%252BTunable%252BSmiles%252BRearrangement%26aulast%3DLiu%26aufirst%3DShihui%26date%3D2015%26date%3D2015%26volume%3D2015%26issue%3D14%26spage%3D3048%26epage%3D3052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sally  Temraz</span>, <span class="hlFld-ContribAuthor ">Raafat  Alameddine</span>, <span class="hlFld-ContribAuthor ">Ali  Shamseddine</span>. </span><span class="cited-content_cbyCitation_article-title">B-type proto-oncogene-mutated tumors of colon cancer. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Oncology</span><span> <strong>2015,</strong> <em>27 </em>
                                    (3)
                                     , 276-281. <a href="https://doi.org/10.1097/CCO.0000000000000184" title="DOI URL">https://doi.org/10.1097/CCO.0000000000000184</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1097/CCO.0000000000000184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1097%2FCCO.0000000000000184%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Oncology%26atitle%3DB-type%252Bproto-oncogene-mutated%252Btumors%252Bof%252Bcolon%252Bcancer%26aulast%3DTemraz%26aufirst%3DSally%26date%3D2015%26volume%3D27%26issue%3D3%26spage%3D276%26epage%3D281" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm500007h/production/images/medium/jm-2014-00007h_0009.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm500007h/production/images/large/jm-2014-00007h_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500007h&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm500007h/production/images/medium/jm-2014-00007h_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm500007h/production/images/large/jm-2014-00007h_0002.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of FDA approved B-Raf<sup>V600E</sup> inhibitors vemurafenib (<b>1</b>) and dabrafinib (<b>2</b>), EGFR inhibitor gefitinib (<b>3</b>), and the new B-Raf/EGFR dual inhibitor <b>4</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm500007h/production/images/large/jm-2014-00007h_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500007h&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm500007h/production/images/medium/jm-2014-00007h_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm500007h/production/images/large/jm-2014-00007h_0006.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Syntheses of Compounds <b>4</b>, <b>5</b>, and <b>6</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm500007h/production/images/large/jm-2014-00007h_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500007h&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) PyBOP, Et<sub>3</sub>N, THF, rt, 12 h, 46–85%; (b) H<sub>2</sub>, 10% Pd/C, CH<sub>3</sub>OH, rt, 8 h, 68–92%; (c) HATU, DIEA, DMF, rt, 12 h, 47–62%; (d) Pd(OAc)<sub>2</sub>, 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene, Et<sub>3</sub>N, CH<sub>3</sub>OH, CO, 100 °C, 12 h, 52–83%; (e) LiOH, MeOH:THF:H<sub>2</sub>O (1:1:2), rt, 3.0 h, 44–89%.</p></p></figure><figure data-id="cht1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm500007h/production/images/medium/jm-2014-00007h_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm500007h/production/images/large/jm-2014-00007h_0001.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 1. Strategies for the Structural Optimization of Initial “Hit” Compound <b>4</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm500007h/production/images/large/jm-2014-00007h_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500007h&amp;id=cht1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm500007h/production/images/medium/jm-2014-00007h_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm500007h/production/images/large/jm-2014-00007h_0003.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Clinical drug <b>1</b> potently and sustainably inhibits the activation of the MAPK path way in SK-MEL-28 melanoma cancer cells, but its effect on p-Erk is transient in the vemurafenib-resistant SK-MEL-28-PR30 cells. (A) The vemurafenib-induced resistant cancer cells harbor a high level of EGFR as determined by Western blot analysis but not k-Ras or n-Ras mutation. (B) Drug <b>1</b> potently and sustainably inhibits the activation of the MAPK path way in SK-MEL-28 melanoma cancer cells, but p-Erk reaccumulation was observed in the vemurafenib-resistant SK-MEL-28-PR30 cells after 24 h of treatment of <b>1</b>. Western blots were preformed after SK-MEL-28 and SK-MEL-28-PR30 cells were treated with drug <b>1</b> for the indicated time (2, 24, and 48 h).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm500007h/production/images/large/jm-2014-00007h_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500007h&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm500007h/production/images/medium/jm-2014-00007h_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm500007h/production/images/large/jm-2014-00007h_0004.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Inhibitor <b>6a</b> dose-dependenty inhibits the activation of the MAPK path way and the phosphorylation of EGFR in SK-MEL-28 PR30, A375 melanoma cancer cells, and WiDr, HT29 colorectal cancer cells. Western blots were performed after the cells were treated with <b>6a</b> for 2.0 h.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm500007h/production/images/large/jm-2014-00007h_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500007h&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm500007h/production/images/medium/jm-2014-00007h_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm500007h/production/images/large/jm-2014-00007h_0005.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Inhibitor <b>6a</b> potently and sustainably inhibits the activation of the MAPK path way in SK-MEL-28 PR30 melanoma cancer cells and WiDr colorectal cancer cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-6/jm500007h/production/images/large/jm-2014-00007h_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500007h&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i51">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58644" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58644" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 45 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Peyssonnaux, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eychene, A.</span><span> </span><span class="NLM_article-title">The Raf/MEK/ERK pathway: new concepts of activation</span> <span class="citation_source-journal">Biol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">53</span><span class="NLM_x">–</span> <span class="NLM_lpage">62</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm500007h&amp;key=10.1016%2FS0248-4900%2801%2901125-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm500007h&amp;key=11730323" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm500007h&amp;key=1%3ACAS%3A528%3ADC%252BD3MXptVOju7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2001&pages=53-62&author=C.+Peyssonnauxauthor=A.+Eychene&title=The+Raf%2FMEK%2FERK+pathway%3A+new+concepts+of+activation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The Raf/MEK/ERK pathway: New concepts of activation</span></div><div class="casAuthors">Peyssonnaux, Carole; Eychene, Alain</div><div class="citationInfo"><span class="NLM_cas:title">Biology of the Cell</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">1/2</span>),
    <span class="NLM_cas:pages">53-62</span>CODEN:
                <span class="NLM_cas:coden">BCELDF</span>;
        ISSN:<span class="NLM_cas:issn">0248-4900</span>.
    
            (<span class="NLM_cas:orgname">Editions Scientifiques et Medicales Elsevier</span>)
        </div><div class="casAbstract">A review.  The Raf/MEK/ERK signaling was the first MAP kinase cascade to be characterized.  It is probably one of the most well known signal transduction pathways among biologists because of its implication in a wide variety of cellular functions as diverse -and occasionally contradictory- as cell proliferation, cell-cycle arrest, terminal differentiation and apoptosis.  Discovery and understanding of this pathway have benefited from the combination of both genetic studies in worms and flies and biochem. studies in mammalian cells.  However, ten years after, this field is still under debate and new mol. partners in the cascade continue to increase the complexity of its regulation.  This review deals with the emergence of new concepts in the activation and regulation of the Raf/MEK/ERK module.  In particular, the preponderant role of B-Raf is underlined, and the role of novel regulators such as KSR is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyjiXSFlBQ6rVg90H21EOLACvtfcHk0lh7gjrZuUAjRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXptVOju7s%253D&md5=cde3db5b205a1305dc2e6262deea65ec</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS0248-4900%2801%2901125-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0248-4900%252801%252901125-X%26sid%3Dliteratum%253Aachs%26aulast%3DPeyssonnaux%26aufirst%3DC.%26aulast%3DEychene%26aufirst%3DA.%26atitle%3DThe%2520Raf%252FMEK%252FERK%2520pathway%253A%2520new%2520concepts%2520of%2520activation%26jtitle%3DBiol.%2520Cell%26date%3D2001%26volume%3D93%26spage%3D53%26epage%3D62" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Dhillon, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rath, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolch, W.</span><span> </span><span class="NLM_article-title">MAP kinase signalling pathways in cancer</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">3279</span><span class="NLM_x">–</span> <span class="NLM_lpage">3290</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm500007h&amp;key=10.1038%2Fsj.onc.1210421" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm500007h&amp;key=17496922" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm500007h&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlt1WktLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=3279-3290&author=A.+S.+Dhillonauthor=S.+Haganauthor=O.+Rathauthor=W.+Kolch&title=MAP+kinase+signalling+pathways+in+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">MAP kinase signaling pathways in cancer</span></div><div class="casAuthors">Dhillon, A. S.; Hagan, S.; Rath, O.; Kolch, W.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3279-3290</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cancer can be perceived as a disease of communication between and within cells.  The aberrations are pleiotropic, but mitogen-activated protein kinase (MAPK) pathways feature prominently.  Here, we discuss recent findings and hypotheses on the role of MAPK pathways in cancer.  Cancerous mutations in MAPK pathways are frequently mostly affecting Ras and B-Raf in the extracellular signal-regulated kinase pathway.  Stress-activated pathways, such as Jun N-terminal kinase and p38, largely seem to counteract malignant transformation.  The balance and integration between these signals may widely vary in different tumors, but are important for the outcome and the sensitivity to drug therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2AJjwZsw0PbVg90H21EOLACvtfcHk0lh7gjrZuUAjRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlt1WktLc%253D&md5=510709dcee2bbe62c7d48dbd8f270130</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1210421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1210421%26sid%3Dliteratum%253Aachs%26aulast%3DDhillon%26aufirst%3DA.%2BS.%26aulast%3DHagan%26aufirst%3DS.%26aulast%3DRath%26aufirst%3DO.%26aulast%3DKolch%26aufirst%3DW.%26atitle%3DMAP%2520kinase%2520signalling%2520pathways%2520in%2520cancer%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D3279%26epage%3D3290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Marais, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, C. J.</span><span> </span><span class="NLM_article-title">Control of the ERK MAP kinase cascade by Ras and Raf</span> <span class="citation_source-journal">Cancer Surv.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">101</span><span class="NLM_x">–</span> <span class="NLM_lpage">125</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm500007h&amp;key=8909797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm500007h&amp;key=1%3ACAS%3A528%3ADyaK28XntlSns7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1996&pages=101-125&author=R.+Maraisauthor=C.+J.+Marshall&title=Control+of+the+ERK+MAP+kinase+cascade+by+Ras+and+Raf"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Control of the ERK MAP kinase cascade by Ras and Raf</span></div><div class="casAuthors">Marais, R.; Marshall, C. J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Surveys</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">Cell Signalling</span>),
    <span class="NLM_cas:pages">101-125</span>CODEN:
                <span class="NLM_cas:coden">CASUD7</span>;
        ISSN:<span class="NLM_cas:issn">0261-2429</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">A review, with ∼125 refs., on Mek activators, how Raf proteins are activated, and possibilities for therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHudK_EtTwhrVg90H21EOLACvtfcHk0lh7gjrZuUAjRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XntlSns7k%253D&md5=e01ca3a4a1e327f46311a04e73e0fa79</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMarais%26aufirst%3DR.%26aulast%3DMarshall%26aufirst%3DC.%2BJ.%26atitle%3DControl%2520of%2520the%2520ERK%2520MAP%2520kinase%2520cascade%2520by%2520Ras%2520and%2520Raf%26jtitle%3DCancer%2520Surv.%26date%3D1996%26volume%3D27%26spage%3D101%26epage%3D125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Garnett, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marais, R.</span><span> </span><span class="NLM_article-title">Guilty as charged: B-RAF is a human oncogene</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">313</span><span class="NLM_x">–</span> <span class="NLM_lpage">319</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2004&pages=313-319&author=M.+J.+Garnettauthor=R.+Marais&title=Guilty+as+charged%3A+B-RAF+is+a+human+oncogene"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGarnett%26aufirst%3DM.%2BJ.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DGuilty%2520as%2520charged%253A%2520B-RAF%2520is%2520a%2520human%2520oncogene%26jtitle%3DCancer%2520Cell%26date%3D2004%26volume%3D6%26spage%3D313%26epage%3D319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Davies, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bignell, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephens, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edkins, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clegg, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teague, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woffendin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garnett, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bottomley, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dicks, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ewing, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawes, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosmidou, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menzies, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mould, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hooper, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayatilake, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gusterson, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shipley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hargrave, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard-Jones, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maitland, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chenevix-Trench, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riggins, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bigner, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmieri, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cossu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flanagan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, J. W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuen, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegler, H. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darrow, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paterson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marais, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wooster, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stratton, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Futreal, P. A.</span><span> </span><span class="NLM_article-title">Mutations of the BRAF gene in human cancer</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">417</span><span class="NLM_x">, </span> <span class="NLM_fpage">949</span><span class="NLM_x">–</span> <span class="NLM_lpage">954</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm500007h&amp;key=10.1038%2Fnature00766" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm500007h&amp;key=12068308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm500007h&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvVagsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=417&publication_year=2002&pages=949-954&author=H.+Daviesauthor=G.+R.+Bignellauthor=C.+Coxauthor=P.+Stephensauthor=S.+Edkinsauthor=S.+Cleggauthor=J.+Teagueauthor=H.+Woffendinauthor=M.+J.+Garnettauthor=W.+Bottomleyauthor=N.+Davisauthor=N.+Dicksauthor=R.+Ewingauthor=Y.+Floydauthor=K.+Grayauthor=S.+Hallauthor=R.+Hawesauthor=J.+Hughesauthor=V.+Kosmidouauthor=A.+Menziesauthor=C.+Mouldauthor=A.+Parkerauthor=C.+Stevensauthor=S.+Wattauthor=S.+Hooperauthor=R.+Wilsonauthor=H.+Jayatilakeauthor=B.+A.+Gustersonauthor=C.+Cooperauthor=J.+Shipleyauthor=D.+Hargraveauthor=K.+Pritchard-Jonesauthor=N.+Maitlandauthor=G.+Chenevix-Trenchauthor=G.+J.+Rigginsauthor=D.+D.+Bignerauthor=G.+Palmieriauthor=A.+Cossuauthor=A.+Flanaganauthor=A.+Nicholsonauthor=J.+W.+C.+Hoauthor=S.+Y.+Leungauthor=S.+T.+Yuenauthor=B.+L.+Weberauthor=H.+F.+Sieglerauthor=T.+L.+Darrowauthor=H.+Patersonauthor=R.+Maraisauthor=C.+J.+Marshallauthor=R.+Woosterauthor=M.+R.+Strattonauthor=P.+A.+Futreal&title=Mutations+of+the+BRAF+gene+in+human+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations of the BRAF gene in human cancer</span></div><div class="casAuthors">Davies, Helen; Bignell, Graham R.; Cox, Charles; Stephens, Philip; Edkins, Sarah; Clegg, Sheila; Teague, Jon; Woffendin, Hayley; Garnett, Mathew J.; Bottomley, William; Davis, Neil; Dicks, Ed; Ewing, Rebecca; Floyd, Yvonne; Gray, Kristian; Hall, Sarah; Hawes, Rachel; Hughes, Jaime; Kosmidou, Vivian; Menzies, Andrew; Mould, Catherine; Parker, Adrian; Stevens, Claire; Watt, Stephen; Hooper, Steven; Wilson, Rebecca; Jayatilake, Hiran; Gusterson, Barry A.; Cooper, Colin; Shipley, Janet; Hargrave, Darren; Pritchard-Jones, Katherine; Maitland, Norman; Chenevix-Trench, Georgia; Riggins, Gregory J.; Bigner, Darell D.; Palmieri, Giuseppe; Cossu, Antonio; Flanagan, Adrienne; Nicholson, Andrew; Ho, Judy W. C.; Leung, Suet Y.; Yuen, Siu T.; Weber, Barbara L.; Seigler, Hilliard F.; Darrow, Timothy L.; Paterson, Hugh; Marais, Richard; Marshall, Christopher J.; Wooster, Richard; Stratton, Michael R.; Futreal, P. Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">417</span>
        (<span class="NLM_cas:issue">6892</span>),
    <span class="NLM_cas:pages">949-954</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cancers arise owing to the accumulation of mutations in crit. genes that alter normal programs of cell proliferation, differentiation and death.  As the first stage of a systematic genome-wide screen for these genes, we have prioritized for anal. signalling pathways in which at least one gene is mutated in human cancer.  The RAS-RAF-MEK-ERK-MAP kinase pathway mediates cellular responses to growth signals.  RAS is mutated to an oncogenic form in about 15% of human cancer.  The three RAF genes code for cytoplasmic serine/threonine kinases that are regulated by binding RAS.  Here we report BRAF somatic missense mutations in 66% of malignant melanomas and at lower frequency in a wide range of human cancers.  All mutations are within the kinase domain, with a single substitution (V599E) accounting for 80%.  Mutated BRAF proteins have elevated kinase activity and are transforming in NIH3T3 cells.  Furthermore, RAS function is not required for the growth of cancer cell lines with the V599E mutation.  As BRAF is a serine/threonine kinase that is commonly activated by somatic point mutation in human cancer, it may provide new therapeutic opportunities in malignant melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPBmhJC0GAjrVg90H21EOLACvtfcHk0lgM--uLHtljvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvVagsLo%253D&md5=4625be53ad9a382d51b6ee753d0c17e8</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnature00766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature00766%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DH.%26aulast%3DBignell%26aufirst%3DG.%2BR.%26aulast%3DCox%26aufirst%3DC.%26aulast%3DStephens%26aufirst%3DP.%26aulast%3DEdkins%26aufirst%3DS.%26aulast%3DClegg%26aufirst%3DS.%26aulast%3DTeague%26aufirst%3DJ.%26aulast%3DWoffendin%26aufirst%3DH.%26aulast%3DGarnett%26aufirst%3DM.%2BJ.%26aulast%3DBottomley%26aufirst%3DW.%26aulast%3DDavis%26aufirst%3DN.%26aulast%3DDicks%26aufirst%3DN.%26aulast%3DEwing%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DY.%26aulast%3DGray%26aufirst%3DK.%26aulast%3DHall%26aufirst%3DS.%26aulast%3DHawes%26aufirst%3DR.%26aulast%3DHughes%26aufirst%3DJ.%26aulast%3DKosmidou%26aufirst%3DV.%26aulast%3DMenzies%26aufirst%3DA.%26aulast%3DMould%26aufirst%3DC.%26aulast%3DParker%26aufirst%3DA.%26aulast%3DStevens%26aufirst%3DC.%26aulast%3DWatt%26aufirst%3DS.%26aulast%3DHooper%26aufirst%3DS.%26aulast%3DWilson%26aufirst%3DR.%26aulast%3DJayatilake%26aufirst%3DH.%26aulast%3DGusterson%26aufirst%3DB.%2BA.%26aulast%3DCooper%26aufirst%3DC.%26aulast%3DShipley%26aufirst%3DJ.%26aulast%3DHargrave%26aufirst%3DD.%26aulast%3DPritchard-Jones%26aufirst%3DK.%26aulast%3DMaitland%26aufirst%3DN.%26aulast%3DChenevix-Trench%26aufirst%3DG.%26aulast%3DRiggins%26aufirst%3DG.%2BJ.%26aulast%3DBigner%26aufirst%3DD.%2BD.%26aulast%3DPalmieri%26aufirst%3DG.%26aulast%3DCossu%26aufirst%3DA.%26aulast%3DFlanagan%26aufirst%3DA.%26aulast%3DNicholson%26aufirst%3DA.%26aulast%3DHo%26aufirst%3DJ.%2BW.%2BC.%26aulast%3DLeung%26aufirst%3DS.%2BY.%26aulast%3DYuen%26aufirst%3DS.%2BT.%26aulast%3DWeber%26aufirst%3DB.%2BL.%26aulast%3DSiegler%26aufirst%3DH.%2BF.%26aulast%3DDarrow%26aufirst%3DT.%2BL.%26aulast%3DPaterson%26aufirst%3DH.%26aulast%3DMarais%26aufirst%3DR.%26aulast%3DMarshall%26aufirst%3DC.%2BJ.%26aulast%3DWooster%26aufirst%3DR.%26aulast%3DStratton%26aufirst%3DM.%2BR.%26aulast%3DFutreal%26aufirst%3DP.%2BA.%26atitle%3DMutations%2520of%2520the%2520BRAF%2520gene%2520in%2520human%2520cancer%26jtitle%3DNature%26date%3D2002%26volume%3D417%26spage%3D949%26epage%3D954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Yuen, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bignell, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephens, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edkins, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsui, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Futreal, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stratton, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wooster, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, S. Y.</span><span> </span><span class="NLM_article-title">Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">6451</span><span class="NLM_x">–</span> <span class="NLM_lpage">6455</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=6451-6455&author=S.+T.+Yuenauthor=H.+Daviesauthor=T.+L.+Chanauthor=J.+W.+Hoauthor=G.+R.+Bignellauthor=C.+Coxauthor=P.+Stephensauthor=S.+Edkinsauthor=W.+W.+Tsuiauthor=A.+S.+Chanauthor=P.+A.+Futrealauthor=M.+R.+Strattonauthor=R.+Woosterauthor=S.+Y.+Leung&title=Similarity+of+the+phenotypic+patterns+associated+with+BRAF+and+KRAS+mutations+in+colorectal+neoplasia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYuen%26aufirst%3DS.%2BT.%26aulast%3DDavies%26aufirst%3DH.%26aulast%3DChan%26aufirst%3DT.%2BL.%26aulast%3DHo%26aufirst%3DJ.%2BW.%26aulast%3DBignell%26aufirst%3DG.%2BR.%26aulast%3DCox%26aufirst%3DC.%26aulast%3DStephens%26aufirst%3DP.%26aulast%3DEdkins%26aufirst%3DS.%26aulast%3DTsui%26aufirst%3DW.%2BW.%26aulast%3DChan%26aufirst%3DA.%2BS.%26aulast%3DFutreal%26aufirst%3DP.%2BA.%26aulast%3DStratton%26aufirst%3DM.%2BR.%26aulast%3DWooster%26aufirst%3DR.%26aulast%3DLeung%26aufirst%3DS.%2BY.%26atitle%3DSimilarity%2520of%2520the%2520phenotypic%2520patterns%2520associated%2520with%2520BRAF%2520and%2520KRAS%2520mutations%2520in%2520colorectal%2520neoplasia%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26spage%3D6451%26epage%3D6455" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Kimura, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nikiforova, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knauf, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nikiforov, Y. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fagin, J. A.</span><span> </span><span class="NLM_article-title">High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">1454</span><span class="NLM_x">–</span> <span class="NLM_lpage">1457</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=1454-1457&author=E.+T.+Kimuraauthor=M.+N.+Nikiforovaauthor=Z.+W.+Zhuauthor=J.+A.+Knaufauthor=Y.+E.+Nikiforovauthor=J.+A.+Fagin&title=High+prevalence+of+BRAF+mutations+in+thyroid+cancer%3A+genetic+evidence+for+constitutive+activation+of+the+RET%2FPTC-RAS-BRAF+signaling+pathway+in+papillary+thyroid+carcinoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKimura%26aufirst%3DE.%2BT.%26aulast%3DNikiforova%26aufirst%3DM.%2BN.%26aulast%3DZhu%26aufirst%3DZ.%2BW.%26aulast%3DKnauf%26aufirst%3DJ.%2BA.%26aulast%3DNikiforov%26aufirst%3DY.%2BE.%26aulast%3DFagin%26aufirst%3DJ.%2BA.%26atitle%3DHigh%2520prevalence%2520of%2520BRAF%2520mutations%2520in%2520thyroid%2520cancer%253A%2520genetic%2520evidence%2520for%2520constitutive%2520activation%2520of%2520the%2520RET%252FPTC-RAS-BRAF%2520signaling%2520pathway%2520in%2520papillary%2520thyroid%2520carcinoma%26jtitle%3DCancer%2520Res.%26date%3D2003%26volume%3D63%26spage%3D1454%26epage%3D1457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Wellbrock, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurlstone, A.</span><span> </span><span class="NLM_article-title">BRAF as therapeutic target in melanoma</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">80</span><span class="NLM_x">, </span> <span class="NLM_fpage">561</span><span class="NLM_x">–</span> <span class="NLM_lpage">567</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2010&pages=561-567&author=C.+Wellbrockauthor=A.+Hurlstone&title=BRAF+as+therapeutic+target+in+melanoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWellbrock%26aufirst%3DC.%26aulast%3DHurlstone%26aufirst%3DA.%26atitle%3DBRAF%2520as%2520therapeutic%2520target%2520in%2520melanoma%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2010%26volume%3D80%26spage%3D561%26epage%3D567" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Tuveson, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herlyn, M.</span><span> </span><span class="NLM_article-title">BRAF as a potential therapeutic target in melanoma and other malignancies</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">95</span><span class="NLM_x">–</span> <span class="NLM_lpage">98</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2003&pages=95-98&author=D.+A.+Tuvesonauthor=B.+L.+Weberauthor=M.+Herlyn&title=BRAF+as+a+potential+therapeutic+target+in+melanoma+and+other+malignancies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTuveson%26aufirst%3DD.%2BA.%26aulast%3DWeber%26aufirst%3DB.%2BL.%26aulast%3DHerlyn%26aufirst%3DM.%26atitle%3DBRAF%2520as%2520a%2520potential%2520therapeutic%2520target%2520in%2520melanoma%2520and%2520other%2520malignancies%26jtitle%3DCancer%2520Cell%26date%3D2003%26volume%3D4%26spage%3D95%26epage%3D98" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Tsai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mamo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bremer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillette, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haass, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sproesser, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smalley, K. S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fong, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marimuthu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settachatgul, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shellooe, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantwell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlessinger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, K. Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habets, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ibrahim, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirth, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Artis, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herlyn, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bollag, G.</span><span> </span><span class="NLM_article-title">Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">3041</span><span class="NLM_x">–</span> <span class="NLM_lpage">3046</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm500007h&amp;key=10.1073%2Fpnas.0711741105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm500007h&amp;key=18287029" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm500007h&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjtVSitrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=3041-3046&author=J.+Tsaiauthor=J.+T.+Leeauthor=W.+Wangauthor=J.+Zhangauthor=H.+Choauthor=S.+Mamoauthor=R.+Bremerauthor=S.+Gilletteauthor=J.+Kongauthor=N.+K.+Haassauthor=K.+Sproesserauthor=L.+Liauthor=K.+S.+M.+Smalleyauthor=D.+Fongauthor=Y.+L.+Zhuauthor=A.+Marimuthuauthor=H.+Nguyenauthor=B.+Lamauthor=J.+Liuauthor=I.+Cheungauthor=J.+Riceauthor=Y.+Suzukiauthor=C.+Luuauthor=C.+Settachatgulauthor=R.+Shellooeauthor=J.+Cantwellauthor=S.+H.+Kimauthor=J.+Schlessingerauthor=K.+Y.+J.+Zhangauthor=B.+L.+Westauthor=B.+Powellauthor=G.+Habetsauthor=C.+Zhangauthor=P.+N.+Ibrahimauthor=P.+Hirthauthor=D.+R.+Artisauthor=M.+Herlynauthor=G.+Bollag&title=Discovery+of+a+selective+inhibitor+of+oncogenic+B-Raf+kinase+with+potent+antimelanoma+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity</span></div><div class="casAuthors">Tsai, James; Lee, John T.; Wang, Weiru; Zhang, Jiazhong; Cho, Hanna; Mamo, Shumeye; Bremer, Ryan; Gillette, Sam; Kong, Jun; Haass, Nikolas K.; Sproesser, Katrin; Li, Ling; Smalley, Keiran S. M.; Fong, Daniel; Zhu, Yong-Liang; Marimuthu, Adhirai; Nguyen, Hoa; Lam, Billy; Liu, Jennifer; Cheung, Ivana; Rice, Julie; Suzuki, Yoshihisa; Luu, Catherine; Settachatgul, Calvin; Shellooe, Rafe; Cantwell, John; Kim, Sung-Hou; Schlessinger, Joseph; Zhang, Kam Y. J.; West, Brian L.; Powell, Ben; Habets, Gaston; Zhang, Chao; Ibrahim, Prabha N.; Hirth, Peter; Artis, Dean R.; Herlyn, Meenhard; Bollag, Gideon</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3041-3046</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">BRAFV600E is the most frequent oncogenic protein kinase mutation known.  Furthermore, inhibitors targeting "active" protein kinases have demonstrated significant utility in the therapeutic repertoire against cancer.  Therefore, the authors pursued the development of specific kinase inhibitors targeting B-Raf, and the V600E allele in particular.  By using a structure-guided discovery approach, a potent and selective inhibitor of active B-Raf has been discovered.  PLX4720, a 7-azaindole deriv. that inhibits B-RafV600E with an IC50 of 13 nM, defines a class of kinase inhibitor with marked selectivity in both biochem. and cellular assays.  PLX4720 preferentially inhibits the active B-RafV600E kinase compared with a broad spectrum of other kinases, and potent cytotoxic effects are also exclusive to cells bearing the V600E allele.  Consistent with the high degree of selectivity, ERK phosphorylation is potently inhibited by PLX4720 in B-RafV600E-bearing tumor cell lines but not in cells lacking oncogenic B-Raf.  In melanoma models, PLX4720 induces cell cycle arrest and apoptosis exclusively in B-RafV600E-pos. cells.  In B-RafV600E-dependent tumor xenograft models, orally dosed PLX4720 causes significant tumor growth delays, including tumor regressions, without evidence of toxicity.  The work described here represents the entire discovery process, from initial identification through structural and biol. studies in animal models to a promising therapeutic for testing in cancer patients bearing B-RafV600E-driven tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPX53IQCbDJ7Vg90H21EOLACvtfcHk0lhQe4bgNJl5oA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjtVSitrk%253D&md5=273b94202f99984e6eb24723d0c6141f</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0711741105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0711741105%26sid%3Dliteratum%253Aachs%26aulast%3DTsai%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DJ.%2BT.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DCho%26aufirst%3DH.%26aulast%3DMamo%26aufirst%3DS.%26aulast%3DBremer%26aufirst%3DR.%26aulast%3DGillette%26aufirst%3DS.%26aulast%3DKong%26aufirst%3DJ.%26aulast%3DHaass%26aufirst%3DN.%2BK.%26aulast%3DSproesser%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DSmalley%26aufirst%3DK.%2BS.%2BM.%26aulast%3DFong%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DY.%2BL.%26aulast%3DMarimuthu%26aufirst%3DA.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DLam%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DCheung%26aufirst%3DI.%26aulast%3DRice%26aufirst%3DJ.%26aulast%3DSuzuki%26aufirst%3DY.%26aulast%3DLuu%26aufirst%3DC.%26aulast%3DSettachatgul%26aufirst%3DC.%26aulast%3DShellooe%26aufirst%3DR.%26aulast%3DCantwell%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DK.%2BY.%2BJ.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DHabets%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DIbrahim%26aufirst%3DP.%2BN.%26aulast%3DHirth%26aufirst%3DP.%26aulast%3DArtis%26aufirst%3DD.%2BR.%26aulast%3DHerlyn%26aufirst%3DM.%26aulast%3DBollag%26aufirst%3DG.%26atitle%3DDiscovery%2520of%2520a%2520selective%2520inhibitor%2520of%2520oncogenic%2520B-Raf%2520kinase%2520with%2520potent%2520antimelanoma%2520activity%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2008%26volume%3D105%26spage%3D3041%26epage%3D3046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Rheault, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stellwagen, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adjabeng, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hornberger, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrov, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waterson, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickerson, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mook, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laquerre, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossanese, O. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnone, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smitheman, K. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kane-Carson, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moorthy, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moss, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uehling, D. E.</span><span> </span><span class="NLM_article-title">Discovery of dabrafenib: a selective inhibitor of Raf kinases with antitumor activity against B-Raf-driven tumors</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">358</span><span class="NLM_x">–</span> <span class="NLM_lpage">362</span></span><div class="citationLinks">[<a href="/doi/10.1021/ml4000063" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=358-362&author=T.+R.+Rheaultauthor=J.+C.+Stellwagenauthor=G.+M.+Adjabengauthor=K.+R.+Hornbergerauthor=K.+G.+Petrovauthor=A.+G.+Watersonauthor=S.+H.+Dickersonauthor=R.+A.+Mookauthor=S.+G.+Laquerreauthor=A.+J.+Kingauthor=O.+W.+Rossaneseauthor=M.+R.+Arnoneauthor=K.+N.+Smithemanauthor=L.+S.+Kane-Carsonauthor=C.+Hanauthor=G.+S.+Moorthyauthor=K.+G.+Mossauthor=D.+E.+Uehling&title=Discovery+of+dabrafenib%3A+a+selective+inhibitor+of+Raf+kinases+with+antitumor+activity+against+B-Raf-driven+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Fml4000063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml4000063%26sid%3Dliteratum%253Aachs%26aulast%3DRheault%26aufirst%3DT.%2BR.%26aulast%3DStellwagen%26aufirst%3DJ.%2BC.%26aulast%3DAdjabeng%26aufirst%3DG.%2BM.%26aulast%3DHornberger%26aufirst%3DK.%2BR.%26aulast%3DPetrov%26aufirst%3DK.%2BG.%26aulast%3DWaterson%26aufirst%3DA.%2BG.%26aulast%3DDickerson%26aufirst%3DS.%2BH.%26aulast%3DMook%26aufirst%3DR.%2BA.%26aulast%3DLaquerre%26aufirst%3DS.%2BG.%26aulast%3DKing%26aufirst%3DA.%2BJ.%26aulast%3DRossanese%26aufirst%3DO.%2BW.%26aulast%3DArnone%26aufirst%3DM.%2BR.%26aulast%3DSmitheman%26aufirst%3DK.%2BN.%26aulast%3DKane-Carson%26aufirst%3DL.%2BS.%26aulast%3DHan%26aufirst%3DC.%26aulast%3DMoorthy%26aufirst%3DG.%2BS.%26aulast%3DMoss%26aufirst%3DK.%2BG.%26aulast%3DUehling%26aufirst%3DD.%2BE.%26atitle%3DDiscovery%2520of%2520dabrafenib%253A%2520a%2520selective%2520inhibitor%2520of%2520Raf%2520kinases%2520with%2520antitumor%2520activity%2520against%2520B-Raf-driven%2520tumors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D358%26epage%3D362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Bollag, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ibrahim, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolop, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirth, P.</span><span> </span><span class="NLM_article-title">Vemurafenib: the first drug approved for BRAF-mutant cancer</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">873</span><span class="NLM_x">–</span> <span class="NLM_lpage">886</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=873-886&author=G.+Bollagauthor=J.+Tsaiauthor=J.+Z.+Zhangauthor=C.+Zhangauthor=P.+Ibrahimauthor=K.+Nolopauthor=P.+Hirth&title=Vemurafenib%3A+the+first+drug+approved+for+BRAF-mutant+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DTsai%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%2BZ.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DIbrahim%26aufirst%3DP.%26aulast%3DNolop%26aufirst%3DK.%26aulast%3DHirth%26aufirst%3DP.%26atitle%3DVemurafenib%253A%2520the%2520first%2520drug%2520approved%2520for%2520BRAF-mutant%2520cancer%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26spage%3D873%26epage%3D886" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Ballantyne, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garnock-Jones, K. P.</span><span> </span><span class="NLM_article-title">Dabrafenib: first global approval</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">1367</span><span class="NLM_x">–</span> <span class="NLM_lpage">1376</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=1367-1376&author=A.+D.+Ballantyneauthor=K.+P.+Garnock-Jones&title=Dabrafenib%3A+first+global+approval"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBallantyne%26aufirst%3DA.%2BD.%26aulast%3DGarnock-Jones%26aufirst%3DK.%2BP.%26atitle%3DDabrafenib%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2013%26volume%3D73%26spage%3D1367%26epage%3D1376" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Chapman, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hauschild, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haanen, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ascierto, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larkin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dummer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garbe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Testori, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorigan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebbe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jouary, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schadendorf, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Day, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkwood, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eggermont, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dreno, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolop, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G. A.</span><span> </span><span class="NLM_article-title">Improved survival with vemurafenib in melanoma with BRAF V600E mutation</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">364</span><span class="NLM_x">, </span> <span class="NLM_fpage">2507</span><span class="NLM_x">–</span> <span class="NLM_lpage">2516</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm500007h&amp;key=10.1056%2FNEJMoa1103782" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm500007h&amp;key=21639808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm500007h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosVeitbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=2507-2516&author=P.+B.+Chapmanauthor=A.+Hauschildauthor=C.+Robertauthor=J.+B.+Haanenauthor=P.+Asciertoauthor=J.+Larkinauthor=R.+Dummerauthor=C.+Garbeauthor=A.+Testoriauthor=M.+Maioauthor=D.+Hoggauthor=P.+Loriganauthor=C.+Lebbeauthor=T.+Jouaryauthor=D.+Schadendorfauthor=A.+Ribasauthor=S.+J.+O%E2%80%99Dayauthor=J.+A.+Sosmanauthor=J.+M.+Kirkwoodauthor=A.+M.+Eggermontauthor=B.+Drenoauthor=K.+Nolopauthor=J.+Liauthor=B.+Nelsonauthor=J.+Houauthor=R.+J.+Leeauthor=K.+T.+Flahertyauthor=G.+A.+McArthur&title=Improved+survival+with+vemurafenib+in+melanoma+with+BRAF+V600E+mutation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Improved survival with vemurafenib in melanoma with BRAF V600E mutation</span></div><div class="casAuthors">Chapman, Paul B.; Hauschild, Axel; Robert, Caroline; Haanen, John B.; Ascierto, Paolo; Larkin, James; Dummer, Reinhard; Garbe, Claus; Testori, Alessandro; Maio, Michele; Hogg, David; Lorigan, Paul; Lebbe, Celeste; Jouary, Thomas; Schadendorf, Dirk; Ribas, Antoni; O'Day, Steven J.; Sosman, Jeffrey A.; Kirkwood, John M.; Eggermont, Alexander M. M.; Dreno, Brigitte; Nolop, Keith; Li, Jiang; Nelson, Betty; Hou, Jeannie; Lee, Richard J.; Flaherty, Keith T.; McArthur, Grant A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">2507-2516</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Phase 1 and 2 clin. trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E mutation.  METHODS: We conducted a phase 3 randomized clin. trial comparing vemurafenib with dacarbazine in 675 patients with previously untreated, metastatic melanoma with the BRAF V600E mutation.  Patients were randomly assigned to receive either vemurafenib (960 mg orally twice daily) or dacarbazine (1000 mg per square meter of body-surface area i.v. every 3 wk).  Coprimary end points were rates of overall and progression-free survival.  Secondary end points included the response rate, response duration, and safety.  A final anal. was planned after 196 deaths and an interim anal. after 98 deaths.  RESULTS: At 6 mo, overall survival was 840/ (95% confidence interval [CI], 78 to 89) in the vemurafenib group and 64% (95% CI, 56 to 73) in the dacarbazine group.  In the interim anal. for overall survival and final anal. for progression-free survival, vemurafenib was assocd. with a relative redn. of 63% in the risk of death and of 74% in the risk of either death or disease progression, as compared with dacarbazine (P < 0.001 for both comparisons).  After review of the interim anal. by an independent data and safety monitoring board, crossover from dacarbazine to vemurafenib was recommended.  Response rates were 48% for vemurafenib and 5% for dacarbazine.  Common adverse events assocd. with vemurafenib were arthralgia, rash, fatigue, alopecia, keratoacanthoma or squamous-cell carcinoma, photosensitivity, nausea, and diarrhea; 38% of patients required dose modification because of toxic effects.  CONCLUSIONS: Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4NFxmTaDz97Vg90H21EOLACvtfcHk0lj-pSvwPrVkNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosVeitbs%253D&md5=1a4b4f963221888dc63f620e87408070</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1103782&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1103782%26sid%3Dliteratum%253Aachs%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DHauschild%26aufirst%3DA.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DHaanen%26aufirst%3DJ.%2BB.%26aulast%3DAscierto%26aufirst%3DP.%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DDummer%26aufirst%3DR.%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DTestori%26aufirst%3DA.%26aulast%3DMaio%26aufirst%3DM.%26aulast%3DHogg%26aufirst%3DD.%26aulast%3DLorigan%26aufirst%3DP.%26aulast%3DLebbe%26aufirst%3DC.%26aulast%3DJouary%26aufirst%3DT.%26aulast%3DSchadendorf%26aufirst%3DD.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Day%26aufirst%3DS.%2BJ.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DKirkwood%26aufirst%3DJ.%2BM.%26aulast%3DEggermont%26aufirst%3DA.%2BM.%26aulast%3DDreno%26aufirst%3DB.%26aulast%3DNolop%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DNelson%26aufirst%3DB.%26aulast%3DHou%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26atitle%3DImproved%2520survival%2520with%2520vemurafenib%2520in%2520melanoma%2520with%2520BRAF%2520V600E%2520mutation%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D2507%26epage%3D2516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puzanov, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Dwyer, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grippo, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolop, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, P. B.</span><span> </span><span class="NLM_article-title">Inhibition of mutated, activated BRAF in metastatic melanoma</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x">, </span> <span class="NLM_fpage">809</span><span class="NLM_x">–</span> <span class="NLM_lpage">819</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm500007h&amp;key=10.1056%2FNEJMoa1002011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm500007h&amp;key=20818844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm500007h&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVyksb3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=809-819&author=K.+T.+Flahertyauthor=I.+Puzanovauthor=K.+B.+Kimauthor=A.+Ribasauthor=G.+A.+McArthurauthor=J.+A.+Sosmanauthor=P.+J.+O%E2%80%99Dwyerauthor=R.+J.+Leeauthor=J.+F.+Grippoauthor=K.+Nolopauthor=P.+B.+Chapman&title=Inhibition+of+mutated%2C+activated+BRAF+in+metastatic+melanoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of mutated, activated BRAF in metastatic melanoma</span></div><div class="casAuthors">Flaherty, Keith T.; Puzanov, Igor; Kim, Kevin B.; Ribas, Antoni; McArthur, Grant A.; Sosman, Jeffrey A.; O'dwyer, Peter J.; Lee, Richard J.; Grippo, Joseph F.; Nolop, Keith; Chapman, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">809-819</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: The identification of somatic mutations in the gene encoding the serine-threonine protein kinase B-RAF (BRAF) in the majority of melanomas offers an opportunity to test oncogene-targeted therapy for this disease.  Methods: We conducted a multicenter, phase 1, dose-escalation trial of PLX4032 (also known as RG7204), an orally available inhibitor of mutated BRAF, followed by an extension phase involving the max. dose that could be administered without adverse effects (the recommended phase 2 dose).  Patients received PLX4032 twice daily until they had disease progression.  Pharmacokinetic anal. and tumor-response assessments were conducted in all patients.  In selected patients, tumor biopsy was performed before and during treatment to validate BRAF inhibition.  Results: A total of 55 patients (49 of whom had melanoma) were enrolled in the dose-escalation phase, and 32 addnl. patients with metastatic melanoma who had BRAF with the V600E mutation were enrolled in the extension phase.  The recommended phase 2 dose was 960 mg twice daily, with increases in the dose limited by grade 2 or 3 rash, fatigue, and arthralgia.  In the dose-escalation cohort, among the 16 patients with melanoma whose tumors carried the V600E BRAF mutation and who were receiving 240 mg or more of PLX4032 twice daily, 10 had a partial response and 1 had a complete response.  Among the 32 patients in the extension cohort, 24 had a partial response and 2 had a complete response.  The estd. median progression-free survival among all patients was more than 7 mo.  Conclusions: Treatment of metastatic melanoma with PLX4032 in patients with tumors that carry the V600E BRAF mutation resulted in complete or partial tumor regression in the majority of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwq1fkvEjfyLVg90H21EOLACvtfcHk0ljaca4QQONFFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVyksb3M&md5=80f70df0ac490828a42e6c7c0b40067f</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1002011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1002011%26sid%3Dliteratum%253Aachs%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DO%25E2%2580%2599Dwyer%26aufirst%3DP.%2BJ.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DGrippo%26aufirst%3DJ.%2BF.%26aulast%3DNolop%26aufirst%3DK.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26atitle%3DInhibition%2520of%2520mutated%252C%2520activated%2520BRAF%2520in%2520metastatic%2520melanoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D809%26epage%3D819" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuchter, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pavlick, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutson, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moschos, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hersey, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kefford, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawrence, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puzanov, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amaravadi, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chmielowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawrence, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shyr, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolop, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joe, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span> </span><span class="NLM_article-title">Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">366</span><span class="NLM_x">, </span> <span class="NLM_fpage">707</span><span class="NLM_x">–</span> <span class="NLM_lpage">714</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm500007h&amp;key=10.1056%2FNEJMoa1112302" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm500007h&amp;key=22356324" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm500007h&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtFOqtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2012&pages=707-714&author=J.+A.+Sosmanauthor=K.+B.+Kimauthor=L.+Schuchterauthor=R.+Gonzalezauthor=A.+C.+Pavlickauthor=J.+S.+Weberauthor=G.+A.+McArthurauthor=T.+E.+Hutsonauthor=S.+J.+Moschosauthor=K.+T.+Flahertyauthor=P.+Herseyauthor=R.+Keffordauthor=D.+Lawrenceauthor=I.+Puzanovauthor=K.+D.+Lewisauthor=R.+K.+Amaravadiauthor=B.+Chmielowskiauthor=H.+J.+Lawrenceauthor=Y.+Shyrauthor=F.+Yeauthor=J.+Liauthor=K.+B.+Nolopauthor=R.+J.+Leeauthor=A.+K.+Joeauthor=A.+Ribas&title=Survival+in+BRAF+V600-mutant+advanced+melanoma+treated+with+vemurafenib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib</span></div><div class="casAuthors">Sosman, Jeffrey A.; Kim, Kevin B.; Schuchter, Lynn; Gonzalez, Rene; Pavlick, Anna C.; Weber, Jeffrey S.; McArthur, Grant A.; Hutson, Thomas E.; Moschos, Stergios J.; Flaherty, Keith T.; Hersey, Peter; Kefford, Richard; Lawrence, Donald; Puzanov, Igor; Lewis, Karl D.; Amaravadi, Ravi K.; Chmielowski, Bartosz; Lawrence, H. Jeffrey; Shyr, Yu; Ye, Fei; Li, Jiang; Nolop, Keith B.; Lee, Richard J.; Joe, Andrew K.; Ribas, Antoni</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">366</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">707-714</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Approx. 50% of melanomas harbor activating (V600) mutations in the serine-threonine protein kinase B-RAF (BRAF).  The oral BRAF inhibitor vemurafenib (PLX4032) frequently produced tumor regressions in patients with BRAF V600-mutant metastatic melanoma in a phase 1 trial and improved overall survival in a phase 3 trial.  METHODS We designed a multicenter phase 2 trial of vemurafenib in patients with previously treated BRAF V600-mutant metastatic melanoma to investigate the efficacy of vem urafenib with respect to overall response rate (percentage of treated patients with a tumor response), duration of response, and overall survival.  The primary end point was the overall response rate as ascertained by the independent review committee; overall survival was a secondary end point.  RESULTS A total of 132 patients had a median follow-up of 12.9 mo (range, 0.6 to 20.1).  The confirmed overall response rate was 53% (95% confidence interval [CI], 44 to 62; 6% with a complete response and 47% with a partial response), the median duration of response was 6.7 mo (95% CI, 5.6 to 8.6), and the median progression-free survival was 6.8 mo (95% CI, 5.6 to 8.1).  Primary progression was obsd.,in only 14% of patients.  Some patients had a response after receiving vemurafenib for more than 6' months.  The median overall survival was 15.9 mo (95% CI, 11.6 to 18.3).  The most common adverse events were grade 1 or 2 arthralgia, rash, photosensitivity, fatigue, and alopecia.  Cutaneous squamous-cell carcinomas (the majority, keratoacanthoma type) were diagnosed in 26% of patients.  CONCLUSIONS Vemurafenib induces clin. responses in more than half of patients with previously treated BRAF V600-mutant metastatic melanoma.  In this study with a long follow-up, the median overall survival was approx. 16 mo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0-17UBZyghrVg90H21EOLACvtfcHk0ljaca4QQONFFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtFOqtr0%253D&md5=74da93cc5ac6497207f12dd0461d9414</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1112302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1112302%26sid%3Dliteratum%253Aachs%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DSchuchter%26aufirst%3DL.%26aulast%3DGonzalez%26aufirst%3DR.%26aulast%3DPavlick%26aufirst%3DA.%2BC.%26aulast%3DWeber%26aufirst%3DJ.%2BS.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DHutson%26aufirst%3DT.%2BE.%26aulast%3DMoschos%26aufirst%3DS.%2BJ.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DHersey%26aufirst%3DP.%26aulast%3DKefford%26aufirst%3DR.%26aulast%3DLawrence%26aufirst%3DD.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DLewis%26aufirst%3DK.%2BD.%26aulast%3DAmaravadi%26aufirst%3DR.%2BK.%26aulast%3DChmielowski%26aufirst%3DB.%26aulast%3DLawrence%26aufirst%3DH.%2BJ.%26aulast%3DShyr%26aufirst%3DY.%26aulast%3DYe%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DNolop%26aufirst%3DK.%2BB.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DJoe%26aufirst%3DA.%2BK.%26aulast%3DRibas%26aufirst%3DA.%26atitle%3DSurvival%2520in%2520BRAF%2520V600-mutant%2520advanced%2520melanoma%2520treated%2520with%2520vemurafenib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D366%26spage%3D707%26epage%3D714" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Falchook, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, G. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurzrock, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arkenau, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamid, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Infante, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Millward, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pavlick, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Day, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackman, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtis, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebowitz, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ouellet, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kefford, R. F.</span><span> </span><span class="NLM_article-title">Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">379</span><span class="NLM_x">, </span> <span class="NLM_fpage">1893</span><span class="NLM_x">–</span> <span class="NLM_lpage">1901</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm500007h&amp;key=10.1016%2FS0140-6736%2812%2960398-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm500007h&amp;key=22608338" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm500007h&amp;key=1%3ACAS%3A528%3ADC%252BC38Xnt1Kmtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=379&publication_year=2012&pages=1893-1901&author=G.+S.+Falchookauthor=G.+V.+Longauthor=R.+Kurzrockauthor=K.+B.+Kimauthor=T.+H.+Arkenauauthor=M.+P.+Brownauthor=O.+Hamidauthor=J.+R.+Infanteauthor=M.+Millwardauthor=A.+C.+Pavlickauthor=S.+J.+O%E2%80%99Dayauthor=S.+C.+Blackmanauthor=C.+M.+Curtisauthor=P.+Lebowitzauthor=B.+Maauthor=D.+Ouelletauthor=R.+F.+Kefford&title=Dabrafenib+in+patients+with+melanoma%2C+untreated+brain+metastases%2C+and+other+solid+tumours%3A+a+phase+1+dose-escalation+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial</span></div><div class="casAuthors">Falchook, Gerald S.; Long, Georgina V.; Kurzrock, Razelle; Kim, Kevin B.; Arkenau, Tobias H.; Brown, Michael P.; Hamid, Omid; Infante, Jeffrey R.; Millward, Michael; Pavlick, Anna C.; O'Day, Steven J.; Blackman, Samuel C.; Curtis, C. Martin; Lebowitz, Peter; Ma, Bo; Ouellet, Daniele; Kefford, Richard F.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">379</span>
        (<span class="NLM_cas:issue">9829</span>),
    <span class="NLM_cas:pages">1893-1901</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Dabrafenib is an inhibitor of BRAF kinase that is selective for mutant BRAF.  We aimed to assess its safety and tolerability and to establish a recommended phase 2 dose in patients with incurable solid tumors, esp. those with melanoma and untreated, asymptomatic brain metastases.  We undertook a phase 1 trial between May 27, 2009, and March 20, 2012, at eight study centers in Australia and the USA.  Eligible patients had incurable solid tumors, were 18 years or older, and had adequate organ function.  BRAF mutations were mandatory for inclusion later in the study because of an absence of activity in patients with wild-type BRAF.  We used an accelerated dose titrn. method, with the first dose cohort receiving 12 mg dabrafenib daily in a 21-day cycle.  Once doses had been established, we expanded the cohorts to include up to 20 patients.  On the basis of initial data, we chose a recommended phase 2 dose.  Efficacy at the recommended phase 2 dose was studied in patients with BRAF-mutant tumors, including those with non-Val600Glu mutations, in three cohorts: metastatic melanoma, melanoma with untreated brain metastases, and non-melanoma solid tumors.  This study is registered with ClinicalTrials.gov, no. NCT00880321.  We enrolled 184 patients, of whom 156 had metastatic melanoma.  The most common treatment-related adverse events of grade 2 or worse were cutaneous squamous-cell carcinoma (20 patients, 11%), fatigue (14, 8%), and pyrexia (11, 6%).  Dose redns. were necessary in 13 (7%) patients.  No deaths or discontinuations resulted from adverse events, and 140 (76%) patients had no treatment-related adverse events worse than grade 2.  Doses were increased to 300 mg twice daily, with no max. tolerated dose recorded.  On the basis of safety, pharmacokinetic, and response data, we selected a recommended phase 2 dose of 150 mg twice daily.  At the recommended phase 2 dose in 36 patients with Val600 BRAF-mutant melanoma, responses were reported in 25 (69%, 95% CI 51·9-83·7) and confirmed responses in 18 (50%, 32·9-67·1). 21 (78%, 57·7-91·4) of 27 patients with Val600Glu BRAF-mutant melanoma responded and 15 (56%, 35·3-74·5) had a confirmed response.  In Val600 BRAF-mutant melanoma, responses were durable, with 17 patients (47%) on treatment for more than 6 mo.  Responses were recorded in patients with non-Val600Glu BRAF mutations.  In patients with melanoma and untreated brain metastases, nine of ten patients had redns. in size of brain lesions.  In 28 patients with BRAF-mutant non-melanoma solid tumors, apparent antitumor activity was noted in a gastrointestinal stromal tumor, papillary thyroid cancers, non-small-cell lung cancer, ovarian cancer, and colorectal cancer.  Dabrafenib is safe in patients with solid tumors, and an active inhibitor of Val600-mutant BRAF with responses noted in patients with melanoma, brain metastases, and other solid tumors.GlaxoSmithKline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLh2oSdpl4mrVg90H21EOLACvtfcHk0liN4BJQ82rKEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xnt1Kmtbo%253D&md5=f2d104a308316cf613ed8639491a3acf</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2812%2960398-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252812%252960398-5%26sid%3Dliteratum%253Aachs%26aulast%3DFalchook%26aufirst%3DG.%2BS.%26aulast%3DLong%26aufirst%3DG.%2BV.%26aulast%3DKurzrock%26aufirst%3DR.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DArkenau%26aufirst%3DT.%2BH.%26aulast%3DBrown%26aufirst%3DM.%2BP.%26aulast%3DHamid%26aufirst%3DO.%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26aulast%3DMillward%26aufirst%3DM.%26aulast%3DPavlick%26aufirst%3DA.%2BC.%26aulast%3DO%25E2%2580%2599Day%26aufirst%3DS.%2BJ.%26aulast%3DBlackman%26aufirst%3DS.%2BC.%26aulast%3DCurtis%26aufirst%3DC.%2BM.%26aulast%3DLebowitz%26aufirst%3DP.%26aulast%3DMa%26aufirst%3DB.%26aulast%3DOuellet%26aufirst%3DD.%26aulast%3DKefford%26aufirst%3DR.%2BF.%26atitle%3DDabrafenib%2520in%2520patients%2520with%2520melanoma%252C%2520untreated%2520brain%2520metastases%252C%2520and%2520other%2520solid%2520tumours%253A%2520a%2520phase%25201%2520dose-escalation%2520trial%26jtitle%3DLancet%26date%3D2012%26volume%3D379%26spage%3D1893%26epage%3D1901" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Hauschild, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grob, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demidov, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jouary, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gutzmer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Millward, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rutkowski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blank, C. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, W. H.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaempgen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin-Algarra, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karaszewska, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mauch, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiarion-Sileni, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swann, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haney, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mirakhur, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guckert, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodman, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, P. B.</span><span> </span><span class="NLM_article-title">Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">380</span><span class="NLM_x">, </span> <span class="NLM_fpage">358</span><span class="NLM_x">–</span> <span class="NLM_lpage">365</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm500007h&amp;key=10.1016%2FS0140-6736%2812%2960868-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm500007h&amp;key=22735384" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm500007h&amp;key=1%3ACAS%3A528%3ADC%252BC38Xpt1SgtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=380&publication_year=2012&pages=358-365&author=A.+Hauschildauthor=J.+J.+Grobauthor=L.+V.+Demidovauthor=T.+Jouaryauthor=R.+Gutzmerauthor=M.+Millwardauthor=P.+Rutkowskiauthor=C.+U.+Blankauthor=W.+H.+Millerauthor=E.+Kaempgenauthor=S.+Martin-Algarraauthor=B.+Karaszewskaauthor=C.+Mauchauthor=V.+Chiarion-Sileniauthor=A.+M.+Martinauthor=S.+Swannauthor=P.+Haneyauthor=B.+Mirakhurauthor=M.+E.+Guckertauthor=V.+Goodmanauthor=P.+B.+Chapman&title=Dabrafenib+in+BRAF-mutated+metastatic+melanoma%3A+a+multicentre%2C+open-label%2C+phase+3+randomised+controlled+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial</span></div><div class="casAuthors">Hauschild, Axel; Grob, Jean-Jacques; Demidov, Lev V.; Jouary, Thomas; Gutzmer, Ralf; Millward, Michael; Rutkowski, Piotr; Blank, Christian U.; Miller, Wilson H.; Kaempgen, Eckhart; Martin-Algarra, Salvador; Karaszewska, Boguslawa; Mauch, Cornelia; Chiarion-Sileni, Vanna; Martin, Anne-Marie; Swann, Suzanne; Haney, Patricia; Mirakhur, Beloo; Guckert, Mary E.; Goodman, Vicki; Chapman, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">380</span>
        (<span class="NLM_cas:issue">9839</span>),
    <span class="NLM_cas:pages">358-365</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Dabrafenib, an inhibitor of mutated BRAF, has clin. activity with a manageable safety profile in studies of phase 1 and 2 in patients with BRAFV600-mutated metastatic melanoma.  We studied the efficacy of dabrafenib in patients with BRAFV600E-mutated metastatic melanoma.We enrolled patients in this open-label phase 3 trial between Dec 23, 2010, and Sept 1, 2011.  This report is based on a data cutoff date of Dec 19, 2011.  Patients aged 18 years or older with previously untreated, stage IV or unresectable stage III BRAFV600E mutation-pos. melanoma were randomly assigned (3:1) to receive dabrafenib (150 mg twice daily, orally) or dacarbazine (1000 mg/m2 i.v. every 3 wk).  Patients were stratified according to American Joint Committee on Cancer stage (unresectable III+IVM1a+IVM1b vs IVM1c).  The primary endpoint was investigator-assessed progression-free survival and was analyzed by intention to treat; safety was assessed per protocol.  This study is registered with ClinicalTrials.gov, no. NCT01227889.Of the 733 patients screened, 250 were randomly assigned to receive either dabrafenib (187 patients) or dacarbazine (63 patients).  Median progression-free survival was 5·1 mo for dabrafenib and 2·7 mo for dacarbazine, with a hazard ratio (HR) of 0·30 (95% CI 0·18-0·51; p<0·0001).  At data cutoff, 107 (57%) patients in the dabrafenib group and 14 (22%) in the dacarbazine group remained on randomized treatment.  Treatment-related adverse events (grade 2 or higher) occurred in 100 (53%) of the 187 patients who received dabrafenib and in 26 (44%) of the 59 patients who received dacarbazine.  The most common adverse events with dabrafenib were skin-related toxic effects, fever, fatigue, arthralgia, and headache.  The most common adverse events with dacarbazine were nausea, vomiting, neutropenia, fatigue, and asthenia.  Grade 3-4 adverse events were uncommon in both groups.Dabrafenib significantly improved progression-free survival compared with dacarbazine.GlaxoSmithKline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEDYPJULE5c7Vg90H21EOLACvtfcHk0liN4BJQ82rKEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xpt1SgtLg%253D&md5=5e8699780f47bd37e075d39636e0d809</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2812%2960868-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252812%252960868-X%26sid%3Dliteratum%253Aachs%26aulast%3DHauschild%26aufirst%3DA.%26aulast%3DGrob%26aufirst%3DJ.%2BJ.%26aulast%3DDemidov%26aufirst%3DL.%2BV.%26aulast%3DJouary%26aufirst%3DT.%26aulast%3DGutzmer%26aufirst%3DR.%26aulast%3DMillward%26aufirst%3DM.%26aulast%3DRutkowski%26aufirst%3DP.%26aulast%3DBlank%26aufirst%3DC.%2BU.%26aulast%3DMiller%26aufirst%3DW.%2BH.%26aulast%3DKaempgen%26aufirst%3DE.%26aulast%3DMartin-Algarra%26aufirst%3DS.%26aulast%3DKaraszewska%26aufirst%3DB.%26aulast%3DMauch%26aufirst%3DC.%26aulast%3DChiarion-Sileni%26aufirst%3DV.%26aulast%3DMartin%26aufirst%3DA.%2BM.%26aulast%3DSwann%26aufirst%3DS.%26aulast%3DHaney%26aufirst%3DP.%26aulast%3DMirakhur%26aufirst%3DB.%26aulast%3DGuckert%26aufirst%3DM.%2BE.%26aulast%3DGoodman%26aufirst%3DV.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26atitle%3DDabrafenib%2520in%2520BRAF-mutated%2520metastatic%2520melanoma%253A%2520a%2520multicentre%252C%2520open-label%252C%2520phase%25203%2520randomised%2520controlled%2520trial%26jtitle%3DLancet%26date%3D2012%26volume%3D380%26spage%3D358%26epage%3D365" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Johannessen, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boehm, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardwell, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emery, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stransky, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cogdill, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barretina, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caponigro, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hieronymus, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salehi-Ashtiani, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vidal, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, X. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alkan, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myer, V. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finan, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Root, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golub, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dummer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlegel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wargo, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hahn, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garraway, L. A.</span><span> </span><span class="NLM_article-title">COT drives resistance to RAF inhibition through MAP kinase pathway reactivation</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">468</span><span class="NLM_x">, </span> <span class="NLM_fpage">968</span><span class="NLM_x">–</span> <span class="NLM_lpage">972</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=468&publication_year=2010&pages=968-972&author=C.+M.+Johannessenauthor=J.+S.+Boehmauthor=S.+Y.+Kimauthor=S.+R.+Thomasauthor=L.+Wardwellauthor=L.+A.+Johnsonauthor=C.+M.+Emeryauthor=N.+Stranskyauthor=A.+P.+Cogdillauthor=J.+Barretinaauthor=G.+Caponigroauthor=H.+Hieronymusauthor=R.+R.+Murrayauthor=K.+Salehi-Ashtianiauthor=D.+E.+Hillauthor=M.+Vidalauthor=J.+J.+Zhaoauthor=X.+P.+Yangauthor=O.+Alkanauthor=S.+Kimauthor=J.+L.+Harrisauthor=C.+J.+Wilsonauthor=V.+E.+Myerauthor=P.+M.+Finanauthor=D.+E.+Rootauthor=T.+M.+Robertsauthor=T.+Golubauthor=K.+T.+Flahertyauthor=R.+Dummerauthor=B.+L.+Weberauthor=W.+R.+Sellersauthor=R.+Schlegelauthor=J.+A.+Wargoauthor=W.+C.+Hahnauthor=L.+A.+Garraway&title=COT+drives+resistance+to+RAF+inhibition+through+MAP+kinase+pathway+reactivation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJohannessen%26aufirst%3DC.%2BM.%26aulast%3DBoehm%26aufirst%3DJ.%2BS.%26aulast%3DKim%26aufirst%3DS.%2BY.%26aulast%3DThomas%26aufirst%3DS.%2BR.%26aulast%3DWardwell%26aufirst%3DL.%26aulast%3DJohnson%26aufirst%3DL.%2BA.%26aulast%3DEmery%26aufirst%3DC.%2BM.%26aulast%3DStransky%26aufirst%3DN.%26aulast%3DCogdill%26aufirst%3DA.%2BP.%26aulast%3DBarretina%26aufirst%3DJ.%26aulast%3DCaponigro%26aufirst%3DG.%26aulast%3DHieronymus%26aufirst%3DH.%26aulast%3DMurray%26aufirst%3DR.%2BR.%26aulast%3DSalehi-Ashtiani%26aufirst%3DK.%26aulast%3DHill%26aufirst%3DD.%2BE.%26aulast%3DVidal%26aufirst%3DM.%26aulast%3DZhao%26aufirst%3DJ.%2BJ.%26aulast%3DYang%26aufirst%3DX.%2BP.%26aulast%3DAlkan%26aufirst%3DO.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DHarris%26aufirst%3DJ.%2BL.%26aulast%3DWilson%26aufirst%3DC.%2BJ.%26aulast%3DMyer%26aufirst%3DV.%2BE.%26aulast%3DFinan%26aufirst%3DP.%2BM.%26aulast%3DRoot%26aufirst%3DD.%2BE.%26aulast%3DRoberts%26aufirst%3DT.%2BM.%26aulast%3DGolub%26aufirst%3DT.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DDummer%26aufirst%3DR.%26aulast%3DWeber%26aufirst%3DB.%2BL.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DSchlegel%26aufirst%3DR.%26aulast%3DWargo%26aufirst%3DJ.%2BA.%26aulast%3DHahn%26aufirst%3DW.%2BC.%26aulast%3DGarraway%26aufirst%3DL.%2BA.%26atitle%3DCOT%2520drives%2520resistance%2520to%2520RAF%2520inhibition%2520through%2520MAP%2520kinase%2520pathway%2520reactivation%26jtitle%3DNature%26date%3D2010%26volume%3D468%26spage%3D968%26epage%3D972" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Nazarian, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, X. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koya, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Attar, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sazegar, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chodon, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo, R. S.</span><span> </span><span class="NLM_article-title">Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">468</span><span class="NLM_x">, </span> <span class="NLM_fpage">973</span><span class="NLM_x">–</span> <span class="NLM_lpage">977</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm500007h&amp;key=10.1038%2Fnature09626" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm500007h&amp;key=21107323" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm500007h&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsbjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=468&publication_year=2010&pages=973-977&author=R.+Nazarianauthor=H.+B.+Shiauthor=Q.+Wangauthor=X.+J.+Kongauthor=R.+C.+Koyaauthor=H.+Leeauthor=Z.+G.+Chenauthor=M.+K.+Leeauthor=N.+Attarauthor=H.+Sazegarauthor=T.+Chodonauthor=S.+F.+Nelsonauthor=G.+McArthurauthor=J.+A.+Sosmanauthor=A.+Ribasauthor=R.+S.+Lo&title=Melanomas+acquire+resistance+to+B-RAF%28V600E%29+inhibition+by+RTK+or+N-RAS+upregulation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation</span></div><div class="casAuthors">Nazarian, Ramin; Shi, Hubing; Wang, Qi; Kong, Xiangju; Koya, Richard C.; Lee, Hane; Chen, Zugen; Lee, Mi-Kyung; Attar, Narsis; Sazegar, Hooman; Chodon, Thinle; Nelson, Stanley F.; McArthur, Grant; Sosman, Jeffrey A.; Ribas, Antoni; Lo, Roger S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">468</span>
        (<span class="NLM_cas:issue">7326</span>),
    <span class="NLM_cas:pages">973-977</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Activating B-RAF(V600E) (also known as BRAF) kinase mutations occur in ∼7% of human malignancies and ∼60% of melanomas.  Early clin. experience with a novel class I RAF-selective inhibitor, PLX4032, demonstrated an unprecedented 80% anti-tumor response rate among patients with B-RAF(V600E)-pos. melanomas, but acquired drug resistance frequently develops after initial responses.  Hypotheses for mechanisms of acquired resistance to B-RAF inhibition include secondary mutations in B-RAF(V600E), MAPK reactivation, and activation of alternative survival pathways.  Here we show that acquired resistance to PLX4032 develops by mutually exclusive PDGFRβ (also known as PDGFRB) upregulation or N-RAS (also known as NRAS) mutations but not through secondary mutations in B-RAF(V600E).  We used PLX4032-resistant sub-lines artificially derived from B-RAF(V600E)-pos. melanoma cell lines and validated key findings in PLX4032-resistant tumors and tumor-matched, short-term cultures from clin. trial patients.  Induction of PDGFRβ RNA, protein and tyrosine phosphorylation emerged as a dominant feature of acquired PLX4032 resistance in a subset of melanoma sub-lines, patient-derived biopsies and short-term cultures.  PDGFRβ-upregulated tumor cells have low activated RAS levels and, when treated with PLX4032, do not reactivate the MAPK pathway significantly.  In another subset, high levels of activated N-RAS resulting from mutations lead to significant MAPK pathway reactivation upon PLX4032 treatment.  Knockdown of PDGFRβ or N-RAS reduced growth of the resp. PLX4032-resistant subsets.  Overexpression of PDGFRβ or N-RAS(Q61K) conferred PLX4032 resistance to PLX4032-sensitive parental cell lines.  Importantly, MAPK reactivation predicts MEK inhibitor sensitivity.  Thus, melanomas escape B-RAF(V600E) targeting not through secondary B-RAF(V600E) mutations but via receptor tyrosine kinase (RTK)-mediated activation of alternative survival pathway(s) or activated RAS-mediated reactivation of the MAPK pathway, suggesting addnl. therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMqxhHr_chLbVg90H21EOLACvtfcHk0lhPC6H2_2NQXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsbjI&md5=a591f224d5e36fe1d350394bbd49b3a7</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fnature09626&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09626%26sid%3Dliteratum%253Aachs%26aulast%3DNazarian%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DH.%2BB.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DKong%26aufirst%3DX.%2BJ.%26aulast%3DKoya%26aufirst%3DR.%2BC.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DZ.%2BG.%26aulast%3DLee%26aufirst%3DM.%2BK.%26aulast%3DAttar%26aufirst%3DN.%26aulast%3DSazegar%26aufirst%3DH.%26aulast%3DChodon%26aufirst%3DT.%26aulast%3DNelson%26aufirst%3DS.%2BF.%26aulast%3DMcArthur%26aufirst%3DG.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DLo%26aufirst%3DR.%2BS.%26atitle%3DMelanomas%2520acquire%2520resistance%2520to%2520B-RAF%2528V600E%2529%2520inhibition%2520by%2520RTK%2520or%2520N-RAS%2520upregulation%26jtitle%3DNature%26date%3D2010%26volume%3D468%26spage%3D973%26epage%3D977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Villanueva, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vultur, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somasundaram, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukunaga-Kalabis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cipolla, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wubbenhorst, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, X. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gimotty, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kee, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santiago-Walker, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Letrero, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Andrea, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pushparajan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayden, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laquerre, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nathanson, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herlyn, M.</span><span> </span><span class="NLM_article-title">Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">683</span><span class="NLM_x">–</span> <span class="NLM_lpage">695</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm500007h&amp;key=10.1016%2Fj.ccr.2010.11.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm500007h&amp;key=21156289" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm500007h&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFGhsbjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=683-695&author=J.+Villanuevaauthor=A.+Vulturauthor=J.+T.+Leeauthor=R.+Somasundaramauthor=M.+Fukunaga-Kalabisauthor=A.+K.+Cipollaauthor=B.+Wubbenhorstauthor=X.+W.+Xuauthor=P.+A.+Gimottyauthor=D.+Keeauthor=A.+E.+Santiago-Walkerauthor=R.+Letreroauthor=K.+D%E2%80%99Andreaauthor=A.+Pushparajanauthor=J.+E.+Haydenauthor=K.+D.+Brownauthor=S.+Laquerreauthor=G.+A.+McArthurauthor=J.+A.+Sosmanauthor=K.+L.+Nathansonauthor=M.+Herlyn&title=Acquired+resistance+to+BRAF+inhibitors+mediated+by+a+RAF+kinase+switch+in+melanoma+can+be+overcome+by+cotargeting+MEK+and+IGF-1R%2FPI3K"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K</span></div><div class="casAuthors">Villanueva, Jessie; Vultur, Adina; Lee, John T.; Somasundaram, Rajasekharan; Fukunaga-Kalabis, Mizuho; Cipolla, Angela K.; Wubbenhorst, Bradley; Xu, Xiaowei; Gimotty, Phyllis A.; Kee, Damien; Santiago-Walker, Ademi E.; Letrero, Richard; D'Andrea, Kurt; Pushparajan, Anitha; Hayden, James E.; Brown, Kimberly Dahlman; Laquerre, Sylvie; McArthur, Grant A.; Sosman, Jeffrey A.; Nathanson, Katherine L.; Herlyn, Meenhard</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">683-695</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">BRAF is an attractive target for melanoma drug development.  However, resistance to BRAF inhibitors is a significant clin. challenge.  We describe a model of resistance to BRAF inhibitors developed by chronic treatment of BRAFV600E melanoma cells with the BRAF inhibitor SB-590885; these cells are cross-resistant to other BRAF-selective inhibitors.  Resistance involves flexible switching among the three RAF isoforms, underscoring the ability of melanoma cells to adapt to pharmacol. challenges.  IGF-1R/PI3K signaling was enhanced in resistant melanomas, and combined treatment with IGF-1R/PI3K and MEK inhibitors induced death of BRAF inhibitor-resistant cells.  Increased IGF-1R and pAKT levels in a post-relapse human tumor sample are consistent with a role for IGF-1R/PI3K-dependent survival in the development of resistance to BRAF inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgKfw2MUtmLLVg90H21EOLACvtfcHk0lhPC6H2_2NQXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFGhsbjJ&md5=c535681201c592cd8941b68e8a936d0e</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2010.11.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2010.11.023%26sid%3Dliteratum%253Aachs%26aulast%3DVillanueva%26aufirst%3DJ.%26aulast%3DVultur%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DJ.%2BT.%26aulast%3DSomasundaram%26aufirst%3DR.%26aulast%3DFukunaga-Kalabis%26aufirst%3DM.%26aulast%3DCipolla%26aufirst%3DA.%2BK.%26aulast%3DWubbenhorst%26aufirst%3DB.%26aulast%3DXu%26aufirst%3DX.%2BW.%26aulast%3DGimotty%26aufirst%3DP.%2BA.%26aulast%3DKee%26aufirst%3DD.%26aulast%3DSantiago-Walker%26aufirst%3DA.%2BE.%26aulast%3DLetrero%26aufirst%3DR.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DK.%26aulast%3DPushparajan%26aufirst%3DA.%26aulast%3DHayden%26aufirst%3DJ.%2BE.%26aulast%3DBrown%26aufirst%3DK.%2BD.%26aulast%3DLaquerre%26aufirst%3DS.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DNathanson%26aufirst%3DK.%2BL.%26aulast%3DHerlyn%26aufirst%3DM.%26atitle%3DAcquired%2520resistance%2520to%2520BRAF%2520inhibitors%2520mediated%2520by%2520a%2520RAF%2520kinase%2520switch%2520in%2520melanoma%2520can%2520be%2520overcome%2520by%2520cotargeting%2520MEK%2520and%2520IGF-1R%252FPI3K%26jtitle%3DCancer%2520Cell%26date%3D2010%26volume%3D18%26spage%3D683%26epage%3D695" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Poulikakos, P. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Persaud, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janakiraman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, X. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moriceau, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atefi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Titz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabay, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahlman, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tadi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wargo, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelley, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Misteli, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graeber, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solit, D. B.</span><span> </span><span class="NLM_article-title">RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">480</span><span class="NLM_x">, </span> <span class="NLM_fpage">387</span><span class="NLM_x">–</span> <span class="NLM_lpage">390</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm500007h&amp;key=10.1038%2Fnature10662" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm500007h&amp;key=22113612" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm500007h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFWqtL%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=480&publication_year=2011&pages=387-390&author=P.+I.+Poulikakosauthor=Y.+Persaudauthor=M.+Janakiramanauthor=X.+J.+Kongauthor=C.+Ngauthor=G.+Moriceauauthor=H.+B.+Shiauthor=M.+Atefiauthor=B.+Titzauthor=M.+T.+Gabayauthor=M.+Saltonauthor=K.+B.+Dahlmanauthor=M.+Tadiauthor=J.+A.+Wargoauthor=K.+T.+Flahertyauthor=M.+C.+Kelleyauthor=T.+Misteliauthor=P.+B.+Chapmanauthor=J.+A.+Sosmanauthor=T.+G.+Graeberauthor=A.+Ribasauthor=R.+S.+Loauthor=N.+Rosenauthor=D.+B.+Solit&title=RAF+inhibitor+resistance+is+mediated+by+dimerization+of+aberrantly+spliced+BRAF%28V600E%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)</span></div><div class="casAuthors">Poulikakos, Poulikos I.; Persaud, Yogindra; Janakiraman, Manickam; Kong, Xiangju; Ng, Charles; Moriceau, Gatien; Shi, Hubing; Atefi, Mohammad; Titz, Bjoern; Gabay, May Tal; Salton, Maayan; Dahlman, Kimberly B.; Tadi, Madhavi; Wargo, Jennifer A.; Flaherty, Keith T.; Kelley, Mark C.; Misteli, Tom; Chapman, Paul B.; Sosman, Jeffrey A.; Graeber, Thomas G.; Ribas, Antoni; Lo, Roger S.; Rosen, Neal; Solit, David B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">480</span>
        (<span class="NLM_cas:issue">7377</span>),
    <span class="NLM_cas:pages">387-390</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Although clin. trials have shown that RAF inhibitors prolong the survival of patients with BRAF-mutant melanoma, resistance inevitably develops; resistance is shown here to be frequently mediated by the expression of splicing variants of mutant BRAF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0XPUFDxeK5rVg90H21EOLACvtfcHk0lh1_MVURtO6Hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFWqtL%252FN&md5=b239591d5efd1d965deabf0527c3b9a6</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnature10662&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature10662%26sid%3Dliteratum%253Aachs%26aulast%3DPoulikakos%26aufirst%3DP.%2BI.%26aulast%3DPersaud%26aufirst%3DY.%26aulast%3DJanakiraman%26aufirst%3DM.%26aulast%3DKong%26aufirst%3DX.%2BJ.%26aulast%3DNg%26aufirst%3DC.%26aulast%3DMoriceau%26aufirst%3DG.%26aulast%3DShi%26aufirst%3DH.%2BB.%26aulast%3DAtefi%26aufirst%3DM.%26aulast%3DTitz%26aufirst%3DB.%26aulast%3DGabay%26aufirst%3DM.%2BT.%26aulast%3DSalton%26aufirst%3DM.%26aulast%3DDahlman%26aufirst%3DK.%2BB.%26aulast%3DTadi%26aufirst%3DM.%26aulast%3DWargo%26aufirst%3DJ.%2BA.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DKelley%26aufirst%3DM.%2BC.%26aulast%3DMisteli%26aufirst%3DT.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DGraeber%26aufirst%3DT.%2BG.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DLo%26aufirst%3DR.%2BS.%26aulast%3DRosen%26aufirst%3DN.%26aulast%3DSolit%26aufirst%3DD.%2BB.%26atitle%3DRAF%2520inhibitor%2520resistance%2520is%2520mediated%2520by%2520dimerization%2520of%2520aberrantly%2520spliced%2520BRAF%2528V600E%2529%26jtitle%3DNature%26date%3D2011%26volume%3D480%26spage%3D387%26epage%3D390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Shi, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, X. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo, R. S.</span><span> </span><span class="NLM_article-title">Combinatorial treatments that overcome PDGFR beta-driven resistance of melanoma cells to B-V600E-RAF inhibition</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">5067</span><span class="NLM_x">–</span> <span class="NLM_lpage">5074</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=5067-5074&author=H.+B.+Shiauthor=X.+J.+Kongauthor=A.+Ribasauthor=R.+S.+Lo&title=Combinatorial+treatments+that+overcome+PDGFR+beta-driven+resistance+of+melanoma+cells+to+B-V600E-RAF+inhibition"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DH.%2BB.%26aulast%3DKong%26aufirst%3DX.%2BJ.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DLo%26aufirst%3DR.%2BS.%26atitle%3DCombinatorial%2520treatments%2520that%2520overcome%2520PDGFR%2520beta-driven%2520resistance%2520of%2520melanoma%2520cells%2520to%2520B-V600E-RAF%2520inhibition%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D5067%26epage%3D5074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Wagle, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emery, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pochanard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kehoe, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johannessen, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macconaill, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hahn, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garraway, L. A.</span><span> </span><span class="NLM_article-title">Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">3085</span><span class="NLM_x">–</span> <span class="NLM_lpage">3096</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm500007h&amp;key=10.1200%2FJCO.2010.33.2312" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm500007h&amp;key=21383288" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm500007h&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFCqtLfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=3085-3096&author=N.+Wagleauthor=C.+Emeryauthor=M.+F.+Bergerauthor=M.+J.+Davisauthor=A.+Sawyerauthor=P.+Pochanardauthor=S.+M.+Kehoeauthor=C.+M.+Johannessenauthor=L.+E.+Macconaillauthor=W.+C.+Hahnauthor=M.+Meyersonauthor=L.+A.+Garraway&title=Dissecting+therapeutic+resistance+to+RAF+inhibition+in+melanoma+by+tumor+genomic+profiling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling</span></div><div class="casAuthors">Wagle, Nikhil; Emery, Caroline; Berger, Michael F.; Davis, Matthew J.; Sawyer, Allison; Pochanard, Panisa; Kehoe, Sarah M.; Johannessen, Cory M.; MacConaill, Laura E.; Hahn, William C.; Meyerson, Matthew; Garraway, Levi A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3085-3096</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A detailed understanding of the mechanisms by which tumors acquire resistance to targeted anticancer agents should speed the development of treatment strategies with lasting clin. efficacy.  RAF inhibition in BRAF-mutant melanoma exemplifies the promise and challenge of many targeted drugs; although response rates are high, resistance invariably develops.  Here, we articulate overarching principles of resistance to kinase inhibitors, as well as a translational approach to characterize resistance in the clin. setting through tumor mutation profiling.  As a proof of principle, we performed targeted, massively parallel sequencing of 138 cancer genes in a tumor obtained from a patient with melanoma who developed resistance to PLX4032 after an initial dramatic response.  The resulting profile identified an activating mutation at codon 121 in the downstream kinase MEK1 that was absent in the corresponding pretreatment tumor.  The MEK1C121S mutation was shown to increase kinase activity and confer robust resistance to both RAF and MEK inhibition in vitro.  Thus, MEK1C121S or functionally similar mutations are predicted to confer resistance to combined MEK/RAF inhibition.  These results provide an instructive framework for assessing mechanisms of acquired resistance to kinase inhibition and illustrate the use of emerging technologies in a manner that may accelerate personalized cancer medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpK-2C4fs22UbVg90H21EOLACvtfcHk0liPCQnkOEKcZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFCqtLfO&md5=d872acb5ba41d7eccc2717e31d856dd3</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1200%2FJCO.2010.33.2312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2010.33.2312%26sid%3Dliteratum%253Aachs%26aulast%3DWagle%26aufirst%3DN.%26aulast%3DEmery%26aufirst%3DC.%26aulast%3DBerger%26aufirst%3DM.%2BF.%26aulast%3DDavis%26aufirst%3DM.%2BJ.%26aulast%3DSawyer%26aufirst%3DA.%26aulast%3DPochanard%26aufirst%3DP.%26aulast%3DKehoe%26aufirst%3DS.%2BM.%26aulast%3DJohannessen%26aufirst%3DC.%2BM.%26aulast%3DMacconaill%26aufirst%3DL.%2BE.%26aulast%3DHahn%26aufirst%3DW.%2BC.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DGarraway%26aufirst%3DL.%2BA.%26atitle%3DDissecting%2520therapeutic%2520resistance%2520to%2520RAF%2520inhibition%2520in%2520melanoma%2520by%2520tumor%2520genomic%2520profiling%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D29%26spage%3D3085%26epage%3D3096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Corcoran, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turke, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coffee, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishino, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cogdill, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Della Pelle, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dias-Santagata, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hung, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piris, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wargo, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mino-Kenudson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span> </span><span class="NLM_article-title">EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">227</span><span class="NLM_x">–</span> <span class="NLM_lpage">235</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=227-235&author=R.+B.+Corcoranauthor=H.+Ebiauthor=A.+B.+Turkeauthor=E.+M.+Coffeeauthor=M.+Nishinoauthor=A.+P.+Cogdillauthor=R.+D.+Brownauthor=P.+Della+Pelleauthor=D.+Dias-Santagataauthor=K.+E.+Hungauthor=K.+T.+Flahertyauthor=A.+Pirisauthor=J.+A.+Wargoauthor=J.+Settlemanauthor=M.+Mino-Kenudsonauthor=J.+A.+Engelman&title=EGFR-mediated+re-activation+of+MAPK+signaling+contributes+to+insensitivity+of+BRAF+mutant+colorectal+cancers+to+RAF+inhibition+with+vemurafenib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCorcoran%26aufirst%3DR.%2BB.%26aulast%3DEbi%26aufirst%3DH.%26aulast%3DTurke%26aufirst%3DA.%2BB.%26aulast%3DCoffee%26aufirst%3DE.%2BM.%26aulast%3DNishino%26aufirst%3DM.%26aulast%3DCogdill%26aufirst%3DA.%2BP.%26aulast%3DBrown%26aufirst%3DR.%2BD.%26aulast%3DDella%2BPelle%26aufirst%3DP.%26aulast%3DDias-Santagata%26aufirst%3DD.%26aulast%3DHung%26aufirst%3DK.%2BE.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DPiris%26aufirst%3DA.%26aulast%3DWargo%26aufirst%3DJ.%2BA.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DEGFR-mediated%2520re-activation%2520of%2520MAPK%2520signaling%2520contributes%2520to%2520insensitivity%2520of%2520BRAF%2520mutant%2520colorectal%2520cancers%2520to%2520RAF%2520inhibition%2520with%2520vemurafenib%26jtitle%3DCancer%2520Discovery%26date%3D2012%26volume%3D2%26spage%3D227%26epage%3D235" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Prahallad, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Nicolantonio, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salazar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zecchin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beijersbergen, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bardelli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernards, R.</span><span> </span><span class="NLM_article-title">Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">483</span><span class="NLM_x">, </span> <span class="NLM_fpage">100</span><span class="NLM_x">–</span> <span class="NLM_lpage">103</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm500007h&amp;key=10.1038%2Fnature10868" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Fjm500007h&amp;key=22281684" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm500007h&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtFOktb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=483&publication_year=2012&pages=100-103&author=A.+Prahalladauthor=C.+Sunauthor=S.+D.+Huangauthor=F.+Di+Nicolantonioauthor=R.+Salazarauthor=D.+Zecchinauthor=R.+L.+Beijersbergenauthor=A.+Bardelliauthor=R.+Bernards&title=Unresponsiveness+of+colon+cancer+to+BRAF%28V600E%29+inhibition+through+feedback+activation+of+EGFR"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR</span></div><div class="casAuthors">Prahallad, Anirudh; Sun, Chong; Huang, Sidong; Di Nicolantonio, Federica; Salazar, Ramon; Zecchin, Davide; Beijersbergen, Roderick L.; Bardelli, Alberto; Bernards, Rene</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">483</span>
        (<span class="NLM_cas:issue">7387</span>),
    <span class="NLM_cas:pages">100-103</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Inhibition of the BRAF(V600E) oncoprotein by the small-mol. drug PLX4032 (vemurafenib) is highly effective in the treatment of melanoma.  However, colon cancer patients harbouring the same BRAF(V600E) oncogenic lesion have poor prognosis and show only a very limited response to this drug.  To investigate the cause of the limited therapeutic effect of PLX4032 in BRAF(V600E) mutant colon tumors, here we performed an RNA-interference-based genetic screen in human cells to search for kinases whose knockdown synergizes with BRAF(V600E) inhibition.  We report that blockade of the epidermal growth factor receptor (EGFR) shows strong synergy with BRAF(V600E) inhibition.  We find in multiple BRAF(V600E) mutant colon cancers that inhibition of EGFR by the antibody drug cetuximab or the small-mol. drugs gefitinib or erlotinib is strongly synergistic with BRAF(V600E) inhibition, both in vitro and in vivo.  Mechanistically, we find that BRAF(V600E) inhibition causes a rapid feedback activation of EGFR, which supports continued proliferation in the presence of BRAF(V600E) inhibition.  Melanoma cells express low levels of EGFR and are therefore not subject to this feedback activation.  Consistent with this, we find that ectopic expression of EGFR in melanoma cells is sufficient to cause resistance to PLX4032.  Our data suggest that BRAF(V600E) mutant colon cancers (approx. 8-10% of all colon cancers), for which there are currently no targeted treatment options available, might benefit from combination therapy consisting of BRAF and EGFR inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT_L3CIRBzo7Vg90H21EOLACvtfcHk0ljkIjf04KIczQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtFOktb4%253D&md5=439e08cc65e43eb82188becb960b9943</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnature10868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature10868%26sid%3Dliteratum%253Aachs%26aulast%3DPrahallad%26aufirst%3DA.%26aulast%3DSun%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DS.%2BD.%26aulast%3DDi%2BNicolantonio%26aufirst%3DF.%26aulast%3DSalazar%26aufirst%3DR.%26aulast%3DZecchin%26aufirst%3DD.%26aulast%3DBeijersbergen%26aufirst%3DR.%2BL.%26aulast%3DBardelli%26aufirst%3DA.%26aulast%3DBernards%26aufirst%3DR.%26atitle%3DUnresponsiveness%2520of%2520colon%2520cancer%2520to%2520BRAF%2528V600E%2529%2520inhibition%2520through%2520feedback%2520activation%2520of%2520EGFR%26jtitle%3DNature%26date%3D2012%26volume%3D483%26spage%3D100%26epage%3D103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Shi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moriceau, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koya, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nazarian, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pupo, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bacchiocchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahlman, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chmielowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halaban, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kefford, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, G. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo, R. S.</span><span> </span><span class="NLM_article-title">Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">414</span><span class="NLM_x">–</span> <span class="NLM_lpage">424</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=414-424&author=H.+Shiauthor=G.+Moriceauauthor=X.+Kongauthor=R.+C.+Koyaauthor=R.+Nazarianauthor=G.+M.+Pupoauthor=A.+Bacchiocchiauthor=K.+B.+Dahlmanauthor=B.+Chmielowskiauthor=J.+A.+Sosmanauthor=R.+Halabanauthor=R.+F.+Keffordauthor=G.+V.+Longauthor=A.+Ribasauthor=R.+S.+Lo&title=Preexisting+MEK1+exon+3+mutations+in+V600E%2FKBRAF+melanomas+do+not+confer+resistance+to+BRAF+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DH.%26aulast%3DMoriceau%26aufirst%3DG.%26aulast%3DKong%26aufirst%3DX.%26aulast%3DKoya%26aufirst%3DR.%2BC.%26aulast%3DNazarian%26aufirst%3DR.%26aulast%3DPupo%26aufirst%3DG.%2BM.%26aulast%3DBacchiocchi%26aufirst%3DA.%26aulast%3DDahlman%26aufirst%3DK.%2BB.%26aulast%3DChmielowski%26aufirst%3DB.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DHalaban%26aufirst%3DR.%26aulast%3DKefford%26aufirst%3DR.%2BF.%26aulast%3DLong%26aufirst%3DG.%2BV.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DLo%26aufirst%3DR.%2BS.%26atitle%3DPreexisting%2520MEK1%2520exon%25203%2520mutations%2520in%2520V600E%252FKBRAF%2520melanomas%2520do%2520not%2520confer%2520resistance%2520to%2520BRAF%2520inhibitors%26jtitle%3DCancer%2520Discovery%26date%3D2012%26volume%3D2%26spage%3D414%26epage%3D424" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Shi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moriceau, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koya, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chodon, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scolyer, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahlman, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kefford, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, G. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo, R. S.</span><span> </span><span class="NLM_article-title">Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance</span> <span class="citation_source-journal">Nat. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">724</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Fjm500007h&amp;key=10.1038%2Fncomms1727" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Fjm500007h&amp;key=22395615" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm500007h&amp;key=1%3ACAS%3A280%3ADC%252BC383ptFKqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=724&author=H.+Shiauthor=G.+Moriceauauthor=X.+Kongauthor=M.+K.+Leeauthor=H.+Leeauthor=R.+C.+Koyaauthor=C.+Ngauthor=T.+Chodonauthor=R.+A.+Scolyerauthor=K.+B.+Dahlmanauthor=J.+A.+Sosmanauthor=R.+F.+Keffordauthor=G.+V.+Longauthor=S.+F.+Nelsonauthor=A.+Ribasauthor=R.+S.+Lo&title=Melanoma+whole-exome+sequencing+identifies+%28V600E%29B-RAF+amplification-mediated+acquired+B-RAF+inhibitor+resistance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance</span></div><div class="casAuthors">Shi Hubing; Moriceau Gatien; Kong Xiangju; Lee Mi-Kyung; Lee Hane; Koya Richard C; Ng Charles; Chodon Thinle; Scolyer Richard A; Dahlman Kimberly B; Sosman Jeffrey A; Kefford Richard F; Long Georgina V; Nelson Stanley F; Ribas Antoni; Lo Roger S</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">724</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The development of acquired drug resistance hampers the long-term success of B-RAF inhibitor therapy for melanoma patients.  Here we show (V600E)B-RAF copy-number gain as a mechanism of acquired B-RAF inhibitor resistance in 4 out of 20 (20%) patients treated with B-RAF inhibitor.  In cell lines, (V600E)B-RAF overexpression and knockdown conferred B-RAF inhibitor resistance and sensitivity, respectively.  In (V600E)B-RAF amplification-driven (versus mutant N-RAS-driven) B-RAF inhibitor resistance, extracellular signal-regulated kinase reactivation is saturable, with higher doses of vemurafenib down-regulating phosho-extracellular signal-regulated kinase and re-sensitizing melanoma cells to B-RAF inhibitor.  These two mechanisms of extracellular signal-regulated kinase reactivation are sensitive to the MEK1/2 inhibitor AZD6244/selumetinib or its combination with the B-RAF inhibitor vemurafenib.  In contrast to mutant N-RAS-mediated (V600E)B-RAF bypass, which is sensitive to C-RAF knockdown, (V600E)B-RAF amplification-mediated resistance functions largely independently of C-RAF.  Thus, alternative clinical strategies may potentially overcome distinct modes of extracellular signal-regulated kinase reactivation underlying acquired B-RAF inhibitor resistance in melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSE43gvtkJkR8K3uFsUIZtkfW6udTcc2ea7HhFAenMhBrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC383ptFKqsw%253D%253D&md5=1bf7d0cdb4dccbef8da9397f23f39ee3</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fncomms1727&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms1727%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DH.%26aulast%3DMoriceau%26aufirst%3DG.%26aulast%3DKong%26aufirst%3DX.%26aulast%3DLee%26aufirst%3DM.%2BK.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DKoya%26aufirst%3DR.%2BC.%26aulast%3DNg%26aufirst%3DC.%26aulast%3DChodon%26aufirst%3DT.%26aulast%3DScolyer%26aufirst%3DR.%2BA.%26aulast%3DDahlman%26aufirst%3DK.%2BB.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DKefford%26aufirst%3DR.%2BF.%26aulast%3DLong%26aufirst%3DG.%2BV.%26aulast%3DNelson%26aufirst%3DS.%2BF.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DLo%26aufirst%3DR.%2BS.%26atitle%3DMelanoma%2520whole-exome%2520sequencing%2520identifies%2520%2528V600E%2529B-RAF%2520amplification-mediated%2520acquired%2520B-RAF%2520inhibitor%2520resistance%26jtitle%3DNat.%2520Commun.%26date%3D2012%26volume%3D3%26spage%3D724" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Straussman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morikawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barzily-Rokni, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, Z. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mongare, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gould, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frederick, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, Z. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solit, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogino, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wargo, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golub, T. R.</span><span> </span><span class="NLM_article-title">Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">487</span><span class="NLM_x">, </span> <span class="NLM_fpage">500</span><span class="NLM_x">–</span> <span class="NLM_lpage">504</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Fjm500007h&amp;key=10.1038%2Fnature11183" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Fjm500007h&amp;key=22763439" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm500007h&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFWjtL3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=487&publication_year=2012&pages=500-504&author=R.+Straussmanauthor=T.+Morikawaauthor=K.+Sheeauthor=M.+Barzily-Rokniauthor=Z.+R.+Qianauthor=J.+Y.+Duauthor=A.+Davisauthor=M.+M.+Mongareauthor=J.+Gouldauthor=D.+T.+Frederickauthor=Z.+A.+Cooperauthor=P.+B.+Chapmanauthor=D.+B.+Solitauthor=A.+Ribasauthor=R.+S.+Loauthor=K.+T.+Flahertyauthor=S.+Oginoauthor=J.+A.+Wargoauthor=T.+R.+Golub&title=Tumour+micro-environment+elicits+innate+resistance+to+RAF+inhibitors+through+HGF+secretion"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion</span></div><div class="casAuthors">Straussman, Ravid; Morikawa, Teppei; Shee, Kevin; Barzily-Rokni, Michal; Qian, Zhi Rong; Du, Jinyan; Davis, Ashli; Mongare, Margaret M.; Gould, Joshua; Frederick, Dennie T.; Cooper, Zachary A.; Chapman, Paul B.; Solit, David B.; Ribas, Antoni; Lo, Roger S.; Flaherty, Keith T.; Ogino, Shuji; Wargo, Jennifer A.; Golub, Todd R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">487</span>
        (<span class="NLM_cas:issue">7408</span>),
    <span class="NLM_cas:pages">500-504</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Drug resistance presents a challenge to the treatment of cancer patients.  Many studies have focused on cell-autonomous mechanisms of drug resistance.  By contrast, the authors proposed that the tumor micro-environment confers innate resistance to therapy.  Here the authors developed a co-culture system to systematically assay the ability of 23 stromal cell types to influence the innate resistance of 45 cancer cell lines to 35 anticancer drugs.  The authors found that stroma-mediated resistance is common, particularly to targeted agents.  The authors characterized further the stroma-mediated resistance of BRAF-mutant melanoma to RAF inhibitors because most patients with this type of cancer show some degree of innate resistance.  Proteomic anal. showed that stromal cell secretion of hepatocyte growth factor (HGF) resulted in activation of the HGF receptor MET, reactivation of the mitogen-activated protein kinase (MAPK), and phosphatidylinositol-3-OH kinase (PI(3)K)-AKT signaling pathways, and immediate resistance to RAF inhibition.  Immunohistochem. expts. confirmed stromal cell expression of HGF in patients with BRAF-mutant melanoma and showed a significant correlation between HGF expression by stromal cells and innate resistance to RAF inhibitor treatment.  Dual inhibition of RAF and either HGF or MET resulted in reversal of drug resistance, suggesting RAF plus HGF or MET inhibitory combination therapy as a potential therapeutic strategy for BRAF-mutant melanoma.  A similar resistance mechanism was uncovered in a subset of BRAF-mutant colorectal and glioblastoma cell lines.  More generally, this study indicates that the systematic dissection of interactions between tumors and their micro-environment can uncover important mechanisms underlying drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwanlhJUTP4LVg90H21EOLACvtfcHk0li0JivMPPkSBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFWjtL3J&md5=0616b5feed3c5dc2a53ee2ee382a6c33</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fnature11183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11183%26sid%3Dliteratum%253Aachs%26aulast%3DStraussman%26aufirst%3DR.%26aulast%3DMorikawa%26aufirst%3DT.%26aulast%3DShee%26aufirst%3DK.%26aulast%3DBarzily-Rokni%26aufirst%3DM.%26aulast%3DQian%26aufirst%3DZ.%2BR.%26aulast%3DDu%26aufirst%3DJ.%2BY.%26aulast%3DDavis%26aufirst%3DA.%26aulast%3DMongare%26aufirst%3DM.%2BM.%26aulast%3DGould%26aufirst%3DJ.%26aulast%3DFrederick%26aufirst%3DD.%2BT.%26aulast%3DCooper%26aufirst%3DZ.%2BA.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DSolit%26aufirst%3DD.%2BB.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DLo%26aufirst%3DR.%2BS.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DOgino%26aufirst%3DS.%26aulast%3DWargo%26aufirst%3DJ.%2BA.%26aulast%3DGolub%26aufirst%3DT.%2BR.%26atitle%3DTumour%2520micro-environment%2520elicits%2520innate%2520resistance%2520to%2520RAF%2520inhibitors%2520through%2520HGF%2520secretion%26jtitle%3DNature%26date%3D2012%26volume%3D487%26spage%3D500%26epage%3D504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Antony, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emery, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garraway, L. A.</span><span> </span><span class="NLM_article-title">C-RAF mutations confer resistance to RAF inhibitors</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">4840</span><span class="NLM_x">–</span> <span class="NLM_lpage">4851</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=4840-4851&author=R.+Antonyauthor=C.+M.+Emeryauthor=A.+M.+Sawyerauthor=L.+A.+Garraway&title=C-RAF+mutations+confer+resistance+to+RAF+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAntony%26aufirst%3DR.%26aulast%3DEmery%26aufirst%3DC.%2BM.%26aulast%3DSawyer%26aufirst%3DA.%2BM.%26aulast%3DGarraway%26aufirst%3DL.%2BA.%26atitle%3DC-RAF%2520mutations%2520confer%2520resistance%2520to%2520RAF%2520inhibitors%26jtitle%3DCancer%2520Res.%26date%3D2013%26volume%3D73%26spage%3D4840%26epage%3D4851" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Lito, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solit, D. B.</span><span> </span><span class="NLM_article-title">Tumor adaptation and resistance to RAF inhibitors</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1401</span><span class="NLM_x">–</span> <span class="NLM_lpage">1409</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Fjm500007h&amp;key=10.1038%2Fnm.3392" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Fjm500007h&amp;key=24202393" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm500007h&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslCntbvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=1401-1409&author=P.+Litoauthor=N.+Rosenauthor=D.+B.+Solit&title=Tumor+adaptation+and+resistance+to+RAF+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor adaptation and resistance to RAF inhibitors</span></div><div class="casAuthors">Lito, Piro; Rosen, Neal; Solit, David B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1401-1409</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  RAF kinase inhibitors have substantial therapeutic effects in patients with BRAF-mutant melanoma.  However, only rarely do tumors regress completely, and the therapeutic effects are often temporary.  Several mechanisms of resistance to RAF inhibitors have been proposed.  The majority of these cause ERK signaling to become insensitive to treatment with RAF inhibitors by increasing the amt. of RAF dimers in cells, whereas others bypass the dependence of the tumor on mutant RAF.  One motivation for studying mechanisms of drug resistance is that such efforts may suggest new therapeutic targets or rational combination strategies that delay or prevent the emergence of drug-resistant clones.  Here, we review the current model of RAF inhibitor resistance with a focus on the implications of this model on ongoing lab. and clin. efforts to develop more effective therapeutic strategies for patients with BRAF-mutant tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpApldbPW5lXLVg90H21EOLACvtfcHk0lhCcneaDJx4lA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslCntbvN&md5=32718ee0a8ea50be5d6412ce0086cf3d</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fnm.3392&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3392%26sid%3Dliteratum%253Aachs%26aulast%3DLito%26aufirst%3DP.%26aulast%3DRosen%26aufirst%3DN.%26aulast%3DSolit%26aufirst%3DD.%2BB.%26atitle%3DTumor%2520adaptation%2520and%2520resistance%2520to%2520RAF%2520inhibitors%26jtitle%3DNat.%2520Med.%26date%3D2013%26volume%3D19%26spage%3D1401%26epage%3D1409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Kopetz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hecht, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Dwyer, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolop, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saltz, L.</span><span> </span><span class="NLM_article-title">PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl</span><span class="NLM_x">) </span> <span class="NLM_fpage">a3534</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=a3534&issue=Suppl&author=S.+Kopetzauthor=J.+Desaiauthor=E.+Chanauthor=J.+R.+Hechtauthor=P.+J.+O%E2%80%99Dwyerauthor=R.+J.+Leeauthor=K.+B.+Nolopauthor=L.+Saltz&title=PLX4032+in+metastatic+colorectal+cancer+patients+with+mutant+BRAF+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKopetz%26aufirst%3DS.%26aulast%3DDesai%26aufirst%3DJ.%26aulast%3DChan%26aufirst%3DE.%26aulast%3DHecht%26aufirst%3DJ.%2BR.%26aulast%3DO%25E2%2580%2599Dwyer%26aufirst%3DP.%2BJ.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DNolop%26aufirst%3DK.%2BB.%26aulast%3DSaltz%26aufirst%3DL.%26atitle%3DPLX4032%2520in%2520metastatic%2520colorectal%2520cancer%2520patients%2520with%2520mutant%2520BRAF%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26issue%3DSuppl%26spage%3Da3534" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Al-Marrawi, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saroya, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brennan, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dykes, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El-Deiry, W. S.</span><span> </span><span class="NLM_article-title">Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer</span> <span class="citation_source-journal">Cancer Biol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">703</span><span class="NLM_x">–</span> <span class="NLM_lpage">710</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Fjm500007h&amp;key=10.4161%2Fcbt.25191" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Fjm500007h&amp;key=23792568" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm500007h&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjs1yit7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=703-710&author=M.+Y.+Al-Marrawiauthor=B.+S.+Saroyaauthor=M.+C.+Brennanauthor=Z.+Yangauthor=T.+M.+Dykesauthor=W.+S.+El-Deiry&title=Off-label+use+of+cetuximab+plus+sorafenib+and+panitumumab+plus+regorafenib+to+personalize+therapy+for+a+patient+with+V600E+BRAF-mutant+metastatic+colon+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer</span></div><div class="casAuthors">Al-Marrawi, Mhd. Yaser; Saroya, Bikramajit Singh; Brennan, Matthew C.; Yang, Zhaohai; Dykes, Thomas M.; El-Deiry, Wafik S.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biology & Therapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">703-710</span>CODEN:
                <span class="NLM_cas:coden">CBTAAO</span>;
        ISSN:<span class="NLM_cas:issn">1538-4047</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">Sorafenib, the first agent developed to target BRAF mutant melanoma, is a multi-kinase inhibitor that was approved by the FDA for therapy of kidney and subsequently liver cancer, and is currently in clin. trials for thyroid, lung and brain cancer.  Colorectal cancer with V600E BRAF mutation has shown relative resistance to std. chemotherapy regimens, as well as lack of efficacy to vemurafenib in clin. trials.  New treatments are needed for BRAF-mutant colorectal cancer.  We report a case of a patient with BRAF-mutant metastatic colon cancer whose disease had progressed on FOLFOX plus bevacizumab and subsequent FOLFIRI plus cetuximab.  Based on preclin. data published in Nature in 2012 suggesting that successful therapeutic targeting of BRAF in colorectal cancer may require concomitant targeting of the EGFR, we offered this patient without other attractive options the combination of sorafenib plus cetuximab, in off-label use with informed consent.  Sorafenib and cetuximab therapy led to a mixed radiog. response with some areas showing dramatic improvement and other areas showing stable disease over a 7 mo period which is a notably long period of progression-free survival for V600E BRAF mutated colon cancer.  The cetuximab plus sorafenib therapy was very well-tolerated by the patient who remained on it long enough until another therapy option, regorafenib, was approved in Sept. 2012.  The patient was offered single agent regorafenib at the time of progression.  At the time of progression on single agent regorafenib, panitumumab was combined with regorafenib and this was also well-tolerated and appeared to slow disease progression.  Further study of these approaches in the clinic as personalized treatment of BRAF-mutant advanced colorectal cancer is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrW8SBZhzKdGrVg90H21EOLACvtfcHk0ljH3mS9ckuAxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjs1yit7k%253D&md5=3f4d41340207576d2d49af3579574f10</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.4161%2Fcbt.25191&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcbt.25191%26sid%3Dliteratum%253Aachs%26aulast%3DAl-Marrawi%26aufirst%3DM.%2BY.%26aulast%3DSaroya%26aufirst%3DB.%2BS.%26aulast%3DBrennan%26aufirst%3DM.%2BC.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DDykes%26aufirst%3DT.%2BM.%26aulast%3DEl-Deiry%26aufirst%3DW.%2BS.%26atitle%3DOff-label%2520use%2520of%2520cetuximab%2520plus%2520sorafenib%2520and%2520panitumumab%2520plus%2520regorafenib%2520to%2520personalize%2520therapy%2520for%2520a%2520patient%2520with%2520V600E%2520BRAF-mutant%2520metastatic%2520colon%2520cancer%26jtitle%3DCancer%2520Biol.%2520Ther.%26date%3D2013%26volume%3D14%26spage%3D703%26epage%3D710" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Abel, E. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basile, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kugell, C. H.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witkiewicz, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amaravadi, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karakousis, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuchter, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ertel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fortina, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aplin, A. E.</span><span> </span><span class="NLM_article-title">Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">123</span><span class="NLM_x">, </span> <span class="NLM_fpage">2155</span><span class="NLM_x">–</span> <span class="NLM_lpage">2168</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2013&pages=2155-2168&author=E.+V.+Abelauthor=K.+J.+Basileauthor=C.+H.+Kugellauthor=A.+K.+Witkiewiczauthor=K.+Leauthor=R.+K.+Amaravadiauthor=G.+C.+Karakousisauthor=X.+Xuauthor=W.+Xuauthor=L.+M.+Schuchterauthor=J.+B.+Leeauthor=A.+Ertelauthor=P.+Fortinaauthor=A.+E.+Aplin&title=Melanoma+adapts+to+RAF%2FMEK+inhibitors+through+FOXD3-mediated+upregulation+of+ERBB3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAbel%26aufirst%3DE.%2BV.%26aulast%3DBasile%26aufirst%3DK.%2BJ.%26aulast%3DKugell%26aufirst%3DC.%2BH.%26aulast%3DWitkiewicz%26aufirst%3DA.%2BK.%26aulast%3DLe%26aufirst%3DK.%26aulast%3DAmaravadi%26aufirst%3DR.%2BK.%26aulast%3DKarakousis%26aufirst%3DG.%2BC.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DSchuchter%26aufirst%3DL.%2BM.%26aulast%3DLee%26aufirst%3DJ.%2BB.%26aulast%3DErtel%26aufirst%3DA.%26aulast%3DFortina%26aufirst%3DP.%26aulast%3DAplin%26aufirst%3DA.%2BE.%26atitle%3DMelanoma%2520adapts%2520to%2520RAF%252FMEK%2520inhibitors%2520through%2520FOXD3-mediated%2520upregulation%2520of%2520ERBB3%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2013%26volume%3D123%26spage%3D2155%26epage%3D2168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">DeVita, V. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schein, P. S.</span><span> </span><span class="NLM_article-title">The Use of drugs in combination for the treatment of cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1973</span><span class="NLM_x">, </span> <span class="NLM_volume">288</span><span class="NLM_x">, </span> <span class="NLM_fpage">998</span><span class="NLM_x">–</span> <span class="NLM_lpage">1006</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Fjm500007h&amp;key=10.1056%2FNEJM197305102881905" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Fjm500007h&amp;key=4348752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm500007h&amp;key=1%3ACAS%3A280%3ADyaE3s7ltlGgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=1973&pages=998-1006&author=V.+T.+DeVitaauthor=P.+S.+Schein&title=The+Use+of+drugs+in+combination+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">The use of drugs in combination for the treatment of cancer: rationale and results</span></div><div class="casAuthors">DeVita V T; Schein P S</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1973</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">998-1006</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRso8dNAqdVHYIRAdBLKY41fW6udTcc2eZKss1G6onISbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaE3s7ltlGgtQ%253D%253D&md5=34ad3e72f5e5668f5cdd5e54829a8bad</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1056%2FNEJM197305102881905&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM197305102881905%26sid%3Dliteratum%253Aachs%26aulast%3DDeVita%26aufirst%3DV.%2BT.%26aulast%3DSchein%26aufirst%3DP.%2BS.%26atitle%3DThe%2520Use%2520of%2520drugs%2520in%2520combination%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1973%26volume%3D288%26spage%3D998%26epage%3D1006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Pegram, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konecny, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Callaghan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beryt, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pietras, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slamon, D. J.</span><span> </span><span class="NLM_article-title">Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">739</span><span class="NLM_x">–</span> <span class="NLM_lpage">749</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Fjm500007h&amp;key=10.1093%2Fjnci%2Fdjh131" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Fjm500007h&amp;key=15150302" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Fjm500007h&amp;key=1%3ACAS%3A528%3ADC%252BD2cXkt1Sqsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2004&pages=739-749&author=M.+D.+Pegramauthor=G.+E.+Konecnyauthor=C.+O%E2%80%99Callaghanauthor=M.+Berytauthor=R.+Pietrasauthor=D.+J.+Slamon&title=Rational+combinations+of+trastuzumab+with+chemotherapeutic+drugs+used+in+the+treatment+of+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Combinations of Trastuzumab With Chemotherapeutic Drugs Used in the Treatment of Breast Cancer</span></div><div class="casAuthors">Pegram, Mark D.; Konecny, Gottfried E.; O'Callaghan, Carminda; Beryt, Malgorzata; Pietras, Richard; Slamon, Dennis J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">739-749</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Trastuzumab, a humanized anti-HER2 antibody, increases the clin. benefit of first-line chemotherapy in patients with metastatic breast cancers that overexpress HER2.  We characterized interactions between trastuzumab and chemotherapeutic agents commonly used in the treatment of breast cancer.  Multiple drug effect/combination index isobologram anal. was used to study the efficacy of chemotherapeutic drug plus trastuzumab combinations tested against four HER2-overexpressing breast cancer cell lines (SK-BR-3, BT-474, MDA-MB-361, and MDA-MB-453).  Combination index values were derived from parameters of the median effect plots, and statistical tests were used to det. whether the mean combination index values at multiple effect levels were statistically significantly different from a combination index value of 1.0.  Values less than 1.0 indicate synergistic interactions, values greater than 1.0 indicate antagonistic interactions, and values equal to 1.0 indicate additive interactions.  At a wide range of clin. achievable drug concns., synergistic interactions were obsd. in all four breast cancer cell lines for trastuzumab plus carboplatin (mean combination index values ranged from 0.32 [P<.001] to 0.53 [P<.001]), 4-hydroxycyclophosphamide (mean combination index values ranged from 0.38 [P<.001] to 0.73 [P = .010]), docetaxel (mean combination index values ranged from 0.30 [P<.001] to 0.62 [P<.001]), and vinorelbine (mean combination index values ranged from 0.24 [P<.001] to 0.78 [P<.034]).  Additive interactions were obsd. in all four cell lines with trastuzumab plus doxorubicin, epirubicin, and paclitaxel.  Interactions between trastuzumab and gemcitabine were synergistic at low concns. of gemcitabine and antagonistic at high concns.  A synergistic interaction was obsd. with a three-drug combination of docetaxel plus carboplatin plus trastuzumab in SK-BR-3 cells (mean combination index value = 0.09; P<.001).  Consistent synergistic interactions of trastuzumab plus carboplatin, 4-hydroxycyclophosphamide, docetaxel, or vinorelbine across a wide range of clin. relevant concns. in HER2-overexpressing breast cancer cells indicate that these are rational combinations to test in human clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZ5NdDhTJwpLVg90H21EOLACvtfcHk0lheVqV2F8mgLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXkt1Sqsbo%253D&md5=1fb831bd3fbb62277de025c4a99f383d</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjh131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjh131%26sid%3Dliteratum%253Aachs%26aulast%3DPegram%26aufirst%3DM.%2BD.%26aulast%3DKonecny%26aufirst%3DG.%2BE.%26aulast%3DO%25E2%2580%2599Callaghan%26aufirst%3DC.%26aulast%3DBeryt%26aufirst%3DM.%26aulast%3DPietras%26aufirst%3DR.%26aulast%3DSlamon%26aufirst%3DD.%2BJ.%26atitle%3DRational%2520combinations%2520of%2520trastuzumab%2520with%2520chemotherapeutic%2520drugs%2520used%2520in%2520the%2520treatment%2520of%2520breast%2520cancer%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2004%26volume%3D96%26spage%3D739%26epage%3D749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodi, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callahan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konto, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolchok, J.</span><span> </span><span class="NLM_article-title">Hepatotoxicity with combination of vemurafenib and ipilimumab</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">368</span><span class="NLM_x">, </span> <span class="NLM_fpage">1365</span><span class="NLM_x">–</span> <span class="NLM_lpage">1366</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Fjm500007h&amp;key=10.1056%2FNEJMc1302338" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Fjm500007h&amp;key=23550685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Fjm500007h&amp;key=1%3ACAS%3A528%3ADC%252BC3sXls1aktbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2013&pages=1365-1366&author=A.+Ribasauthor=F.+S.+Hodiauthor=M.+Callahanauthor=C.+Kontoauthor=J.+Wolchok&title=Hepatotoxicity+with+combination+of+vemurafenib+and+ipilimumab"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatotoxicity with combination of vemurafenib and ipilimumab</span></div><div class="casAuthors">Ribas, Antoni; Hodi, F. Stephen; Callahan, Margaret; Konto, Cyril; Wolchok, Jedd</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">368</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1365-1366</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4C-d0ldXxG7Vg90H21EOLACvtfcHk0lheVqV2F8mgLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXls1aktbg%253D&md5=e903ecac16e34bc5ee83d9d24338d950</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1056%2FNEJMc1302338&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMc1302338%26sid%3Dliteratum%253Aachs%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DHodi%26aufirst%3DF.%2BS.%26aulast%3DCallahan%26aufirst%3DM.%26aulast%3DKonto%26aufirst%3DC.%26aulast%3DWolchok%26aufirst%3DJ.%26atitle%3DHepatotoxicity%2520with%2520combination%2520of%2520vemurafenib%2520and%2520ipilimumab%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D368%26spage%3D1365%26epage%3D1366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Rowbottom, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faraoni, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Setti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ezawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sprankle, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abraham, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Struss, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibney, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armstrong, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunawardane, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nepomuceno, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valenta, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hua, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardner, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cramer, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gitnick, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Apuy, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones-Bolin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghose, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herbertz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ator, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorsey, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhagwat, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holladay, M. W.</span><span> </span><span class="NLM_article-title">Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">1082</span><span class="NLM_x">–</span> <span class="NLM_lpage">1105</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm2009925" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1082-1105&author=M.+W.+Rowbottomauthor=R.+Faraoniauthor=Q.+Chaoauthor=B.+T.+Campbellauthor=A.+G.+Laiauthor=E.+Settiauthor=M.+Ezawaauthor=K.+G.+Sprankleauthor=S.+Abrahamauthor=L.+Tranauthor=B.+Strussauthor=M.+Gibneyauthor=R.+C.+Armstrongauthor=R.+N.+Gunawardaneauthor=R.+R.+Nepomucenoauthor=I.+Valentaauthor=H.+L.+Huaauthor=M.+F.+Gardnerauthor=M.+D.+Cramerauthor=D.+Gitnickauthor=D.+E.+Inskoauthor=J.+L.+Apuyauthor=S.+Jones-Bolinauthor=A.+K.+Ghoseauthor=T.+Herbertzauthor=M.+A.+Atorauthor=B.+D.+Dorseyauthor=B.+Ruggeriauthor=M.+Williamsauthor=S.+Bhagwatauthor=J.+Jamesauthor=M.+W.+Holladay&title=Identification+of+1-%283-%286%2C7-dimethoxyquinazolin-4-yloxy%29phenyl%29-3-%285-%281%2C1%2C1-trifluoro-2-methylpropan-2-yl%29isoxazol-3-yl%29urea+hydrochloride+%28CEP-32496%29%2C+a+highly+potent+and+orally+efficacious+inhibitor+of+V-RAF+murine+sarcoma+viral+oncogene+homologue+B1+%28BRAF%29+V600E"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm2009925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2009925%26sid%3Dliteratum%253Aachs%26aulast%3DRowbottom%26aufirst%3DM.%2BW.%26aulast%3DFaraoni%26aufirst%3DR.%26aulast%3DChao%26aufirst%3DQ.%26aulast%3DCampbell%26aufirst%3DB.%2BT.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DSetti%26aufirst%3DE.%26aulast%3DEzawa%26aufirst%3DM.%26aulast%3DSprankle%26aufirst%3DK.%2BG.%26aulast%3DAbraham%26aufirst%3DS.%26aulast%3DTran%26aufirst%3DL.%26aulast%3DStruss%26aufirst%3DB.%26aulast%3DGibney%26aufirst%3DM.%26aulast%3DArmstrong%26aufirst%3DR.%2BC.%26aulast%3DGunawardane%26aufirst%3DR.%2BN.%26aulast%3DNepomuceno%26aufirst%3DR.%2BR.%26aulast%3DValenta%26aufirst%3DI.%26aulast%3DHua%26aufirst%3DH.%2BL.%26aulast%3DGardner%26aufirst%3DM.%2BF.%26aulast%3DCramer%26aufirst%3DM.%2BD.%26aulast%3DGitnick%26aufirst%3DD.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DApuy%26aufirst%3DJ.%2BL.%26aulast%3DJones-Bolin%26aufirst%3DS.%26aulast%3DGhose%26aufirst%3DA.%2BK.%26aulast%3DHerbertz%26aufirst%3DT.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26aulast%3DRuggeri%26aufirst%3DB.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DBhagwat%26aufirst%3DS.%26aulast%3DJames%26aufirst%3DJ.%26aulast%3DHolladay%26aufirst%3DM.%2BW.%26atitle%3DIdentification%2520of%25201-%25283-%25286%252C7-dimethoxyquinazolin-4-yloxy%2529phenyl%2529-3-%25285-%25281%252C1%252C1-trifluoro-2-methylpropan-2-yl%2529isoxazol-3-yl%2529urea%2520hydrochloride%2520%2528CEP-32496%2529%252C%2520a%2520highly%2520potent%2520and%2520orally%2520efficacious%2520inhibitor%2520of%2520V-RAF%2520murine%2520sarcoma%2520viral%2520oncogene%2520homologue%2520B1%2520%2528BRAF%2529%2520V600E%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D1082%26epage%3D1105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Zhang, Q. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diao, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">You, Q. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, H. Y.</span><span> </span><span class="NLM_article-title">Design and discovery of 4-anilinoquinazoline ureas as multikinase inhibitors targeting BRAF, VEGFR-2 and EGFR</span> <span class="citation_source-journal">MedChemComm</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">979</span><span class="NLM_x">–</span> <span class="NLM_lpage">986</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=979-986&author=Q.+W.+Zhangauthor=Y.+Y.+Diaoauthor=F.+Wangauthor=Y.+Fuauthor=F.+Tangauthor=Q.+D.+Youauthor=H.+Y.+Zhou&title=Design+and+discovery+of+4-anilinoquinazoline+ureas+as+multikinase+inhibitors+targeting+BRAF%2C+VEGFR-2+and+EGFR"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DQ.%2BW.%26aulast%3DDiao%26aufirst%3DY.%2BY.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DFu%26aufirst%3DY.%26aulast%3DTang%26aufirst%3DF.%26aulast%3DYou%26aufirst%3DQ.%2BD.%26aulast%3DZhou%26aufirst%3DH.%2BY.%26atitle%3DDesign%2520and%2520discovery%2520of%25204-anilinoquinazoline%2520ureas%2520as%2520multikinase%2520inhibitors%2520targeting%2520BRAF%252C%2520VEGFR-2%2520and%2520EGFR%26jtitle%3DMedChemComm%26date%3D2013%26volume%3D4%26spage%3D979%26epage%3D986" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Heffron, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, B. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivero, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staben, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsui, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Do, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dotson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Folkes, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldsmith, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldsmith, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunzner, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesnick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathieu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nonomiya, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuttleworth, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutherlin, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, B. Y.</span><span> </span><span class="NLM_article-title">Rational design of phosphoinositide 3-kinase alpha inhibitors that exhibit selectivity over the phosphoinositide 3-kinase beta isoform</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">7815</span><span class="NLM_x">–</span> <span class="NLM_lpage">7833</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm2007084" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7815-7833&author=T.+P.+Heffronauthor=B.+Q.+Weiauthor=A.+Oliveroauthor=S.+T.+Stabenauthor=V.+Tsuiauthor=S.+Doauthor=J.+Dotsonauthor=A.+J.+Folkesauthor=P.+Goldsmithauthor=R.+Goldsmithauthor=J.+Gunznerauthor=J.+Lesnickauthor=C.+Lewisauthor=S.+Mathieuauthor=J.+Nonomiyaauthor=S.+Shuttleworthauthor=D.+P.+Sutherlinauthor=N.+C.+Wanauthor=S.+M.+Wangauthor=C.+Wiesmannauthor=B.+Y.+Zhu&title=Rational+design+of+phosphoinositide+3-kinase+alpha+inhibitors+that+exhibit+selectivity+over+the+phosphoinositide+3-kinase+beta+isoform"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm2007084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2007084%26sid%3Dliteratum%253Aachs%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26aulast%3DWei%26aufirst%3DB.%2BQ.%26aulast%3DOlivero%26aufirst%3DA.%26aulast%3DStaben%26aufirst%3DS.%2BT.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DDo%26aufirst%3DS.%26aulast%3DDotson%26aufirst%3DJ.%26aulast%3DFolkes%26aufirst%3DA.%2BJ.%26aulast%3DGoldsmith%26aufirst%3DP.%26aulast%3DGoldsmith%26aufirst%3DR.%26aulast%3DGunzner%26aufirst%3DJ.%26aulast%3DLesnick%26aufirst%3DJ.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DMathieu%26aufirst%3DS.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DShuttleworth%26aufirst%3DS.%26aulast%3DSutherlin%26aufirst%3DD.%2BP.%26aulast%3DWan%26aufirst%3DN.%2BC.%26aulast%3DWang%26aufirst%3DS.%2BM.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DZhu%26aufirst%3DB.%2BY.%26atitle%3DRational%2520design%2520of%2520phosphoinositide%25203-kinase%2520alpha%2520inhibitors%2520that%2520exhibit%2520selectivity%2520over%2520the%2520phosphoinositide%25203-kinase%2520beta%2520isoform%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7815%26epage%3D7833" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Joseph, E. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pratilas, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poulikakos, P. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tadi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halilovic, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Persaud, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xing, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viale, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bollag, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solit, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, N.</span><span> </span><span class="NLM_article-title">The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">14903</span><span class="NLM_x">–</span> <span class="NLM_lpage">14908</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Fjm500007h&amp;key=10.1073%2Fpnas.1008990107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Fjm500007h&amp;key=20668238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Fjm500007h&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVOjsLrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=14903-14908&author=E.+W.+Josephauthor=C.+A.+Pratilasauthor=P.+I.+Poulikakosauthor=M.+Tadiauthor=W.+Q.+Wangauthor=B.+S.+Taylorauthor=E.+Halilovicauthor=Y.+Persaudauthor=F.+Xingauthor=A.+Vialeauthor=J.+Tsaiauthor=P.+B.+Chapmanauthor=G.+Bollagauthor=D.+B.+Solitauthor=N.+Rosen&title=The+RAF+inhibitor+PLX4032+inhibits+ERK+signaling+and+tumor+cell+proliferation+in+a+V600E+BRAF-selective+manner"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner</span></div><div class="casAuthors">Joseph, Eric W.; Pratilas, Christine A.; Poulikakos, Poulikos I.; Tadi, Madhavi; Wang, Weiqing; Taylor, Barry S.; Halilovic, Ensar; Persaud, Yogindra; Xing, Feng; Viale, Agnes; Tsai, James; Chapman, Paul B.; Bollag, Gideon; Solit, David B.; Rosen, Neal</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">14903-14908, S14903/1-S14903/8</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Tumors with mutant BRAF and some with mutant RAS are dependent upon ERK signaling for proliferation, and their growth is suppressed by MAPK/ERK kinase (MEK) inhibitors.  In contrast, tumor cells with human EGF receptor (HER) kinase activation proliferate in a MEK-independent manner.  These findings have led to the development of RAF and MEK inhibitors as anticancer agents.  Like MEK inhibitors, the RAF inhibitor PLX4032 inhibits the proliferation of BRAFV600E tumor cells but not that of HER kinase-dependent tumors.  However, tumors with RAS mutation that are sensitive to MEK inhibition are insensitive to PLX4032.  MEK inhibitors inhibit ERK phosphorylation in all normal and tumor cells, whereas PLX4032 inhibits ERK signaling only in tumor cells expressing BRAFV600E.  In contrast, the drug activates MEK and ERK phosphorylation in cells with wild-type BRAF.  In BRAFV600E tumor cells, MEK and RAF inhibitors affect the expression of a common set of genes.  PLX4032 inhibits ERK signaling output in mutant BRAF cells, whereas it transiently activates the expression of these genes in tumor cells with wild-type RAF.  Thus, PLX4032 inhibits ERK signaling output in a mutant BRAF-selective manner.  These data explain why the drug selectively inhibits the growth of mutant BRAF tumors and suggest that it will not cause toxicity resulting from the inhibition of ERK signaling in normal cells.  This selectivity may lead to a broader therapeutic index and help explain the greater antitumor activity obsd. with this drug than with MEK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_6Gff4DQiprVg90H21EOLACvtfcHk0lj_A-PgpuHFjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVOjsLrP&md5=c5c99b7faca898bd8e4b1d4ae82a5f84</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1008990107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1008990107%26sid%3Dliteratum%253Aachs%26aulast%3DJoseph%26aufirst%3DE.%2BW.%26aulast%3DPratilas%26aufirst%3DC.%2BA.%26aulast%3DPoulikakos%26aufirst%3DP.%2BI.%26aulast%3DTadi%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DW.%2BQ.%26aulast%3DTaylor%26aufirst%3DB.%2BS.%26aulast%3DHalilovic%26aufirst%3DE.%26aulast%3DPersaud%26aufirst%3DY.%26aulast%3DXing%26aufirst%3DF.%26aulast%3DViale%26aufirst%3DA.%26aulast%3DTsai%26aufirst%3DJ.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DSolit%26aufirst%3DD.%2BB.%26aulast%3DRosen%26aufirst%3DN.%26atitle%3DThe%2520RAF%2520inhibitor%2520PLX4032%2520inhibits%2520ERK%2520signaling%2520and%2520tumor%2520cell%2520proliferation%2520in%2520a%2520V600E%2520BRAF-selective%2520manner%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2010%26volume%3D107%26spage%3D14903%26epage%3D14908" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Wakeling, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guy, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodburn, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curry, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barker, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, K. H.</span><span> </span><span class="NLM_article-title">AZD1839 (Iressa): An orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">5749</span><span class="NLM_x">–</span> <span class="NLM_lpage">5754</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=5749-5754&author=A.+E.+Wakelingauthor=S.+P.+Guyauthor=J.+R.+Woodburnauthor=S.+E.+Ashtonauthor=B.+J.+Curryauthor=A.+J.+Barkerauthor=K.+H.+Gibson&title=AZD1839+%28Iressa%29%3A+An+orally+active+inhibitor+of+epidermal+growth+factor+signaling+with+potential+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWakeling%26aufirst%3DA.%2BE.%26aulast%3DGuy%26aufirst%3DS.%2BP.%26aulast%3DWoodburn%26aufirst%3DJ.%2BR.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DCurry%26aufirst%3DB.%2BJ.%26aulast%3DBarker%26aufirst%3DA.%2BJ.%26aulast%3DGibson%26aufirst%3DK.%2BH.%26atitle%3DAZD1839%2520%2528Iressa%2529%253A%2520An%2520orally%2520active%2520inhibitor%2520of%2520epidermal%2520growth%2520factor%2520signaling%2520with%2520potential%2520for%2520cancer%2520therapy%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26spage%3D5749%26epage%3D5754" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Muhsin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkpatrick, P.</span><span> </span><span class="NLM_article-title">Gefitinib</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">515</span><span class="NLM_x">–</span> <span class="NLM_lpage">516</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2003&pages=515-516&author=M.+Muhsinauthor=J.+Grahamauthor=P.+Kirkpatrick&title=Gefitinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMuhsin%26aufirst%3DM.%26aulast%3DGraham%26aufirst%3DJ.%26aulast%3DKirkpatrick%26aufirst%3DP.%26atitle%3DGefitinib%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2003%26volume%3D2%26spage%3D515%26epage%3D516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Jares-Erijman, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jovin, T. M.</span><span> </span><span class="NLM_article-title">FRET imaging</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">1387</span><span class="NLM_x">–</span> <span class="NLM_lpage">1395</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Fjm500007h&amp;key=10.1038%2Fnbt896" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Fjm500007h&amp;key=14595367" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Fjm500007h&amp;key=1%3ACAS%3A528%3ADC%252BD3sXosFOksbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2003&pages=1387-1395&author=E.+A.+Jares-Erijmanauthor=T.+M.+Jovin&title=FRET+imaging"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">FRET imaging</span></div><div class="casAuthors">Jares-Erijman, Elizabeth A.; Jovin, Thomas M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1387-1395</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Foerster (or Fluorescence) Resonance Energy Transfer (FRET) is unique in generating fluorescence signals sensitive to mol. conformation, assocn., and sepn. in the 1-10 nm range.  We introduce a revised photophys. framework for the phenomenon and provide a systematic catalog of FRET techniques adapted to imaging systems, including new approaches proposed as suitable prospects for implementation.  Applications extending from a single mol. to live cells will benefit from multidimensional microscopy techniques, particularly those adapted for optical sectioning and incorporating new algorithms for resolving the component contributions to images of complex mol. systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTN4i2irXbCLVg90H21EOLACvtfcHk0liIfjIo66Y0qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXosFOksbo%253D&md5=01814592b10786fdb8f660c4a23dfa78</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Fnbt896&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt896%26sid%3Dliteratum%253Aachs%26aulast%3DJares-Erijman%26aufirst%3DE.%2BA.%26aulast%3DJovin%26aufirst%3DT.%2BM.%26atitle%3DFRET%2520imaging%26jtitle%3DNat.%2520Biotechnol.%26date%3D2003%26volume%3D21%26spage%3D1387%26epage%3D1395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Zheng, X. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bair, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumeister, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowman, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckmelter, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caligiuri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clodfelter, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, Y. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kley, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, X. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liederer, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ly, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oeh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sampath, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skelton, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tremayne, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, G. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuen, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dragovich, P. S.</span><span> </span><span class="NLM_article-title">Identification of amides derived from 1<i>H</i>-pyrazolo [3,4-<i>b</i>]pyridine-5-carboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">5488</span><span class="NLM_x">–</span> <span class="NLM_lpage">5497</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=5488-5497&author=X.+Z.+Zhengauthor=K.+W.+Bairauthor=P.+Bauerauthor=T.+Baumeisterauthor=K.+K.+Bowmanauthor=A.+J.+Buckmelterauthor=M.+Caligiuriauthor=K.+H.+Clodfelterauthor=Y.+Z.+Fengauthor=B.+S.+Hanauthor=Y.+C.+Hoauthor=N.+Kleyauthor=H.+Liauthor=X.+R.+Liangauthor=B.+M.+Liedererauthor=J.+Linauthor=J.+Lyauthor=T.+O%E2%80%99Brienauthor=J.+Oehauthor=A.+Ohauthor=D.+J.+Reynoldsauthor=D.+Sampathauthor=G.+Sharmaauthor=N.+Skeltonauthor=C.+C.+Smithauthor=J.+Tremayneauthor=L.+L.+Wangauthor=W.+R.+Wangauthor=Z.+G.+Wangauthor=H.+X.+Wuauthor=J.+S.+Wuauthor=Y.+Xiaoauthor=G.+X.+Yangauthor=P.+W.+Yuenauthor=M.+Zakauthor=P.+S.+Dragovich&title=Identification+of+amides+derived+from+1H-pyrazolo+%5B3%2C4-b%5Dpyridine-5-carboxylic+acid+as+potent+inhibitors+of+human+nicotinamide+phosphoribosyltransferase+%28NAMPT%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DX.%2BZ.%26aulast%3DBair%26aufirst%3DK.%2BW.%26aulast%3DBauer%26aufirst%3DP.%26aulast%3DBaumeister%26aufirst%3DT.%26aulast%3DBowman%26aufirst%3DK.%2BK.%26aulast%3DBuckmelter%26aufirst%3DA.%2BJ.%26aulast%3DCaligiuri%26aufirst%3DM.%26aulast%3DClodfelter%26aufirst%3DK.%2BH.%26aulast%3DFeng%26aufirst%3DY.%2BZ.%26aulast%3DHan%26aufirst%3DB.%2BS.%26aulast%3DHo%26aufirst%3DY.%2BC.%26aulast%3DKley%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DLiang%26aufirst%3DX.%2BR.%26aulast%3DLiederer%26aufirst%3DB.%2BM.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DLy%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DT.%26aulast%3DOeh%26aufirst%3DJ.%26aulast%3DOh%26aufirst%3DA.%26aulast%3DReynolds%26aufirst%3DD.%2BJ.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DSharma%26aufirst%3DG.%26aulast%3DSkelton%26aufirst%3DN.%26aulast%3DSmith%26aufirst%3DC.%2BC.%26aulast%3DTremayne%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%2BL.%26aulast%3DWang%26aufirst%3DW.%2BR.%26aulast%3DWang%26aufirst%3DZ.%2BG.%26aulast%3DWu%26aufirst%3DH.%2BX.%26aulast%3DWu%26aufirst%3DJ.%2BS.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DG.%2BX.%26aulast%3DYuen%26aufirst%3DP.%2BW.%26aulast%3DZak%26aufirst%3DM.%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26atitle%3DIdentification%2520of%2520amides%2520derived%2520from%25201H-pyrazolo%2520%255B3%252C4-b%255Dpyridine-5-carboxylic%2520acid%2520as%2520potent%2520inhibitors%2520of%2520human%2520nicotinamide%2520phosphoribosyltransferase%2520%2528NAMPT%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D5488%26epage%3D5497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i46"><a href="/doi/suppl/10.1021/jm500007h">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_45502"></div></div></div></div></div><hr /></hr><p class="last"><sup>1</sup>H NMR and <sup>13</sup>C NMR for final compounds, biological data, and assay details. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm500007h/suppl_file/jm500007h_si_001.pdf">jm500007h_si_001.pdf (2.16 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm500007h&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2014.57.issue-6%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Fjm500007h%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm500007h" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677a64441ff43d18","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
